U.S. patent application number 13/105018 was filed with the patent office on 2011-11-17 for process for selectively polymerizing ethylene and catalyst therefor.
Invention is credited to Xiuhua Cui, Robert D. Froese, Jerzy Klosin, Pulikkottil J. Thomas.
Application Number | 20110282018 13/105018 |
Document ID | / |
Family ID | 44462019 |
Filed Date | 2011-11-17 |
United States Patent
Application |
20110282018 |
Kind Code |
A1 |
Klosin; Jerzy ; et
al. |
November 17, 2011 |
PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST
THEREFOR
Abstract
The present invention generally relates to a process that
selectively polymerizes ethylene in the presence of an
alpha-olefin, and to a metal-ligand complex (precatalyst) and
catalyst useful in such processes, and to related compositions. The
present invention also generally relates to ligands and
intermediates useful for preparing the metal-ligand complex and to
processes of their preparation.
Inventors: |
Klosin; Jerzy; (Midland,
MI) ; Thomas; Pulikkottil J.; (Midland, MI) ;
Froese; Robert D.; (Midland, MI) ; Cui; Xiuhua;
(Pearland, TX) |
Family ID: |
44462019 |
Appl. No.: |
13/105018 |
Filed: |
May 11, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61467627 |
Mar 25, 2011 |
|
|
|
Current U.S.
Class: |
526/170 ;
502/117; 548/403; 548/444 |
Current CPC
Class: |
C08F 4/65908 20130101;
C08F 210/16 20130101; C08F 4/659 20130101; C08F 4/64193 20130101;
C08F 210/16 20130101; C08F 210/14 20130101; C08F 4/659 20130101;
C08F 2500/03 20130101; C08F 4/65912 20130101; C08F 10/00 20130101;
C08F 210/14 20130101; C08F 210/16 20130101; C08F 4/64193 20130101;
C08F 2500/03 20130101; C08F 10/00 20130101 |
Class at
Publication: |
526/170 ;
548/403; 502/117; 548/444 |
International
Class: |
C08F 4/76 20060101
C08F004/76; C07D 403/12 20060101 C07D403/12; B01J 31/22 20060101
B01J031/22; C08F 10/14 20060101 C08F010/14; C07F 7/00 20060101
C07F007/00 |
Foreign Application Data
Date |
Code |
Application Number |
May 17, 2010 |
US |
PCT/US2010/035096 |
Claims
1. A process for selectively polymerizing ethylene in the presence
of an alpha-olefin, the process comprising a step of contacting
together a catalytic amount of a catalyst, ethylene, and an
alpha-olefin, wherein the catalyst comprises a mixture or reaction
product of ingredients (a) and (b) that is prepared before the
contacting step, wherein ingredient (a) comprises a metal-ligand
complex (also referred to herein as a precatalyst) and ingredient
(b) comprises an activating co-catalyst; ethylene comprises
ingredient (c); and the alpha-olefin comprises ingredient (d); the
metal-ligand complex of ingredient (a) being one or more
metal-ligand complexes (also referred to herein as precatalysts) of
formula (I): ##STR00060## wherein: M is titanium, zirconium, or
hafnium, each independently being in a formal oxidation state of
+2, +3, or +4; n is an integer of from 0 to 3, wherein when n is 0,
X is absent; Each X independently is a monodentate ligand that is
neutral, monoanionic, or dianionic; or two X are taken together to
form a bidentate ligand that is neutral, monoanionic, or dianionic;
X and n are chosen in such a way that the metal-ligand complex of
formula (I) is, overall, neutral; Each Z independently is O, S,
Nhydrocarbyl, or Phydrocarbyl; L is hydrocarbylene or
heterohydrocarbylene, wherein the hydrocarbylene has a portion that
comprises a 1-carbon atom to 6-carbon atom linker backbone linking
the Z atoms in formula (I) and the heterohydrocarbylene has a
portion that comprises a 1-atom to 6-atom linker backbone linking
the Z atoms in formula (I), wherein each atom of the 1-atom to
6-atom linker backbone of the heterohydrocarbylene independently is
a carbon atom or a heteroatom, wherein each heteroatom
independently is O, S, S(O), S(O).sub.2, Si(R.sup.C).sub.2,
Ge(R.sup.C).sub.2, P(R.sup.P), or N(R.sup.N), wherein independently
each R.sup.C is unsubstituted (C.sub.1-C.sub.18)hydrocarbyl or the
two R.sup.C are taken together to form a
(C.sub.2-C.sub.19)alkylene, each R.sup.P is unsubstituted
(C.sub.1-C.sub.18)hydrocarbyl; and each R.sup.N is unsubstituted
(C.sub.1-C.sub.18)hydrocarbyl, a hydrogen atom or absent; At least
one of R.sup.1a, R.sup.2a, R.sup.1b, R.sup.2b independently is a
hydrocarbyl, heterohydrocarbyl, or halogen atom; and each of the
other of R.sup.1a, R.sup.2a, R.sup.1b, and R.sup.2b independently
is a hydrogen atom, hydrocarbyl, heterohydrocarbyl, or halogen
atom; Each of R.sup.3a, R.sup.4a, R.sup.3b, R.sup.4b, R.sup.6c,
R.sup.7c, R.sup.8c, R.sup.6d, R.sup.7d, and R.sup.8d independently
is a hydrogen atom; hydrocarbyl; heterohydrocarbyl; or halogen
atom; Each of R.sup.5c and R.sup.5d independently is an aryl or
heteroaryl; Each of the aforementioned aryl, heteroaryl,
hydrocarbyl, heterohydrocarbyl, hydrocarbylene, and
heterohydrocarbylene groups independently is unsubstituted or
substituted with one or more substituents R.sup.S; and Each R.sup.S
independently is a halogen atom, polyfluoro substitution, perfluoro
substitution, unsubstituted (C.sub.1-C.sub.18)alkyl, F.sub.3C--,
FCH.sub.2O--, F.sub.2HCO--, F.sub.3CO--, R.sub.3Si--, R.sub.3Ge--,
RO--, RS--, RS(O)--, RS(O).sub.2--, R.sub.2P--, R.sub.2N--,
R.sub.2C.dbd.N--, NC--, RC(O)O--, ROC(O)--, RC(O)N(R)--, or
R.sub.2NC(O)--, or two of the R.sup.S are taken together to form an
unsubstituted (C.sub.1-C.sub.18)alkylene, wherein each R
independently is an unsubstituted (C.sub.1-C.sub.18)alkyl; wherein
the activating co-catalyst of the ingredient (b) comprises one or
more activating co-catalysts, or a reaction product thereof,
wherein the ratio of total number of moles of the one or more
metal-ligand complexes of formula (I) to total number of moles of
the one or more activating co-catalysts is from 1:10,000 to 100:1;
wherein the contacting step is performed under olefin polymerizing
conditions and prepares a rich polyethylene in presence of
unpolymerized alpha-olefin, wherein the rich polyethylene is a
polymeric molecule, or segment thereof, consisting substantially of
ethylene repeat units; or a mixture or blend of two or more such
polymeric molecules; and wherein the process forms reactive chains
and is characterizable by a reaction rate constant k.sub.11 for
adding the ethylene to a first reactive chain end comprising an
ethylene residual; a reaction rate constant k.sub.12 for adding the
alpha-olefin to a second reactive chain end comprising an ethylene
residual; and a reactivity ratio r.sub.1 equal to k.sub.11 divided
by k.sub.12 of greater than 14; and wherein every metal-ligand
complex of formula (I) and catalyst based on any one or more of the
following ligands (a) to (f) are excluded: ##STR00061## (a) Each D
is anthracen-9-yl; (b) Each D is
1,2,3,4,5,6,7,8-octahydroanthracen-9-yl; (c) Each D is
9H-carbozol-9-yl; or (d) Each D is
3,5-bis(1,1-dimethylethyl)phenyl; ##STR00062## (e) Each E is
1,1-dimethylethyl; or (f) Each E is methoxy.
2. The process as in claim 1, wherein at least one of R.sup.1a and
R.sup.1b is not a hydrogen atom or at least one of R.sup.2a and
R.sup.2b is hydrocarbyl having at least 4 carbon atoms or a
heterohydrocarbyl having at least 3 carbon atoms.
3. The process as in claim 1, wherein each Z is O.
4. The process as in claim 1, wherein each of R.sup.5c and R.sup.5d
independently is a 9H-carbazol-9-yl, 2,7-disubstituted
9H-carbazol-9-yl or 3,6-disubstituted 9H-carbazol-9-yl, wherein
each substituent is R.sup.S.
5. The process as in claim 4, wherein the metal-ligand complex of
formula (I) is a metal-ligand complex of formula (Ia), (If), or
(Ip): ##STR00063## wherein in formulas (Ip) and (Iq), R.sup.1a,
R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, and R.sup.3b, where
present, are not hydrogen and in formulas (Ia), (If), (Ip) and (Iq)
each R.sup.55 and R.sup.65 independently is hydrogen atom or an
unsubstituted (C.sub.1-C.sub.12)alkyl.
6. The process as in claim 1, wherein each of R.sup.5c and R.sup.5d
independently is a (C.sub.6-C.sub.40)aryl that is a
2,4-disubstituted phenyl wherein each substituent is R.sup.S;
2,5-disubstituted phenyl wherein each substituent is R.sup.S;
2,6-disubstituted phenyl wherein each substituent is R.sup.S;
3,5-disubstituted phenyl wherein each substituent is R.sup.S;
2,4,6-trisubstituted phenyl wherein each substituent is R.sup.S;
naphthyl or substituted naphthyl wherein each substituent is
R.sup.S; 1,2,3,4-tetrahydronaphthyl; anthracenyl;
1,2,3,4-tetrahydroanthracenyl;
1,2,3,4,5,6,7,8-octahydroanthracenyl; phenanthrenyl; or
1,2,3,4,5,6,7,8-octahydrophenanthrenyl.
7. The process as in claim 1, wherein the reactivity ratio r.sub.1
is greater than or equal to 20.
8. The process as in claim 1, wherein at least one of R.sup.1a,
R.sup.2a, R.sup.3a, and R.sup.3b is not methyl when R.sup.7c and
R.sup.7d are each methyl.
9. The process as in claim 1, wherein at least one of the one or
more than one metal-ligand complexes of formula (I) is any one of
metal-ligand complexes (1), (2), (10), (11), and (20) to (23):
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3',5'-difluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (1);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3',5'-dichloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (2);
(2',2''-(propane-1,3-diylbis(oxy))bis(3',5'-dimethyl-3-(3,6-di-tert-butyl-
-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (10);
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-ethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (11);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-5'-fluoro-3'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2--
ol))dimethyl-hafnium, (20);
(2',2''-(butane-1,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (21);
(2',2''-(ethane-1,2-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (22); and
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-zirconium, (23).
10. The process as in claim 1, wherein at least one of the one or
more than one metal-ligand complexes of formula (I) is metal-ligand
complex (3) or (13):
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (3); or
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-5'-fluoro-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (13).
11. The process as in claim 1, wherein at least one of the one or
more than one metal-ligand complexes of formula (I) is any one of
metal-ligand complexes (3a), (6a), (6b), (19a), (4) to (9), (12),
(14) to (19), (24), and (25):
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(9H-carbazol--
9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafn-
ium, (3a);
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert--
butyl-9H-carbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-
-ol))dimethyl-hafnium, (6a);
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-(1-methylethyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2--
ol))dimethyl-hafnium, (6b);
(2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))-(5''-c-
hloro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl-
)biphenyl-2-ol))dimethyl-hafnium, (19a);
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-octyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (4);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3'-chloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafniu-
m, (5);
(2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-but-
yl-9H-carbazol-9-yl)-5'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol-
))dimethyl-hafnium, (6);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafniu-
m, (7);
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-cyano-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
)dimethyl-hafnium, (8);
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-dimethylamino-3-(3,6-di-tert-but-
yl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol-
))dimethyl-hafnium, (9);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3'-methyl-5'-tert-butyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))d-
imethyl-hafnium, (12);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(9H-carbazol-9-yl)-5'-chloro-3'-m-
ethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafnium,
(14);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3'-methyl-5'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2--
ol))dimethyl-hafnium, (15);
(2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(3',5'-dichloro-3-
-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphen-
yl-2-ol))dimethyl-hafnium, (16);
(2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-
-di-tert-butyl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)b-
iphenyl-2-ol))dimethyl-hafnium, (17);
(2',2''-(propane-1,3-diylbis(oxy))bis(3'-bromo-5'-chloro-3-(3,6-di-tert-b-
utyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (18);
(2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(3'',5'-
'-dichloro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-
-2-yl)biphenyl-2-ol))dimethyl-hafnium, (19);
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3',5'-dichloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-t-
itanium, (24); and
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-titanium, (25).
12. The process as in claim 1, wherein at least one of the one or
more than one metal-ligand complexes of formula (I) is any one of
metal-ligand complexes (26) to (34):
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-methoxy-3-(3,6-di-tert-butyl-9H--
carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dime-
thyl-hafnium, (26);
(2',2''-(propane-1,3-diylbis(oxy))bis(3',4'-dimethyl-3-(3,6-di-tert-butyl-
-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (27);
(2',2''-(propane-1,3-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl--
hafnium, (28);
(2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-5'-(tert-butyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
)dimethyl-hafnium, (29);
(2',2''-(butane-1,4-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-tert-butyl-
-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (30);
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-4'-(tert-butyl)-3-(3,6-di-
-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
)dimethyl-hafnium, (31);
(2',2''-(pentane-1,5-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (32);
(2',2''-(pentane-2,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (33); and
(2',2''-(hexane-1,6-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (34).
13. A metal-ligand complex of formula (I) as described in claim
1.
14. A catalyst comprising or prepared from one or more metal-ligand
complexes of formula (I) as described in claim 13 and one or more
activating co-catalysts, or a reaction product thereof, wherein the
ratio of total number of moles of the one or more metal-ligand
complexes of formula (I) to total number of moles of the one or
more activating co-catalysts is from 1:10,000 to 100:1.
15. A ligand of formula (Q): ##STR00064## or a Group 1 or 2 metal
salt thereof, wherein the Group 1 or 2 metal is a cation of any one
of the metals of Groups 1 and 2 of the Periodic Table of the
Elements; and L, Z, R.sup.1a, R.sup.2a, R.sup.3a, R.sup.4a,
R.sup.1b, R.sup.2b, R.sup.3b, R.sup.4b, R.sup.5c, R.sup.6c,
R.sup.7c, R.sup.8c, R.sup.5d, R.sup.6d, R.sup.7d, and R.sup.8d are
as defined in claim 1 except at least one of R.sup.1a, R.sup.1b,
R.sup.3a, and R.sup.3b is not methyl when R.sup.7c and R.sup.7d are
each methyl.
16. The ligand as in claim 15, wherein the ligand is any one of
ligands (Q1), (Q2), (Q10), (Q11), and (Q20) to (Q22):
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3',5'-difluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q1);
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3',5'-dichloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q2);
2',2''-(propane-1,3-diylbis(oxy))bis(3',5'-dimethyl-3-(3,6-di-tert-butyl--
9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q10);
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-ethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q11);
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-5'-fluoro-3'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q20);
2',2''-(butane-1,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-bu-
tyl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q21); and
2',2''-(ethane-1,2-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q22).
17. The ligand as in claim 15, wherein the ligand is ligand (Q3) or
(Q13):
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
, (Q3); or
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-5'-fluoro-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2--
ol), (Q13).
18. The ligand as in claim 15, wherein the ligand is any one of
ligands (Q3a), (Q6a), (Q6b), (Q19a), (Q4) to (Q9), (Q12), and (Q14)
to (Q19):
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(9H-carbazol-9-yl)-3'-me-
thyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol), (Q3a);
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q6a);
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-3'-(1-methylethyl)-5-(2,4,4-trimethylpentan-2-yl)biphe-
nyl-2-ol), (Q6b);
2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-carb-
azol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(5''-chl-
oro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)b-
iphenyl-2-ol), (Q19a)
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-octyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q4);
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3'-chloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol), (Q5);
2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-5'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q6);
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol), (Q7);
2',2''-(propane-1,3-diylbis(oxy))bis(5'-cyano-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q8);
2',2''-(propane-1,3-diylbis(oxy))bis(5'-dimethylamino-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
, (Q9);
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carba-
zol-9-yl)-3'-methyl-5'-tert-butyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-
-ol), (Q12);
2',2''-(propane-1,3-diylbis(oxy))bis(3-(9H-carbazol-9-yl)-5'-chloro-3'-me-
thyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol), (Q14);
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3'-methyl-5'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q15);
2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(3',5'-d-
ichloro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2--
yl)biphenyl-2-ol), (Q16);
2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6--
di-tert-butyl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)bi-
phenyl-2-ol), (Q17);
2',2''-(propane-1,3-diylbis(oxy))bis(3'-bromo-5'-chloro-3-(3,6-di-tert-bu-
tyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q18); and
2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H--
carbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(3''-
,5''-dichloro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpen-
tan-2-yl)biphenyl-2-ol), (Q19).
19. The ligand as in claim 15, wherein the ligand is any one of
ligands (Q23) to (Q31):
2',2''-(pentane-1,5-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q23);
2',2''-(pentane-2,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
, (Q24);
2',2''-(hexane-1,6-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
, (Q25);
2',2''-(propane-1,3-diylbis(oxy))bis(5'-methoxy-3-(3,6-di-tert-bu-
tyl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q26);
2',2''-(propane-1,3-diylbis(oxy))bis(3',4'-dimethyl-3-(3,6-di-t-
ert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q27);
2',2''-(propane-1,3-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-ter-
t-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q28);
2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-5'-(tert-butyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-
-2-ol), (Q29);
2',2''-(butane-1,4-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-tert-butyl--
9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q30); and
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-4'-(tert-butyl)-3-(3,6-di--
tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q31).
Description
[0001] This application claims benefit under 35 U.S.C. .sctn.119(a)
of PCT International Application Number PCT/US2010/035096 filed May
17, 2010, and under 35 U.S.C. .sctn.119(e) of U.S. Provisional
Application No. 61/467,627 filed Mar. 25, 2011, and the entire
contents of both applications are hereby incorporated herein by
reference.
[0002] The present invention generally relates to a process that
selectively polymerizes ethylene in the presence of an
alpha-olefin, and to a metal-ligand complex (precatalyst) and
catalyst useful in such process, and to related compositions. The
present invention also generally relates to ligands and
intermediates useful for preparing the metal-ligand complex and to
processes of their preparation. Other related inventions are
described herein.
[0003] U.S. Pat. No. 6,869,904 B2 and U.S. Pat. No. 7,060,848 B2
mention, among other things, ligands, compositions, metal-ligand
complexes and arrays with substituted bridged bis-aromatic or
bridged bis-biaromatic ligands. The patents also mention methods of
making and using the same and catalysts useful in transformations
such as the polymerization of monomers into polymers. The catalysts
have, among other things, high comonomer incorporation into
ethylene/olefin copolymers, where such olefins are for example
1-octene, propylene or styrene. The catalysts also polymerize
propylene into isotactic polypropylene. Also mentioned are a number
of specific ligands including ligands LL102 to LL105. U.S. Pat. No.
6,869,904 B2 and U.S. Pat. No. 7,060,848 B2 do not mention or
disclose any species of a metal-ligand complex or catalyst wherein
the ligand is LL102, LL103, LL104, or LL105. Specific ligands
LL102, LL103, LL104, LL105, LL133, and LL144 are mentioned in US
2006/0025548 A1. PCT International Patent Application Publication
Number WO 2007/136494 A2 mentions, among other things, a catalyst
composition comprising a zirconium complex of a polyvalent aryloxy
ether and the use thereof in a continuous solution polymerization
of ethylene, one or more C3-C30 olefins, and a conjugated or
non-conjugated diene to prepare interpolymers having improved
processing properties. The catalyst system contains a catalyst
covalently bonded to an activator.
[0004] A problem addressed by the present invention includes
providing new processes and catalysts for selectively polymerizing
ethylene in the presence of an alpha-olefin.
BRIEF SUMMARY OF THE INVENTION
[0005] In some embodiments the present invention relates to a
process for selectively polymerizing ethylene in a mixture
comprising ethylene and an alpha-olefin, and to a metal-ligand
complex (precatalyst) and catalyst useful in such process, and to
related compositions. The present invention also generally relates
to ligands and intermediates useful for preparing the metal-ligand
complex and to processes of their preparation. Other related
inventions are described herein. The invention process is
especially useful for preparing polyethylenes, polyolefin mixtures
or blends, and poly(ethylene alpha-olefin copolymers), including
poly(ethylene alpha-olefin) block copolymers, also known as olefin
block copolymers.
[0006] In a first embodiment, the present invention is a process
for selectively polymerizing ethylene in the presence of an
alpha-olefin, the process comprising a step of contacting together
a catalytic amount of a catalyst, ethylene, and an alpha-olefin,
wherein the catalyst comprises a mixture or reaction product of
ingredients (a) and (b) that is prepared before the contacting
step, wherein ingredient (a) comprises a metal-ligand complex (also
referred to herein as a precatalyst) and ingredient (b) comprises
an activating co-catalyst; ethylene comprises ingredient (c); and
the alpha-olefin comprises ingredient (d) (ingredient letters are
for ease of reference herein); the metal-ligand complex of
ingredient (a) being one or more metal-ligand complexes of formula
(I):
##STR00001##
wherein:
[0007] M is titanium, zirconium, or hafnium, each independently
being in a formal oxidation state of +2, +3, or +4;
[0008] n is an integer of from 0 to 3, wherein when n is 0, X is
absent (i.e., (X).sub.n is absent);
[0009] Each X independently is a monodentate ligand that is
neutral, monoanionic, or dianionic; or two X are taken together to
form a bidentate ligand that is neutral, monoanionic, or
dianionic;
[0010] X and n are chosen in such a way that the metal-ligand
complex of formula (I) is, overall, neutral;
[0011] Each Z independently is O, S, Nhydrocarbyl, or
Phydrocarbyl;
[0012] L is hydrocarbylene or heterohydrocarbylene, wherein the
hydrocarbylene has a portion that comprises a 1-carbon atom to
6-carbon atom linker backbone linking the Z atoms in formula (I)
(to which L is bonded) and the heterohydrocarbylene has a portion
that comprises a 1-atom to 6-atom linker backbone linking the Z
atoms in formula (I), wherein each atom of the 1-atom to 6-atom
linker backbone of the heterohydrocarbylene independently is a
carbon atom or heteroatom, wherein each heteroatom independently is
O, S, S(O), S(O).sub.2, Si(R.sup.C).sub.2, Ge(R.sup.C).sub.2,
P(R.sup.P), or N(R.sup.N), wherein independently each R.sup.C is
unsubstituted (C.sub.1-C.sub.18)hydrocarbyl or the two R.sup.C are
taken together to form a (C.sub.2-C.sub.19)alkylene (e.g., the two
R.sup.C together with the silicon atom to which they are both
bonded form a 3-membered to 20-membered silacycloalkyl), each
R.sup.P is unsubstituted (C.sub.1-C.sub.18)hydrocarbyl; and each
R.sup.N is unsubstituted (C.sub.1-C.sub.18)hydrocarbyl, a hydrogen
atom or absent (e.g., absent when N comprises --N.dbd. as in a
N-containing heteroaryl);
[0013] At least one of R.sup.1a, R.sup.2a, R.sup.1b, and R.sup.2b
independently is a hydrocarbyl, heterohydrocarbyl, or halogen atom;
and each of the others of R.sup.1a, R.sup.2a, R.sup.1b, and
R.sup.2b independently is a hydrogen, atom, hydrocarbyl,
heterohydrocarbyl, or halogen atom;
[0014] Each of R.sup.3a, R.sup.4a, R.sup.3b, R.sup.4b, R.sup.6c,
R.sup.7c, R.sup.8c, R.sup.6d, R.sup.7d, and R.sup.8d independently
is a hydrogen atom; hydrocarbyl; heterohydrocarbyl; or halogen
atom;
[0015] Each of R.sup.5c and R.sup.5d independently is an aryl or
heteroaryl;
[0016] Each of the aforementioned aryl, heteroaryl, hydrocarbyl,
heterohydrocarbyl, hydrocarbylene, and heterohydrocarbylene groups
independently is unsubstituted or substituted with one or more
substituents R.sup.S (up to and including persubstitution by
R.sup.S); and
[0017] Each R.sup.S independently is a halogen atom, polyfluoro
substitution (that is one of the one or more substituents R.sup.S
stands for two or more fluoro substituents, which formally
respectively replace two or more hydrogen atoms of an unsubstituted
version of the substituted group), perfluoro substitution (that is
the one R.sup.S stands for as many fluoro substituents as
carbon-bonded hydrogen atoms (i.e., H--C) of an unsubstituted
version of the substituted group that is substituted thereby),
unsubstituted (C.sub.1-C.sub.18)alkyl, F.sub.3C--, FCH.sub.2O--,
F.sub.2HCO--, F.sub.3CO--, R.sub.3Si--, R.sub.3Ge--, RO--, RS--,
RS(O)--, RS(O).sub.2--, R.sub.2P--, R.sub.2N--, R.sub.2C.dbd.N--,
NC--, RC(O)O--, ROC(O)--, RC(O)N(R)--, or R.sub.2NC(O)--, or two of
the R.sup.S are taken together to form an unsubstituted
(C.sub.1-C.sub.18)alkylene, wherein each R independently is an
unsubstituted (C.sub.1-C.sub.18)alkyl;
[0018] wherein the activating co-catalyst of the ingredient (b)
comprises one or more activating co-catalysts, or a reaction
product thereof, wherein the ratio of total number of moles of the
one or more metal-ligand complexes of formula (I) to total number
of moles of the one or more activating co-catalysts is from
1:10,000 to 100:1;
[0019] wherein the contacting step is performed under olefin
polymerizing conditions (described later) and prepares a rich
polyethylene in presence of unpolymerized alpha-olefin (e.g., a
(C.sub.3-C.sub.40)alpha-olefin); and
[0020] wherein the process forms reactive chains (in situ) and is
characterizable by a reaction rate constant k.sub.11 for adding the
ethylene (a monomer) to a first reactive chain end comprising an
ethylene residual; a reaction rate constant k.sub.12 for adding the
alpha-olefin (a comonomer) to a second reactive chain end
comprising an ethylene residual; and a reactivity ratio r.sub.1
equal to k.sub.11 divided by k.sub.12 of greater than 14,
preferably greater than or equal to 20 (i.e.,
r.sub.1=k.sub.11/k.sub.12.gtoreq.20). For determining r.sub.1,
preferably the olefin polymerization conditions comprise a
polymerization temperature of at least 140 degrees Celsius
(.degree. C.). Preferably, the polymerization temperature for
determining r.sub.1 is at most 190.degree. C. The General procedure
for selective polymerization of ethylene in the presence of a
(C.sub.3-C.sub.40)alpha-olefin described later is preferred for
determining r.sub.1.
[0021] The first and second reactive chain ends, and thus the
ethylene residuals thereof, can be different or, preferably, the
same. The term "rich polyethylene" means a polymeric molecule, or
rich polyethylene segment thereof, substantially comprising
ethylene repeat units (as a result of high ethylene polymerization
selectivity characterized by the high reactivity ratio r.sub.1); or
a mixture or blend of two or more such polymeric molecules. For
example, in some embodiments the rich polyethylene segment of the
latter polymeric molecule typically is a portion of a poly(ethylene
alpha-olefin) copolymer. The invention process can prepare the
poly(ethylene alpha-olefin) copolymer when it further employs an
optional promiscuous olefin polymerization catalyst according to
one of the embodiments described later, including preparing a
poly(ethylene alpha-olefin) block copolymer according to one of the
chain shuttling embodiments described later. In other embodiments
the invention process produces a rich polyethylene or a polyolefin
blend or mixture comprising the rich polyethylene, preferably
wherein the rich polyethylene contains no or a minimal amount
(e.g., less than 5 mole percent by nuclear magnetic resonance) of
alpha-olefin-derived repeat units.
[0022] In a second embodiment the present invention is the catalyst
comprising or prepared from the one or more metal-ligand complexes
of formula (I) and one or more activating co-catalysts, or a
reaction product thereof (i.e., a reaction product of a reaction of
at least one of the one or more metal-ligand complexes of formula
(I) with at least one of the one or more activating co-catalysts),
wherein the ratio of total number of moles of the one or more
metal-ligand complexes of formula (I) to total number of moles of
the one or more activating co-catalysts is from 1:10,000 to 100:1.
Typically, the catalyst is prepared in a suitable aprotic solvent
(e.g., alkane(s), aromatic hydrocarbon(s), excess olefin monomer,
or a mixture thereof).
[0023] The present invention also contemplates a catalyst system
(i.e., a catalyst composition) comprising the aforementioned
ingredients (a) and (b). In some embodiments the invention catalyst
system further comprises a molecular weight control agent as an
ingredient (e), and, optionally the promiscuous olefin
polymerization catalyst as an ingredient (f). Ingredients (e) and
(f) are described later. The invention also contemplates additional
ingredients of the catalyst system as described later.
[0024] In another embodiment the present invention is the
metal-ligand complex of formula (I).
[0025] In still another embodiment the present invention is a
ligand of formula (Q):
##STR00002##
or a Group 1 or 2 metal salt thereof, wherein the Group 1 or 2
metal is a cation of any one of the metals of Groups 1 and 2 of the
Periodic Table of the Elements; and L, Z, R.sup.1a, R.sup.2a,
R.sup.3a, R.sup.4a, R.sup.1b, R.sup.2b, R.sup.3b, R.sup.4b,
R.sup.5c, R.sup.6c, R.sup.7c, R.sup.8c, R.sup.5d, R.sup.6d,
R.sup.7d, and R.sup.8d are as defined previously except at least
one of R.sup.1a, R.sup.2a, R.sup.3a, and R.sup.3b is not methyl
when R.sup.7c and R.sup.7d are each methyl.
[0026] The invention also contemplates a process for preparing the
metal-ligand complex of formula (I); a process for preparing the
ligand of formula (Q) or the Group 1 or 2 metal salt thereof; and
contemplates intermediates in the preparation thereof. The
processes are as described later herein.
[0027] The ligand of formula (Q) or the Group 1 or 2 metal salt
thereof, is useful in the process of preparing the metal-ligand
complex of formula (I), which in turn is useful in the process of
preparing the invention catalyst.
[0028] The metal-ligand complex of formula (I) and invention
catalyst derived therefrom with the one or more activating
co-catalysts are useful in the invention process. Preferred
embodiments of the invention process independently are
characterizable by one or more activities of the invention
catalyst, one or more properties of the polyolefin prepared
thereby, or a combination thereof. Especially preferred properties
are those improved over closest prior art, if any. The invention
process is characterizable by its aforementioned high selectivity
for polymerizing ethylene in presence of the alpha-olefin (e.g.,
(C.sub.3-C.sub.40)alpha-olefin) or other polymerizable olefin
(e.g., styrene). This high ethylene polymerizing selectivity is
surprising. Upon careful investigation and without being bound by
theory, it has been discovered from 3-dimensional x-ray crystal
structures of some of the metal-ligand complexes of formula (I)
that R.sup.5c sterically interacts with either R.sup.1a or
R.sup.2a, or both R.sup.1a and R.sup.2a, as the case may be; or
R.sup.5d sterically interacts with either R.sup.1b or R.sup.2b, or
both R.sup.1b and R.sup.2b, as the case may be; or a combination of
such steric interactions thereof when the at least one of R.sup.1a,
R.sup.1b, R.sup.2a, and R.sup.2b, or the aforementioned
combinations thereof, is not a hydrogen atom. In some embodiments
at least one of R.sup.1a and R.sup.1b is not a hydrogen atom or at
least one of R.sup.2a and R.sup.2b is hydrocarbyl having at least 4
carbon atoms or a heterohydrocarbyl having at least 3 carbon atoms.
It is also believed that these steric interactions happen in such a
way so as to cause the invention catalyst prepared from the
metal-ligand complex of formula (I) to polymerize ethylene more
selectively than it polymerizes the sterically larger alpha-olefin
(or other larger olefin comonomer) during the invention process
(i.e., the invention catalyst preferentially polymerizes ethylene
in the presence of the alpha-olefin). Again without being bound by
theory, it is believed that such steric interactions cause the
invention catalyst prepared with or from the metal-ligand complex
of formula (I) to adopt a conformation that allows ethylene to
access the M substantially more easily than the invention catalyst
allows the alpha-olefin to do so. The resulting difference in
polymerization rates (i.e., selectivity) between ethylene and the
alpha-olefin with the invention catalyst in the invention process
can be characterized by the aforementioned reactivity ratio
r.sub.1. These valuable steric interactions have been discovered
for the metal-ligand complex of formula (I). Accordingly, the
process of the first embodiment (also referred to herein as the
"invention process") selectively gives the rich polyethylene (e.g.,
a high density polyethylene) or rich polyethylene segment of the
poly(ethylene alpha-olefin) copolymer in the presence of
alpha-olefin, which is substantially unpolymerized thereby.
[0029] The invention process advantageously is versatile. For
example in some embodiments the invention process can be adapted as
described later to further employ a molecular weight control agent
so as to prepare a molecular weight-controlled rich polyethylene or
molecular weight-controlled poly(ethylene alpha-olefin) copolymer,
as the case may be. In some embodiments the invention process can
be adapted as described later to further employ a combination of a
chain shuttling agent (CSA) and a promiscuous olefin polymerization
catalyst so as to prepare the poly(ethylene alpha-olefin)
copolymer, and preferably a poly(ethylene alpha-olefin) block
copolymer. The poly(ethylene alpha-olefin) block copolymer
comprises one or more rich polyethylene segments and one or more
segments having higher mole percent incorporation of the
alpha-olefin (as a residual thereof) than has the rich polyethylene
segment(s). The rich polyethylene segment(s) of the poly(ethylene
alpha-olefin) block copolymer are sometimes referred to herein as
polyethylene hard segment(s) or simply hard segments. The segments
of the poly(ethylene alpha-olefin) block copolymer having the
higher mole percent incorporation of the alpha-olefin are formed
with the invention process further employing a promiscuous olefin
polymerization catalyst having a reactivity ratio r.sub.1<10 and
are sometimes referred to herein as soft segments. The CSA shuttles
a growing polymeryl chain between the invention catalyst and the
promiscuous olefin polymerization catalyst. Thus the poly(ethylene
alpha-olefin) block copolymer so prepared comprises hard and soft
segments. In other embodiments the invention process lacks a CSA
and can be adapted as described later to prepare a polyolefin
polymer blend or mixture, wherein at least one polyolefin of the
polymer blend or mixture comprises at least a rich polyolefin or
the rich polyethylene segment of the poly(ethylene alpha-olefin)
copolymer.
[0030] In other examples of the versatility of the invention
process, the rich polyethylene or rich polyethylene
segment-containing poly(ethylene alpha-olefin) copolymer prepared
by the invention process can be readily separated, if desired, from
any remaining (unpolymerized) ethylene and polymerizable higher
olefin monomer (e.g., (C.sub.3-C.sub.40)alpha-olefin) by
conventional means (e.g., filtering/washing the rich
polyethylene-containing material or stripping or evaporating of the
higher polymerizable olefin monomer). The process of the present
invention works with any mole ratio of moles of alpha-olefin to
moles of ethylene. Another advantage of the present invention
process is that it is capable of preparing the rich polyethylene or
rich polyethylene segment of the poly(ethylene alpha-olefin)
copolymer in circumstances where it would be desirable to do so in
the presence of the larger polymerizable olefin (i.e., a higher
polymerizable olefin wherein "higher" means higher number of carbon
atoms). Such circumstances include, but are not limited to, use of
ethylene/alpha-olefin feed mixtures to prepare the aforementioned
polyolefin polymer blend or mixture, wherein at least one
polyolefin of the polyolefin polymer blend or mixture comprises the
rich polyethylene or the rich polyethylene segment of the
poly(ethylene alpha-olefin) copolymer. Another advantage is that in
some embodiments the invention process functions as a continuous
process that is capable of preparing in some embodiments new
polyolefin polymer blends or mixtures or new poly(ethylene
alpha-olefin) block copolymers, both of which are thus part of the
present invention.
[0031] The invention process advantageously can prepare novel rich
polyethylenes and rich polyethylene segment-containing polyolefins.
Thus, the present invention also contemplates new rich
polyethylenes and rich polyethylene segment-containing
poly(ethylene alpha-olefin) copolymers, including block copolymers
thereof, i.e., the poly(ethylene alpha-olefin) block copolymers,
prepared by the invention process. Further the rich polyethylenes
prepared by the invention process typically contain vinyl groups.
The invention also contemplates modified polymers prepared by
functionalizing by known means such vinyl groups to give polar
group functionalized derivatives thereof. If desired the polar
group functionalized derivatives can be reacted with
complimentary-reacting monomers or oligomers so as to form polar
group functionalized copolymers.
[0032] As used herein the term "poly(ethylene alpha-olefin) block
copolymer" is used interchangeably herein with the terms "olefin
block copolymer," "OBC," "ethylene/.alpha.-olefin block
interpolymer," and "ethylene/.alpha.-olefin block copolymer". The
terms "alpha-olefin" and ".alpha.-olefin" are used interchangeably
herein. The term "ethylene" means ethene, i.e.,
H.sub.2C.dbd.CH.sub.2. The term "olefin block copolymer" means at
least one molecule comprising at least two chemically distinct
polyolefinyl segments wherein adjacent polyolefinyl segments are
covalently bonded to each other and are preferably joined
end-to-end in a linear manner. Preferably OBC means a composition
that contains a sufficient amount of such molecules such that the
composition may be properly classified as a block copolymer. In a
preferred embodiment at least some of the blocks differ in a manner
as described in U.S. Pat. No. 7,858,706 B2, column 8, line 61, to
column 9, line 2.
[0033] The rich polyethylenes (e.g., a high density polyethylene)
and rich polyethylene-containing materials (e.g., the rich
polyethylene-containing poly(ethylene alpha-olefin) copolymers,
including the poly(ethylene alpha-olefin) block copolymers)
prepared by embodiments of the invention process are useful in
numerous applications such as, for example, synthetic lubricants
and, especially for the OBCs, elastic films for hygiene
applications (e.g., for diaper covers); flexible molded goods for
appliances, tools, consumer goods (e.g., toothbrush handles),
sporting goods, building and construction components, automotive
parts, and medical applications (e.g., medical devices); flexible
gaskets and profiles for appliance (e.g., refrigerator door gaskets
and profiles), building and construction, and automotive
applications; adhesives for packaging (e.g., for use in
manufacturing corrugated cardboard boxes), hygiene applications,
tapes, and labels; and foams for sporting goods (e.g., foam mats),
packaging, consumer goods, and automotive applications.
[0034] Additional embodiments are described in the drawings and the
remainder of the specification, including the claims.
BRIEF DESCRIPTION OF THE DRAWING(S)
[0035] Some embodiments of the present invention are described
herein in relation to the accompanying drawing(s), which will at
least assist in illustrating various features of the
embodiments.
[0036] FIG. 1 shows an illustrative procedure of Scheme 1 for
preparing a first primary intermediate useful in a convergent
synthesis of the ligand of formula (Q).
[0037] FIG. 2 shows an illustrative procedure of Scheme 2 for
preparing a second primary intermediate useful in the convergent
synthesis of the ligand of formula (Q).
[0038] FIG. 3 shows an illustrative procedure of Scheme 3 for
preparing the ligand of formula (Q) from the first and second
primary intermediates.
[0039] FIG. 4 shows an illustrative procedure of Scheme 4 for
preparing the metal-ligand complex of formula (I) from the ligand
of formula (Q).
[0040] FIG. 5 shows structures of ligands (Q1) to (Q8) of Examples
Q1 to Q8.
[0041] FIG. 6 shows structures of ligands (Q9) to (Q16) of Examples
Q9 to Q16.
[0042] FIG. 7 shows structures of ligands (Q17) to (Q24) of
Examples Q17 to Q24.
[0043] FIG. 8 shows an Oak Ridge Thermal Ellipsoid Plot (ORTEP)
depiction of a single crystal structure derived by x-ray analysis
of invention metal-ligand complex (2) (Example 2) with hydrogen
atoms omitted for clarity.
[0044] FIG. 9 shows an ORTEP depiction of a single crystal
structure derived by x-ray analysis of invention metal-ligand
complex (3) (Example 3) with hydrogen atoms omitted for
clarity.
[0045] FIG. 10 shows structures of metal-ligand complexes (1) to
(8) of Examples 1 to 8.
[0046] FIG. 11 shows structures of metal-ligand complexes (9) to
(16) of Examples 9 to 16.
[0047] FIG. 12 shows structures of metal-ligand complexes (17) to
(24) of Examples 17 to 24.
[0048] FIG. 13 shows structures of metal-ligand complexes (25) to
(32) of Examples 25 to 32.
[0049] FIG. 14 shows structures of ligands (Q25) to (Q31) of
Examples Q25 to Q31.
[0050] FIG. 15 shows structures of metal-ligand complexes (33) and
(34) of Examples 33 and 34.
DETAILED DESCRIPTION OF THE INVENTION
[0051] The various embodiments of the present invention that are
summarized previously are incorporated here by reference. For
convenience, the rich polyethylene and rich polyethylene segment of
the poly(ethylene alpha-olefin) copolymer is sometimes referred to
herein simply as the rich polyethylene. Preferably, every aspect of
the invention excludes every metal-ligand complex of formula (I)
and catalyst based on any one or more of the following ligands:
##STR00003##
[0052] (a) Each D is anthracen-9-yl;
[0053] (b) Each D is 1,2,3,4,5,6,7,8-octahydroanthracen-9-yl;
[0054] (c) Each D is 9H-carbozol-9-yl; or
[0055] (d) Each D is 3,5-bis(1,1-dimethylethyl)phenyl;
##STR00004##
[0056] (e) Each E is 1,1-dimethylethyl; or
[0057] (f) Each E is methoxy.
[0058] Ligands (a) to (f) are the same as ligands LL102, LL103,
LL104, LL105, LL133, and LL144, respectively, of US
2006/0025548A1.
[0059] As indicated by the aforementioned usefulness of the ligand
of formula (Q) or the Group 1 or 2 metal salt thereof, in the
process of preparing the metal-ligand complex of formula (I), which
in turn is useful in the process of preparing the invention
catalyst, and as illustrated in FIG. 4, in some embodiments, the
metal-ligand complex of formula (I) is prepared with the ligand of
formula (Q) such that in formula (I) at least one of R.sup.1a,
R.sup.1b, R.sup.3a, R.sup.3b is not methyl when R.sup.7c and
R.sup.7d are each methyl, and the catalyst is preferably prepared
with or from such metal ligand complex of formula (I), and the
process preferably employs such catalyst.
[0060] Unless otherwise stated, each U.S. patent and patent
application, or if portions are referenced only the portions
thereof, referenced in this Detailed Description of the Present
Invention is hereby incorporated herein by reference.
[0061] In the present application, any lower limit of a range of
numbers, or any preferred lower limit of the range, may be combined
with any upper limit of the range, or any preferred upper limit of
the range, to define a preferred aspect or embodiment of the range.
Each range of numbers includes all numbers, both rational and
irrational numbers, subsumed within that range (e.g., the range
from about 1 to about 5 includes, for example, 1, 1.5, 2, 2.75, 3,
3.80, 4, and 5).
[0062] Conflict Resolution: what is written in the present
specification controls any conflict with what is written in a
patent or patent application publication, or a portion thereof that
is incorporated by reference. The structure controls any conflict
with a compound name. Any non-international system of units value
controls any conflict with an International System (SI) of Units
value. A drawing controls any conflict with the written description
thereof.
[0063] In some embodiments, each of the chemical groups (e.g., X,
L, R.sup.1a, etc.) of the metal-ligand complex of formula (I) is
unsubstituted, that is, can be defined without use of a substituent
R.sup.S. In other embodiments, at least one of the chemical groups
of the metal-ligand complex of formula (I) independently contain
one or more of the substituents R.sup.S. Preferably, accounting for
all chemical groups, there are not more than a total of 20 R.sup.S,
more preferably not more than a total of 10 R.sup.S, and still more
preferably not more than a total of 5 R.sup.S in the metal-ligand
complex of formula (I). Where the invention compound contains two
or more substituents R.sup.S, each R.sup.S independently is bonded
to a same or different substituted chemical group. When two or more
R.sup.S are bonded to a same chemical group, they independently are
bonded to a same or different carbon atom or heteroatom, as the
case may be, in the same chemical group up to and including
persubstitution of the chemical group.
[0064] The term "persubstitution" means each hydrogen atom (H)
bonded to a carbon atom or heteroatom of a corresponding
unsubstituted compound or functional group, as the case may be, is
replaced by a substituent (e.g., R.sup.S). The term
"polysubstitution" means at least two, but not all, hydrogen atoms
(H) bonded to carbon atoms or heteroatoms of a corresponding
unsubstituted compound or functional group, as the case may be, are
replaced by substituents (e.g., R.sup.S). In some embodiments, at
least one R.sup.S is polyfluoro substitution or perfluoro
substitution. For present purposes "polyfluoro substitution" and
"perfluoro substitution" each count as one R.sup.S substituent. In
some embodiments each R.sup.S independently is selected from a
group consisting of a halogen atom and any one of polyfluoro
substitution, unsubstituted (C.sub.1-C.sub.18)alkyl, F.sub.3C--,
FCH.sub.2O--, F.sub.2HCO--, F.sub.3CO--, R.sub.3Si--, R.sub.3Ge--,
RO--, RS--, RS(O)--, RS(O).sub.2--, R.sub.2P--, R.sub.2N--,
R.sub.2C.dbd.N--, NC--, RC(O)O--, ROC(O)--, RC(O)N(R)--, and
R.sub.2NC(O)--, wherein each R independently is an unsubstituted
(C.sub.1-C.sub.18)alkyl. In some embodiments each R.sup.S
independently is selected from a group consisting of a halogen
atom, unsubstituted (C.sub.1-C.sub.18)alkyl, and any one of
polyfluoro substitution, F.sub.3C--, FCH.sub.2O--, F.sub.2HCO--,
F.sub.3CO--, R.sub.3Si--, R.sub.3Ge--, RO--, RS--, RS(O)--,
RS(O).sub.2--, R.sub.2P--, R.sub.2N--, R.sub.2C.dbd.N--, NC--,
RC(O)O--, ROC(O)--, RC(O)N(R)--, and R.sub.2NC(O)--. In some
embodiments each R.sup.S independently is selected from a group
consisting of an unsubstituted (C.sub.1-C.sub.18)alkyl and any one
of F.sub.3C--, FCH.sub.2O--, F.sub.2HCO--, F.sub.3CO--,
R.sub.3Si--, R.sub.3Ge--, RO--, RS--, RS(O)--, RS(O).sub.2--,
R.sub.2P--, R.sub.2N--, R.sub.2C.dbd.N--, NC--, RC(O)O--, ROC(O)--,
RC(O)N(R)--, and R.sub.2NC(O)--. In some embodiments two R.sup.S
are taken together to form an unsubstituted
(C.sub.1-C.sub.18)alkylene. Still more preferably substitutents
R.sup.S independently are unsubstituted (C.sub.1-C.sub.18)alkyl, F,
unsubstituted (C.sub.1-C.sub.18)alkylene, or a combination thereof;
and even more preferably unsubstituted (C.sub.1-C.sub.8)alkyl or
unsubstituted (C.sub.1-C.sub.8)alkylene. The
(C.sub.1-C.sub.18)alkylene and (C.sub.1-C.sub.8)alkylene
substituents are especially useful for forming substituted chemical
groups that are bicyclic or tricyclic analogs, as the case may be,
of corresponding monocyclic or bicyclic unsubstituted chemical
groups.
[0065] The term "hydrocarbylene" means a hydrocarbon diradical
having at least one carbon atom wherein each hydrocarbon diradical
independently is aromatic or non-aromatic; saturated or
unsaturated; straight chain or branched chain; cyclic or acyclic;
unsubstituted or substituted; or a combination of at least two
thereof. The radicals of the hydrocarbon diradical can be on same
or, preferably, different carbon atoms. The term "alkylene" is a
hydrocarbylene wherein the hydrocarbon diradical is non-aromatic,
saturated, straight chain or branched, acyclic, and unsubstituted
or substituted. The term "hydrocarbyl" is as defined previously for
hydrocarbylene except whereas hydrocarbylene is the diradical, the
hydrocarbyl is a monoradical and so has a hydrogen atom in place of
the second radical of the diradical. The term "alkyl" is a
hydrocarbyl wherein the hydrocarbon radical is non-aromatic,
saturated, straight chain or branched, acyclic, and unsubstituted
or substituted. Preferably, the substituent of the substituted
alkyl is aryl. The term "heterohydrocarbylene" means a
heterohydrocarbon diradical having at least one carbon atom and
from 1 to 6 heteroatoms; wherein each heterohydrocarbon diradical
independently is aromatic or non-aromatic; saturated or
unsaturated; straight chain or branched chain; cyclic or acyclic;
unsubstituted or substituted; or a combination of at least two
thereof. The radicals of the heterohydrocarbon diradical can be on
same or, preferably, different atoms, each radical-bearing atom
independently being carbon or heteroatom. The term
"heterohydrocarbyl" is as defined previously for
heterohydrocarbylene except whereas heterohydrocarbylene is the
diradical, the heterohydrocarbyl is a monoradical.
[0066] In some embodiments the present invention contemplates
unsubstituted chemical groups or molecules described herein have an
upper limit of at most 40 carbon atoms, but the invention includes
other embodiments having upper limits of lower or higher numbers of
carbon atoms (e.g., at most any one of 4, 6, 8, 10, 12, 15, 20, 30,
39, 60, 100, 1,000, and 100,000 carbons). Likewise in some
embodiments the present invention contemplates such unsubstituted
chemical groups or molecules have a lower limit of at least 1
carbon atom, but the invention includes embodiments having higher
lower limits (e.g., at least any one of 2, 3, 4, 5, 6, 7, and 8
carbons), especially higher lower limits as would be well known for
a smallest aspect of the chemical group or molecule (e.g., at least
3 carbons for a cycloalkyl or alpha-olefin).
[0067] Preferably, each hydrocarbyl independently is an
unsubstituted or substituted alkyl, cycloalkyl (having at least 3
carbon atoms),
(C.sub.3-C.sub.20)cycloalkyl-(C.sub.1-C.sub.20)alkylene, aryl
(having at least 6 carbon atoms), or
(C.sub.6-C.sub.20)aryl-(C.sub.1-C.sub.20)alkylene. Preferably, each
of the aforementioned hydrocarbyl groups independently has a
maximum of 40, more preferably 20, and still more preferably 12
carbon atoms.
[0068] Preferably, each alkyl independently has a maximum of 40,
more preferably 20, sill more preferably 12, and still more
preferably 8 carbon atoms. Examples of unsubstituted
(C.sub.1-C.sub.40)alkyl are unsubstituted (C.sub.1-C.sub.20)alkyl;
unsubstituted (C.sub.1-C.sub.10)alkyl; unsubstituted
(C.sub.1-C.sub.5)alkyl; methyl; ethyl; 1-propyl; 2-propyl; 1-butyl;
2-butyl; 2-methylpropyl; 1,1-dimethylethyl; 1-pentyl; 1-hexyl;
1-heptyl; 1-nonyl; and 1-decyl. Examples of substituted
(C.sub.1-C.sub.40)alkyl are substituted (C.sub.1-C.sub.20)alkyl,
substituted (C.sub.1-C.sub.10)alkyl, trifluoromethyl, and
(C.sub.45)alkyl. The (C.sub.45)alkyl is, for example, a
(C.sub.27-C.sub.40)alkyl substituted by one R.sup.S, which is a
(C.sub.18-C.sub.5)alkyl, respectively. Preferably, each
(C.sub.1-C.sub.5)alkyl independently is methyl, trifluoromethyl,
ethyl, 1-propyl, 2-methylethyl, or 1,1-dimethylethyl.
[0069] Preferably, each aryl independently has from 6 to 40 carbon
atoms. The term "(C.sub.6-C.sub.40)aryl" means an unsubstituted or
substituted (by at least one R.sup.S) mono-, bi- or tricyclic
aromatic hydrocarbon radical of from 6 to 40, preferably from 6 to
14, ring carbon atoms, and the mono-, bi- or tricyclic radical
comprises 1, 2 or 3 rings, respectively, wherein the 1 ring is
aromatic; at least one of the 2 or 3 rings is aromatic; and the 2
or 3 rings independently are fused or non-fused. Other aryl groups
(e.g., (C.sub.6-C.sub.10)aryl)) are defined in an analogous manner.
Preferably, (C.sub.6-C.sub.40)aryl has a maximum of 20 carbon atoms
(i.e., (C.sub.6-C.sub.20)aryl), more preferably 18 carbon atoms,
still more preferably 10 carbon atoms, and even more preferably 6
carbon atoms. Examples of unsubstituted (C.sub.6-C.sub.40)aryl are
unsubstituted (C.sub.6-C.sub.20)aryl; unsubstituted
(C.sub.6-C.sub.18)aryl; phenyl; (C.sub.3-C.sub.6)cycloalkyl-phenyl;
fluorenyl; tetrahydrofluorenyl; indacenyl; hexahydroindacenyl;
indenyl; dihydroindenyl; naphthyl; tetrahydronaphthyl; and
phenanthrene. Examples of substituted (C.sub.6-C.sub.40)aryl are
substituted (C.sub.6-C.sub.20)aryl; substituted (C.sub.6-C.sub.18)
aryl; 2-(C.sub.1-C.sub.5)alkyl-phenyl;
2,4-bis(C.sub.1-C.sub.5)alkyl-phenyl;
2,4-bis[(C.sub.20)alkyl]-phenyl; polyfluorophenyl;
pentafluorophenyl; and fluoren-9-one-1-yl.
[0070] Preferably, each cycloalkyl independently has from 3 to 40
carbon atoms. The term "(C.sub.3-C.sub.40)cycloalkyl" means a
saturated cyclic hydrocarbon radical of from 3 to 40 carbon atoms
that is unsubstituted or substituted by at least one R.sup.S. Other
cycloalkyl groups (e.g., (C.sub.3-C.sub.12)alkyl)) are defined in
an analogous manner. Preferably, (C.sub.3-C.sub.40)cycloalkyl has a
maximum of 20 carbon atoms (i.e., (C.sub.3-C.sub.30)cycloalkyl),
more preferably 10 carbon atoms, and still more preferably 6 carbon
atoms. Examples of unsubstituted (C.sub.3-C.sub.40)cycloalkyl are
unsubstituted (C.sub.3-C.sub.20)cycloalkyl, unsubstituted
(C.sub.3-C.sub.10)cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
Examples of substituted (C.sub.3-C.sub.40)cycloalkyl are
substituted (C.sub.3-C.sub.20)cycloalkyl, substituted
(C.sub.3-C.sub.10)cycloalkyl, cyclopentanon-2-yl, and
1-fluorocyclohexyl.
[0071] Preferably, each hydrocarbylene independently has from 1 to
40 carbon atoms. Examples of (C.sub.1-C.sub.40)hydrocarbylene are
unsubstituted or substituted (C.sub.6-C.sub.40)arylene,
(C.sub.3-C.sub.40)cycloalkylene, and (C.sub.1-C.sub.40)alkylene
(e.g., (C.sub.1-C.sub.20)alkylene). In some embodiments, the
diradicals are on a same carbon atom (e.g., --CH.sub.2--) or on
adjacent carbon atoms (i.e., 1,2-diradicals), or are spaced apart
by one, two, etc. intervening carbon atoms (e.g., respective
1,3-diradicals, 1,4-diradicals, etc.). Preferred is a 1,2-, 1,3-,
1,4-, or an alpha, omega-diradical, and more preferably a
1,2-diradical. The alpha, omega-diradical is a diradical that has a
maximum carbon backbone spacing between the radical carbons. More
preferred is a 1,2-diradical version of (C.sub.6-C.sub.18)arylene,
(C.sub.3-C.sub.20)cycloalkylene, or (C.sub.2-C.sub.20)alkylene; a
1,3-diradical version of (C.sub.6-C.sub.18)arylene,
(C.sub.4-C.sub.20)cycloalkylene, or (C.sub.3-C.sub.20)alkylene; or
a 1,4-diradical version of (C.sub.6-C.sub.18)arylene,
(C.sub.6-C.sub.20)cycloalkylene, or (C.sub.4-C.sub.20)alkylene.
[0072] Preferably, each alkylene independently has from 1 to 40
carbon atoms. The term "(C.sub.1-C.sub.40)alkylene" means a
saturated straight chain or branched chain diradical (i.e., the
radicals are not on ring atoms) of from 1 to 40 carbon atoms that
is unsubstituted or substituted by at least one R.sup.S. Other
alkylene groups (e.g., (C.sub.1-C.sub.12)alkylene)) are defined in
an analogous manner. Examples of unsubstituted
(C.sub.1-C.sub.40)alkylene are unsubstituted
(C.sub.1-C.sub.20)alkylene, including unsubstituted
1,2-(C.sub.2-C.sub.10)alkylene; 1,4-(C.sub.4-C.sub.10)alkylene;
--CH.sub.2--, --CH.sub.2CH.sub.2--, --(CH.sub.2).sub.3--,
##STR00005##
--(CH.sub.2).sub.4--, --(CH.sub.2).sub.5--, --(CH.sub.2).sub.6--,
--(CH.sub.2).sub.7--, --(CH.sub.2).sub.8--, and
--(CH.sub.2).sub.4C(H)(CH.sub.3)--. Examples of substituted
(C.sub.1-C.sub.40)alkylene are substituted
(C.sub.1-C.sub.20)alkylene, --CF.sub.2--, --C(O)--, and
--(CH.sub.2).sub.14C(CH.sub.3).sub.2(CH.sub.2).sub.5-- (i.e., a
6,6-dimethyl substituted normal-1,20-eicosylene). Since as
mentioned previously two R.sup.S may be taken together to form a
(C.sub.1-C.sub.18)alkylene, examples of substituted
(C.sub.1-C.sub.40)alkylene also include
1,2-bis(methylene)cyclopentane, 1,2-bis(methylene)cyclohexane,
2,3-bis(methylene)-7,7-dimethyl-bicyclo[2.2.1]heptane, and
2,3-bis(methylene)bicyclo[2.2.2]octane.
[0073] Preferably, each cycloalkylene independently has from 3 to
40 carbon atoms. The term "(C.sub.3-C.sub.40)cycloalkylene" means a
cyclic diradical (i.e., the radicals are on ring atoms) of from 3
to 40 carbon atoms that is unsubstituted or substituted by at least
one R.sup.S. Examples of unsubstituted
(C.sub.3-C.sub.40)cycloalkylene are 1,3-cyclopropylene,
1,1-cyclopropylene, and 1,2-cyclohexylene. Examples of substituted
(C.sub.3-C.sub.40)cycloalkylene are 2-oxo-1,3-cyclopropylene and
1,2-dimethyl-1,2-cyclohexylene.
[0074] Preferably, each heterohydrocarbyl independently has from 1
to 40 carbon atoms. The term "(C.sub.1-C.sub.40)heterohydrocarbyl"
means a heterohydrocarbon radical of from 1 to 40 carbon atoms and
the term "(C.sub.1-C.sub.40)heterohydrocarbylene means a
heterohydrocarbon diradical of from 1 to 40 carbon atoms, and each
heterohydrocarbon independently has at least one heteroatom
B(R.sup.C) O; S; S(O); S(O).sub.2; Si(R.sup.C).sub.2;
Ge(R.sup.C).sub.2; P(R.sup.P); and N(R.sup.N), wherein
independently each R.sup.C is unsubstituted
(C.sub.1-C.sub.18)hydrocarbyl, each R.sup.P is unsubstituted
(C.sub.1-C.sub.18)hydrocarbyl; and each R.sup.N is unsubstituted
(C.sub.1-C.sub.18)hydrocarbyl or absent (e.g., absent when N
comprises --N.dbd. or tri-carbon substituted N). The radicals of
the diradical can be on same or different type of atoms (e.g., both
on saturated acyclic atoms or one on an acyclic atom and one on
aromatic atom). Other heterohydrocarbyl (e.g.,
(C.sub.1-C.sub.12)heterohydrocarbyl)) and heterohydrocarbylene
groups are defined in an analogous manner. Preferably, the
heteroatom(s) is O; S; S(O); S(O).sub.2; Si(R.sup.C).sub.2;
P(R.sup.P); or N(R.sup.N). The heterohydrocarbon radical and each
of the heterohydrocarbon diradicals independently is on a carbon
atom or heteroatom thereof, although preferably is on a carbon atom
when bonded to a heteroatom in formula (I) or to a heteroatom of
another heterohydrocarbyl or heterohydrocarbylene. Each
(C.sub.1-C.sub.4)heterohydrocarbyl and
(C.sub.1-C.sub.40)heterohydrocarbylene independently is
unsubstituted or substituted (by at least one R.sup.S), aromatic or
non-aromatic, saturated or unsaturated, straight chain or branched
chain, cyclic (including mono- and poly-cyclic, fused and non-fused
polycyclic) or acyclic, or a combination of two or more thereof;
and each is respectively the same as or different from another.
[0075] Preferably, the (C.sub.1-C.sub.40)heterohydrocarbyl
independently is unsubstituted or substituted
(C.sub.1-C.sub.40)heteroalkyl,
(C.sub.1-C.sub.40)hydrocarbyl-B(R.sup.C)--,
(C.sub.1-C.sub.40)hydrocarbyl-O--,
(C.sub.1-C.sub.40)hydrocarbyl-S--,
(C.sub.1-C.sub.40)hydrocarbyl-S(O)--,
(C.sub.1-C.sub.40)hydrocarbyl-S(O).sub.2--,
(C.sub.1-C.sub.40)hydrocarbyl-Si(R.sup.C).sub.2--,
(C.sub.1-C.sub.40)hydrocarbyl-Ge(R.sup.C).sub.2--,
(C.sub.1-C.sub.40)hydrocarbyl-N(R.sup.N)--,
(C.sub.1-C.sub.40)hydrocarbyl-P(R.sup.P)--,
(C.sub.1-C.sub.40)hydrocarbyl-P(R.sup.P)--(C.sub.1-C.sub.20)alkylene-S--,
(C.sub.2-C.sub.40)heterocycloalkyl,
(C.sub.2-C.sub.19)heterocycloalkyl-(C.sub.1-C.sub.20)alkylene,
(C.sub.3-C.sub.20)cycloalkyl-(C.sub.1-C.sub.19)heteroalkylene,
(C.sub.2-C.sub.19)heterocycloalkyl-(C.sub.1-C.sub.20)heteroalkylene,
(C.sub.1-C.sub.40)heteroaryl,
(C.sub.1-C.sub.19)heteroaryl-(C.sub.1-C.sub.20)alkylene,
(C.sub.6-C.sub.20)aryl-(C.sub.1-C.sub.19)heteroalkylene, or
(C.sub.1-C.sub.19)heteroaryl-(C.sub.1-C.sub.20)heteroalkylene. More
preferably, each of the aforementioned groups has a maximum of 20
carbon atoms (not counting carbon atoms from any R.sup.S).
[0076] Preferably, each heteroaryl independently has from 1 to 40
carbon atoms. The term "(C.sub.1-C.sub.40)heteroaryl" means an
unsubstituted or substituted (by at least one R.sup.S) mono-, bi-
or tricyclic heteroaromatic hydrocarbon radical of from 1 to 40
total carbon atoms and from 1 to 4 heteroatoms; from 1 to 44 total
ring atoms, preferably from 5 to 10 total ring atoms, and the
mono-, bi- or tricyclic radical comprises 1, 2 or 3 rings,
respectively, wherein the 1-ring is heteroaromatic; at least one of
the 2 or 3 rings is heteroaromatic; and the 2 or 3 rings
independently are fused or non-fused. Other heteroaryl groups
(e.g., (C.sub.1-C.sub.12)heteroaryl)) are defined in an analogous
manner. The monocyclic heteroaromatic hydrocarbon radical is a
5-membered or 6-membered ring. The 5-membered ring has from 1 to 4
carbon atoms and from 4 to 1 heteroatoms, respectively, each
heteroatom being O, S, N, or P, and preferably O, S, or N. Examples
of 5-membered ring heteroaromatic hydrocarbon radical are
pyrrol-1-yl; pyrrol-2-yl; furan-3-yl; thiophen-2-yl; pyrazol-1-yl;
isoxazol-2-yl; isothiazol-5-yl; imidazol-2-yl; oxazol-4-yl;
thiazol-2-yl; 1,2,4-triazol-1-yl; 1,3,4-oxadiazol-2-yl;
1,3,4-thiadiazol-2-yl; tetrazol-1-yl; tetrazol-2-yl; and
tetrazol-5-yl. The 6-membered ring has 4 or 5 carbon atoms and 2 or
1 heteroatoms, the heteroatoms being N or P, and preferably N.
Examples of 6-membered ring heteroaromatic hydrocarbon radical are
pyridine-2-yl; pyrimidin-2-yl; and pyrazin-2-yl. The bicyclic
heteroaromatic hydrocarbon radical preferably is a fused 5,6- or
6,6-ring system. Examples of the fused 5,6-ring system bicyclic
heteroaromatic hydrocarbon radical are indol-1-yl; and
benzimidazole-1-yl. Examples of the fused 6,6-ring system bicyclic
heteroaromatic hydrocarbon radical are quinolin-2-yl; and
isoquinolin-1-yl. The tricyclic heteroaromatic hydrocarbon radical
preferably is a fused 5,6,5-; 5,6,6-; 6,5,6-; or 6,6,6-ring system.
An example of the fused 5,6,5-ring system is
1,7-dihydropyrrolo[3,2-f]indol-1-yl. An example of the fused
5,6,6-ring system is 1H-benzo[f]indol-1-yl. An example of the fused
6,5,6-ring system is 9H-carbazol-9-yl, which may also be named as a
dibenzo-1H-pyrrole-1-yl. An example of the fused 6,5,6-ring system
is 9H-carbazol-9-yl. An example of the fused 6,6,6-ring system is
acrydin-9-yl. The 5-membered rings and 6-membered rings of the
fused 5,6-; 6,6-; 5,6,5-; 5,6,6-; 6,5,6-; and 6,6,6-ring systems
independently can be as described above for 5-membered and
6-membered rings, respectively, except where the ring fusions
occur.
[0077] The aforementioned heteroalkyl and heteroalkylene groups are
saturated straight or branched chain radicals or diradicals,
respectively, containing at least one carbon atom and at least one
heteroatom (up to 4 heteroatoms) Si(R.sup.C).sub.2,
Ge(R.sup.C).sub.2, P(R.sup.P), N(R.sup.N), N, O, S, S(O), and
S(O).sub.2 as defined above, wherein each of the heteroalkyl and
heteroalkylene groups independently are unsubstituted or
substituted by at least one R.sup.S.
[0078] Preferably, each heterocycloalkyl independently has from 2
to 40 carbon atoms. The term "(C.sub.2-C.sub.40)heterocycloalkyl"
means a cyclic diradical (i.e., the radicals are on ring atoms) of
from 2 to 40 carbon atoms and from 1 to 4 heteroatoms, as described
previously, that is unsubstituted or substituted by at least one
R.sup.S. Examples of unsubstituted
(C.sub.2-C.sub.40)heterocycloalkyl are unsubstituted
(C.sub.2-C.sub.20)heterocycloalkyl, unsubstituted
(C.sub.2-C.sub.10)heterocycloalkyl, aziridin-1-yl, oxetan-2-yl,
tetrahydrofuran-3-yl, pyrrolidin-1-yl,
tetrahydrothiophen-S,S-dioxide-2-yl, morpholin-4-yl,
1,4-dioxan-2-yl, hexahydroazepin-4-yl, 3-oxa-cyclooctyl,
5-thia-cyclononyl, and 2-aza-cyclodecyl.
[0079] The term "halogen atom" means fluorine atom (F), chlorine
atom (Cl), bromine atom (Br), or iodine atom (I) radical.
Preferably each halogen atom independently is the Br, F, or Cl
radical, and more preferably the F or Cl radical. The term "halide"
means fluoride (F.sup.-), chloride (Cl.sup.-), bromide (Br.sup.-),
or iodide (I.sup.-) anion. Preferably, halide is Cl.sup.- or
Br.sup.-.
[0080] Unless otherwise indicated herein the term "heteroatom"
means O, S, S(O), S(O).sub.2, Si(R.sup.C).sub.2, Ge(R.sup.C).sub.2,
P(R.sup.P), or N(R.sup.N), wherein independently each R.sup.C is
unsubstituted (C.sub.1-C.sub.18)hydrocarbyl or the two R.sup.C are
taken together to form a (C.sub.2-C.sub.19)alkylene (e.g., the two
R.sup.C together with the silicon atom to which they are both
bonded form a 3-membered to 20-membered silacycloalkyl), each
R.sup.P is unsubstituted (C.sub.1-C.sub.18)hydrocarbyl; and each
R.sup.N is unsubstituted (C.sub.1-C.sub.18)hydrocarbyl, a hydrogen
atom, or absent (absent when N comprises --N.dbd. as in a
N-containing heteroaryl). Preferably there is no germanium (Ge)
atom in the invention compound or complex.
[0081] Preferably, there are no O--O, S--S, or O--S bonds, other
than O--S bonds in an S(O) or S(O).sub.2 diradical functional
group, in the metal-ligand complex of formula (I). More preferably,
there are no O--O, N--N, P--P, N--P, S--S, or O--S bonds, other
than O--S bonds in an S(O) or S(O).sub.2 diradical functional
group, in the metal-ligand complex of formula (I).
[0082] The term "saturated" means lacking carbon-carbon double
bonds, carbon-carbon triple bonds, and (in heteroatom-containing
groups) carbon-nitrogen, carbon-phosphorous, and carbon-silicon
double bonds. Where a saturated chemical group is substituted by
one or more substituents R.sup.S, one or more double and/or triple
bonds optionally may or may not be present in substituents R.sup.S.
The term "unsaturated" means containing one or more carbon-carbon
double bonds, carbon-carbon triple bonds, and (in
heteroatom-containing groups) carbon-nitrogen, carbon-phosphorous,
and carbon-silicon double bonds, not including any such double
bonds that may be present in substituents R.sup.S, if any, or in
(hetero)aromatic rings, if any.
[0083] In the metal-ligand complex of formula (I) and ligand of
formula (Q) certain variables and chemical groups n, M, X, Z, L,
R.sup.1a, R.sup.2a, R.sup.3a, R.sup.4a, R.sup.1b, R.sup.2b,
R.sup.3b, R.sup.4b, R.sup.5c, R.sup.6c, R.sup.7c, R.sup.8c,
R.sup.5d, R.sup.6d, R.sup.7d, and R.sup.8d, as the formulas allow,
are preferred. Examples of such preferred groups follow.
[0084] Preferably M is zirconium or hafnium, and more preferably M
is hafnium. In some embodiments M is zirconium. In some embodiments
M is titanium. In some embodiments M is in a formal oxidation state
of +2. In some embodiments M is in a formal oxidation state of +3.
In some embodiments M is in a formal oxidation state of +4. The
invention contemplates any combination of a preferred M and a
preferred formal oxidation state.
[0085] In some embodiments n is 0. In some embodiments n is 1. In
some embodiments n is 2. In some embodiments n is 3.
[0086] The X groups are not critical. Certain X are preferred. In
some embodiments each X independently is the monodentate ligand.
Preferably when there are two or more X monodentate ligands, each X
is the same. In some embodiments the monodentate ligand is the
monoanionic ligand. The monoanionic ligand has a net formal
oxidation state of -1. Each monoanionic ligand preferably
independently is hydride, hydrocarbyl carbanion, heterohydrocarbyl
carbanion, halide, nitrate, carbonate, phosphate, sulfate,
HC(O)O.sup.-, hydrocarbylC(O)O.sup.-, HC(O)N(H).sup.-,
hydrocarbylC(O)N(H).sup.-,
hydrocarbylC(O)N(C.sub.1-C.sub.20)hydrocarbyl).sup.-,
R.sup.KR.sup.LB.sup.-, R.sup.KR.sup.LN.sup.-, R.sup.KO.sup.-,
R.sup.KS.sup.-, R.sup.KR.sup.LP.sup.-, or
R.sup.MR.sup.KR.sup.LR.sup.-, wherein each R.sup.K, R.sup.L, and
R.sup.M independently is hydrogen, hydrocarbyl, or
heterohydrocarbyl, or R.sup.K and R.sup.L are taken together to
form a (C.sub.2-C.sub.40)hydrocarbylene or heterohydrocarbylene and
R.sup.M is as defined above.
[0087] In some embodiments at least one monodentate ligand of X
independently is the neutral ligand. Preferably the neutral ligand
is a neutral Lewis base group that is R.sup.XNR.sup.KR.sup.L,
R.sup.KOR.sup.L, R.sup.KSR.sup.L, or R.sup.XPR.sup.KR.sup.L,
wherein each R.sup.X independently is hydrogen, hydrocarbyl,
[(C.sub.1-C.sub.10)hydrocarbyl].sub.3Si,
[(C.sub.1-C.sub.10)hydrocarbyl].sub.3Si(C.sub.1-C.sub.10)hydrocarbyl,
or heterohydrocarbyl and each R.sup.K and R.sup.L independently is
as defined above.
[0088] In some embodiments, each X is a monodentate ligand that
independently is a halogen atom, unsubstituted
(C.sub.1-C.sub.20)hydrocarbyl, unsubstituted
(C.sub.1-C.sub.20)hydrocarbylC(O)O--, or R.sup.KR.sup.LN-- wherein
each of R.sup.K and R.sup.L independently is an unsubstituted
(C.sub.1-C.sub.20)hydrocarbyl. In some embodiments each monodentate
ligand X is a chlorine atom, (C.sub.1-C.sub.10)hydrocarbyl (e.g.,
(C.sub.1-C.sub.6)alkyl or benzyl), unsubstituted
(C.sub.1-C.sub.10)hydrocarbylC(O)O--, or R.sup.KR.sup.LN-- wherein
each of R.sup.K and R.sup.L independently is an unsubstituted
(C.sub.1-C.sub.10)hydrocarbyl.
[0089] In some embodiments there are at least two X and the two X
are taken together to form the bidentate ligand. In some
embodiments the bidentate ligand is a neutral bidentate ligand.
Preferably the neutral bidentate ligand is a diene of formula
(R.sup.D).sub.2C.dbd.C(R.sup.D)--C(R.sup.D).dbd.C(R.sup.D).sub.2,
wherein each R.sup.D independently is H, unsubstituted
(C.sub.1-C.sub.6)alkyl, phenyl, or naphthyl. In some embodiments
the bidentate ligand is a monoanionic-mono (Lewis base) ligand. The
monoanionic-mono (Lewis base) ligand preferably is a 1,3-dionate of
formula (D): R.sup.E--C(O.sup.-).dbd.CH--C(.dbd.O)--R.sup.E (D),
wherein each R.sup.D independently is H, unsubstituted
(C.sub.1-C.sub.6)alkyl, phenyl, or naphthyl. In some embodiments
the bidentate ligand is a dianionic ligand. The dianionic ligand
has a net formal oxidation state of -2. Preferably each dianionic
ligand independently is carbonate, oxalate (i.e.,
.sup.-O.sub.2CC(O)O.sup.-), (C.sub.2-C.sub.40)hydrocarbylene
dicarbanion, heterohydrocarbylene dicarbanion, phosphate, or
sulfate.
[0090] As used herein, the term "carbonate" means an ionic
substance consisting of zero or one cations Q.sup.X and an anion of
the empirical formula CO.sub.3.sup.-2, the ionic substance having
an overall -1 or -2 charge. The term "nitrate" means an ionic
substance consisting of an anion of the empirical formula
NO.sub.3.sup.-, the ionic substance having an overall -1 charge.
The term "oxalate" means an ionic substance consisting of zero or
one cations Q.sup.X and an anion of the empirical formula
.sup.-OC(O)C(O)O.sup.-, the ionic substance having an overall -1 or
-2 charge. The term "phosphate" means an ionic substance consisting
of zero, one, or two cations Q.sup.X and an anion of the empirical
formula PO.sub.4.sup.-3, the ionic substance having an overall -1,
-2, or -3 charge. The term "sulfate" means an ionic substance
consisting of zero or one cations Q.sup.X and an anion of the
empirical formula SO.sub.4.sup.-2, the ionic substance having an
overall -1 or -2 charge. In each of the ionic substances,
preferably Q.sup.X independently is an inorganic cation of hydrogen
atom, lithium, sodium, potassium, calcium, or magnesium, including
hemi calcium and hemi magnesium.
[0091] As previously mentioned, number and charge (neutral,
monoanionic, dianionic) of X are selected depending on the formal
oxidation state of M such that the metal-ligand complex of formula
(I) is, overall, neutral.
[0092] In some embodiments each X is the same, wherein each X is
methyl; ethyl; 1-propyl; 2-propyl; 1-butyl; 2,2,-dimethylpropyl;
trimethylsilylmethyl; phenyl; benzyl; or chloro. In some
embodiments n is 2 and each X is the same.
[0093] In some embodiments at least two X are different. In some
embodiments n is 2 and each X is a different one of methyl; ethyl;
1-propyl; 2-propyl; 1-butyl; 2,2,-dimethylpropyl;
trimethylsilylmethyl; phenyl; benzyl; and chloro.
[0094] The integer n indicates number of X. Preferably n is 2 or 3
and at least two X independently are monoanionic monodentate
ligands and a third X, if present, is a neutral monodentate ligand.
In some embodiments n is 2 at two X are taken together to form a
bidentate ligand. In some embodiments the bidentate ligand is
2,2-dimethyl-2-silapropane-1,3-diyl or 1,3-butadiene.
[0095] More preferably X and n independently are as defined as in
any one of the Examples described later.
[0096] Certain Z groups in formula (I) are preferred. In some
embodiments each Z is different. In some embodiments one Z is O and
one Z is NCH.sub.3. In some embodiments one Z is O and one Z is S.
In some embodiments one Z is S and one Z is Nhydrocarbyl (e.g.,
NCH.sub.3). In some embodiments each Z is the same. In some
embodiments each Z is O. In some embodiments each Z is S. In some
embodiments each Z is Nhydrocarbyl (e.g., NCH.sub.3). In some
embodiments at least one, and in some embodiments each Z is
Phydrocarbyl (e.g., PCH.sub.3).
[0097] A certain L group in formula (I) are preferred. In some
embodiments L is the hydrocarbylene. Preferably the aforementioned
portion that comprises a 1-carbon atom to 6-carbon atom linker
backbone of the hydrocarbylene of L comprises a 2-carbon atom to
5-carbon atom, and more preferably a 3-carbon atom or 4-carbon atom
linker backbone linking the Z atoms in formula (I) to which L is
bonded. In some embodiments L comprises the 1-carbon atom linker
backbone (e.g., L is --CH.sub.2-- or C(.dbd.O)). In some
embodiments L comprises the 2-carbon atom linker backbone (e.g., L
is --CH.sub.2CH.sub.2-- or --CH(CH.sub.3)CH(CH.sub.3)--). In some
embodiments L comprises the 3-carbon atom linker backbone (e.g., L
is --CH.sub.2CH.sub.2CH.sub.2--;
--CH(CH.sub.3)CH.sub.2CH(CH.sub.3)--;
--CH(CH.sub.3)CH(CH.sub.3)CH(CH.sub.3)--;
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--); 1,3-cyclopentane-diyl; or
1,3-cyclohexane-diyl. In some embodiments L comprises the 4-carbon
atom linker backbone (e.g., L is
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--;
--CH.sub.2C(CH.sub.3).sub.2C(CH.sub.3).sub.2CH.sub.2--;
1,2-bis(methylene)cyclohexane; or
2,3-bis(methylene)-bicycico[2.2.2]octane). In some embodiments L
comprises the 5-carbon atom linker backbone (e.g., L is
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2-- or
1,3-bis(methylene)cyclohexane). In some embodiments L comprises the
6-carbon atom linker backbone (e.g., L is
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2-- or
1,2-bis(ethylene)cyclohexane).
[0098] Preferably L is the hydrocarbylene and the hydrocarbylene of
L is a (C.sub.2-C.sub.12)hydrocarbylene, and more preferably
(C.sub.3-C.sub.8)hydrocarbylene. In some embodiments the
hydrocarbylene is an unsubstituted alkylene. In some embodiments
the hydrocarbylene is a substituted alkylene. In some embodiments
the hydrocarbylene is an unsubstituted cycloalkylene or substituted
cycloalkylene, wherein each substituent independently is R.sup.S,
wherein preferably the R.sup.S independently is
(C.sub.1-C.sub.4)alkyl.
[0099] In some embodiments L is the unsubstituted alkylene, and
more preferably L is an acyclic unsubstituted alkylene, and still
more preferably the acyclic unsubstituted alkylene is
--CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--, cis
--CH(CH.sub.3)CH.sub.2CH(CH.sub.3)--, trans
--CH(CH.sub.3)CH.sub.2CH(CH.sub.3)--,
--CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2--,
--CH(CH.sub.3)CH(CH.sub.3)CH(CH.sub.3)--,
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, or
--CH.sub.2C(CH.sub.3).sub.2C(CH.sub.3).sub.2CH.sub.2--. In some
embodiments L is the substituted alkylene, and more preferably L is
a alkylene-substituted alkylene, and still more preferably the
alkylene-substituted alkylene is
trans-1,2-bis(methylene)cyclopentane,
cis-1,2-bis(methylene)cyclopentane,
trans-1,2-bis(methylene)cyclohexane, or
cis-1,2-bis(methylene)cyclohexane. In some embodiments the
alkylene-substituted alkylene is
exo-2,3-bis(methylene)bicyclo[2.2.2]octane or
exo-2,3-bis(methylene)-7,7-dimethyl-bicyclo[2.2.1]heptane. In some
embodiments L is the unsubstituted cycloalkylene, and more
preferably L is cis-1,3-cyclopentane-diyl or
cis-1,3-cyclohexane-diyl. In some embodiments L is the substituted
cycloalkylene, and more preferably L is a alkylene-substituted
cycloalkylene, and still more preferably L is the
alkylene-substituted cycloalkylene that is
exo-bicyclo[2.2.2]octan-2,3-diyl.
[0100] In some embodiments L is the heterohydrocarbylene.
Preferably the aforementioned portion that comprises a 1-atom to
6-atom linker backbone of the heterohydrocarbylene of L comprises a
from 2-atom to 5-atom, and more preferably a 3-atom or 4-atom
linker backbone linking the Z atoms in formula (I) to which L is
bonded. In some embodiments L comprises the 1-atom linker backbone
(e.g., L is --CH(OCH.sub.3)-- or --Si(CH.sub.3).sub.2--). In some
embodiments L comprises the 2-atom linker backbone (e.g., L is
--CH.sub.2CH(OCH.sub.3)-- or --CH.sub.2Si(CH.sub.3).sub.2--). In
some embodiments L comprises the 3-atom linker backbone (e.g., L is
--CH.sub.2CH.sub.2CH(OCH.sub.3)--,
--CH.sub.2Si(CH.sub.3).sub.2CH.sub.2--, or
--CH.sub.2Ge(CH.sub.3).sub.2CH.sub.2--). The
"--CH.sub.2Si(CH.sub.3).sub.2CH.sub.2-" may be referred to herein
as a 1,3-diradical of 2,2-dimethyl-2-silapropane. In some
embodiments L comprises the 4-atom linker backbone (e.g., L is
--CH.sub.2CH.sub.2OCH.sub.2-- or
--CH.sub.2P(CH.sub.3)CH.sub.2CH.sub.2--). In some embodiments L
comprises the 5-atom linker backbone (e.g., L is
--CH.sub.2CH.sub.2OCH.sub.2CH.sub.2-- or
--CH.sub.2CH.sub.2N(CH.sub.3)CH.sub.2CH.sub.2--). In some
embodiments L comprises the 6-atom linker backbone (e.g., L is
--CH.sub.2CH.sub.2C(OCH.sub.3).sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2S(O).sub.2CH.sub.2CH.sub.2--, or
--CH.sub.2CH.sub.2S(O)CH.sub.2CH.sub.2CH.sub.2--). In some
embodiments each atom of the 1-atom to 6-atom linker backbone is a
carbon atom (the heteroatom(s) of the
(C.sub.1-C.sub.40)heterohydrocarbylene thereby being elsewhere
therein). In some embodiments one of the atoms of the 1-atom to
6-atom linker backbone is a heteroatom and the rest of the from 1
to 6 atoms, if any, are carbon atoms. In some embodiments two of
the from 2 to 6 atoms of the 2-atom to 6-atom linker backbone
independently are heteroatoms and the rest of the from 2 to 6
atoms, if any, are carbon atoms. In some embodiments at least one
heteroatom is the Si(R.sup.C).sub.2. In some embodiments each
R.sup.C is unsubstituted (C.sub.1-C.sub.18)hydrocarbyl. In some
embodiments the two R.sup.C are taken together to form a
(C.sub.2-C.sub.19)alkylene (i.e., the 3-membered to 20-membered
silacycloalkyl). In some embodiments at least one heteroatom is the
O. In some embodiments at least one heteroatom is the S(O). In some
embodiments at least one heteroatom is the S(O).sub.2. In some
embodiments at least one heteroatom is the P(R.sup.P). In some
embodiments at least one heteroatom is the N(R.sup.N). Preferably,
there are no O--O, S--S, or O--S bonds, other than O--S bonds in
the S(O) or S(O).sub.2 diradical functional group, in --Z-L-Z--.
More preferably, there are no O--O, N--N, P--P, N--P, S--S, or O--S
bonds, other than O--S bonds in an S(O) or S(O).sub.2 diradical
functional group, in --Z-L-Z--. Preferably the
(C.sub.1-C.sub.40)heterohydrocarbylene is
(C.sub.1-C.sub.11)heterohydrocarbylene, and more preferably
(C.sub.1-C.sub.7)heterohydrocarbylene. More preferably the
(C.sub.1-C.sub.7)heterohydrocarbylene of L is
--CH.sub.2Si(CH.sub.3).sub.2CH.sub.2--;
--CH.sub.2CH.sub.2Si(CH.sub.3).sub.2CH.sub.2--; or
CH.sub.2Si(CH.sub.3).sub.2CH.sub.2CH.sub.2--. Still more preferably
the (C.sub.1-C.sub.7)heterohydrocarbylene of L is
--CH.sub.2Si(CH.sub.3).sub.2CH.sub.2--,
--CH.sub.2Si(CH.sub.2CH.sub.3).sub.2CH.sub.2--,
--CH.sub.2Si(isopropyl).sub.2CH.sub.2--,
--CH.sub.2Si(tetramethylene)CH.sub.2--, or
--CH.sub.2Si(pentamethylene)CH.sub.2--. The
--CH.sub.2Si(tetramethylene)CH.sub.2-- is named
1-silacyclopentan-1,1-dimethylene. The
--CH.sub.2Si(pentamethylene)CH.sub.2-- is named
1-silacyclohexan-1,1-dimethylene.
[0101] More preferably L is defined as in any one of the Examples
described later.
[0102] Certain R.sup.1a, R.sup.2a, R.sup.1b, and R.sup.2b groups
are preferred. In some embodiments one of R.sup.1a, R.sup.2a,
R.sup.1b, and R.sup.2b independently is a hydrocarbyl,
heterohydrocarbyl, or halogen atom; and each of the others of
R.sup.1a, R.sup.2a, R.sup.1b, R.sup.2b is a hydrogen atom. In some
such embodiments it is each of R.sup.2a, R.sup.1b, R.sup.2b that is
a hydrogen atom. In other such embodiments it is each of R.sup.1a,
R.sup.1b, and R.sup.2b that is a hydrogen atom.
[0103] In some embodiments two of R.sup.1a, R.sup.2a, R.sup.1b,
R.sup.2b independently are a hydrocarbyl, heterohydrocarbyl, or
halogen atom; and each of the others of R.sup.1a, R.sup.2a,
R.sup.1b, and R.sup.2b is a hydrogen atom. In some such embodiments
it is each of R.sup.1b and R.sup.2b that is a hydrogen atom. In
other such some embodiments it is each of R.sup.2a and R.sup.2b
that is a hydrogen atom. In still other such some embodiments it is
each of R.sup.1a and R.sup.1b that is a hydrogen atom.
[0104] In some embodiments three of R.sup.1a, R.sup.2a, R.sup.1b,
R.sup.2b independently are a hydrocarbyl, heterohydrocarbyl, or
halogen atom; and the other of R.sup.1a, R.sup.2a, R.sup.1b, and
R.sup.2b is a hydrogen atom. In some such embodiments it is
R.sup.1b that is a hydrogen atom. In other such some embodiments it
is R.sup.2b that is a hydrogen atom.
[0105] In some embodiments each of R.sup.1a, R.sup.2a, R.sup.1b,
R.sup.2b independently is a hydrocarbyl, heterohydrocarbyl, or
halogen atom.
[0106] In some embodiments one of R.sup.1a and R.sup.1b
independently is a hydrocarbyl, heterohydrocarbyl, or halogen atom,
and the other of R.sup.1a and R.sup.1b independently is a hydrogen
atom, hydrocarbyl, heterohydrocarbyl, or halogen atom. In some
embodiments one of R.sup.1a and R.sup.1b independently is a
hydrocarbyl or halogen atom, and the other of R.sup.1a and R.sup.1b
independently is a hydrogen atom, hydrocarbyl, heterohydrocarbyl,
or halogen atom. In some embodiments each of R.sup.1a and R.sup.1b
independently is a hydrocarbyl or halogen atom. In some embodiments
at least one of R.sup.1a and R.sup.1b is hydrocarbyl. In some
embodiments at least one of R.sup.1a and R.sup.1b is halogen
atom.
[0107] In some embodiments one of R.sup.2a and R.sup.2b
independently is a hydrocarbyl, heterohydrocarbyl, or halogen atom,
and the other of R.sup.2a and R.sup.2b independently is a hydrogen
atom, hydrocarbyl, heterohydrocarbyl, or halogen atom. In some
embodiments one of R.sup.2a and R.sup.2b independently is a
hydrocarbyl or halogen atom, and the other of R.sup.2a and R.sup.2b
independently is a hydrogen atom, hydrocarbyl, heterohydrocarbyl,
or halogen atom. In some embodiments each of R.sup.2a and R.sup.2b
independently is a hydrocarbyl or halogen atom. In some embodiments
at least one of R.sup.2a and R.sup.2b is hydrocarbyl. In some
embodiments at least one of R.sup.2a and R.sup.2b is halogen
atom.
[0108] Certain R.sup.3a and R.sup.3b are preferred. In some
embodiments each of R.sup.3a and R.sup.3b is a hydrogen atom. In
some embodiments one of R.sup.3a and R.sup.3b independently is a
hydrocarbyl, heterohydrocarbyl, or halogen atom, and the other of
R.sup.3a and R.sup.3b independently is a hydrogen atom,
hydrocarbyl, heterohydrocarbyl, or halogen atom. In some
embodiments one of R.sup.3a and R.sup.3b independently is a
hydrocarbyl or halogen atom, and the other of R.sup.3a and R.sup.3b
independently is a hydrogen atom, hydrocarbyl, heterohydrocarbyl,
or halogen atom. In some embodiments each of R.sup.3a and R.sup.3b
independently is a hydrocarbyl, heterohydrocarbyl, or halogen atom.
In some embodiments each of R.sup.3a and R.sup.3b independently is
a hydrocarbyl or halogen atom. In some embodiments at least one of
R.sup.3a and R.sup.3b is hydrocarbyl. In some embodiments at least
one of R.sup.3a and R.sup.3b is halogen atom.
[0109] Certain combinations of R.sup.1a, R.sup.1b, R.sup.2a,
R.sup.2b are preferred. In some embodiments R.sup.1a is a hydrogen
atom; R.sup.1b is a hydrocarbyl, heterohydrocarbyl, or halogen
atom; R.sup.2a independently is a hydrocarbyl, heterohydrocarbyl,
or halogen atom; and R.sup.2b independently is a hydrogen atom,
hydrocarbyl, heterohydrocarbyl, or halogen atom. In some
embodiments R.sup.1b independently is hydrocarbyl or halogen
atom.
[0110] In some embodiments each of R.sup.1a and R.sup.1b is a
hydrogen atom; and at least one, and preferably each of R.sup.2a
and R.sup.2b independently is a hydrocarbyl, heterohydrocarbyl, or
halogen atom. In some embodiments at least one and preferably each
of the R.sup.2a and R.sup.2b independently is hydrocarbyl or
halogen atom.
[0111] In some embodiments at least three of R.sup.1a, R.sup.1b,
R.sup.2a, and R.sup.2b independently is a hydrocarbyl,
heterohydrocarbyl, or halogen atom; and the remaining one of
R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b independently is a hydrogen
atom, hydrocarbyl, heterohydrocarbyl, or halogen atom. In some
embodiments at least three and in other embodiments each of
R.sup.1a, R.sup.1b, R.sup.2a, and R.sup.2b independently is a
hydrocarbyl or halogen atom. When at least one of R.sup.1a,
R.sup.1b, R.sup.2a, R.sup.2b is a F, preferably it is R.sup.1a,
R.sup.2a, or each of R.sup.1a and R.sup.1b that is F.
[0112] Certain combinations of R.sup.2a, R.sup.2b, R.sup.3a, and
R.sup.3b are preferred. In some embodiments R.sup.2a is a hydrogen
atom; R.sup.2b is a hydrocarbyl, heterohydrocarbyl, or halogen
atom; R.sup.3a independently is a hydrocarbyl, heterohydrocarbyl,
or halogen atom; and R.sup.3b independently is a hydrogen atom,
hydrocarbyl, heterohydrocarbyl, or halogen atom. In some
embodiments R.sup.2b independently is hydrocarbyl or halogen
atom.
[0113] In some embodiments each of R.sup.2a, R.sup.2b, R.sup.3a,
and R.sup.3b independently is a hydrocarbyl, heterohydrocarbyl, or
halogen atom. In some embodiments at least one and preferably each
of the R.sup.2a, R.sup.2b, R.sup.3a, and R.sup.3b independently is
hydrocarbyl or halogen atom.
[0114] In some embodiments at least three of R.sup.2a, R.sup.2b,
R.sup.3a, and R.sup.3b independently is a hydrocarbyl,
heterohydrocarbyl, or halogen atom; and the remaining one of
R.sup.2a, R.sup.2b, R.sup.3a, and R.sup.3b independently is a
hydrogen atom, hydrocarbyl, heterohydrocarbyl, or halogen atom. In
some embodiments at least three and in other embodiments each of
R.sup.2a, R.sup.2b, R.sup.3a, and R.sup.3b independently is a
hydrocarbyl or halogen atom.
[0115] Certain combinations of R.sup.1a, R.sup.1b, R.sup.2a,
R.sup.2b, R.sup.3a, R.sup.3b are more preferred. In some
embodiments R.sup.2a and R.sup.2b are each hydrogen atom and
R.sup.1a, R.sup.1b, R.sup.3a, and R.sup.3b independently is
hydrocarbyl, heterohydrocarbyl, or halogen atom; and more
preferably R.sup.2a and R.sup.2b are each hydrogen atom and each of
R.sup.1a and R.sup.1b independently is
(C.sub.1-C.sub.6)hydrocarbyl, (C.sub.1-C.sub.5)heterohydrocarbyl,
fluorine atom, or chlorine atom, and each of R.sup.3a, and R.sup.3b
independently is (C.sub.1-C.sub.12)hydrocarbyl,
(C.sub.1-C.sub.11)heterohydrocarbyl, fluorine atom, chlorine atom,
or bromine atom. In some embodiments R.sup.1a and R.sup.1b are each
hydrogen atom; each of R.sup.2a and R.sup.2b independently is
(C.sub.1-C.sub.8)hydrocarbyl, (C.sub.1-C.sub.7)heterohydrocarbyl,
fluorine atom, chlorine atom, or bromine atom; and each of
R.sup.3a, and R.sup.3b independently is
(C.sub.1-C.sub.12)hydrocarbyl, (C.sub.1-C.sub.11)heterohydrocarbyl,
fluorine atom, chlorine atom, or bromine atom.
[0116] Preferably each hydrocarbyl, whenever used to define
R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, or R.sup.3b,
independently is an alkyl or cycloalkyl. Preferably the alkyl is
(C.sub.1-C.sub.12)alkyl, more preferably (C.sub.1-C.sub.8)alkyl,
still more preferably (C.sub.1-C.sub.6)alkyl, and even more
preferably (C.sub.1-C.sub.4)alkyl. Preferably the cycloalkyl is
(C.sub.3-C.sub.6)cycloalkyl, and more preferably
(C.sub.3-C.sub.4)cycloalkyl. Preferably the
(C.sub.3-C.sub.4)cycloalkyl is cyclopropyl. Preferably the
(C.sub.1-C.sub.4)alkyl is methyl, ethyl, 1-propyl, 2-propyl,
1-butyl, 2-butyl, 2-methylpropyl, or 1,1-dimethylethyl, and more
preferably methyl, ethyl, 2-propyl, or 1,1-dimethylethyl. In some
embodiments the (C.sub.1-C.sub.4)alkyl is ethyl, 2-propyl, or
1,1-dimethylethyl. Preferably each halogen atom, whenever used to
define R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, and
R.sup.3b, independently is a fluorine atom or chlorine atom.
[0117] In some embodiments of the metal-ligand complex of formula
(I) each of R.sup.2a and R.sup.2b is a hydrogen atom and at least
one, and in some embodiments each of R.sup.1a, R.sup.1b, R.sup.3a,
and R.sup.3b independently is methyl; ethyl; 2-propyl;
1,1-dimethylethyl; mono-, di-, or trifluoromethyl; methoxy; ethoxy;
1-methylethoxy; mono-, di-, or trifluoromethoxy; halogen atom;
cyano; nitro; dimethylamino; aziridin-1-yl; or cyclopropyl. In some
embodiments at least one, and in some embodiments each of R.sup.2a
and R.sup.2b is a hydrogen atom and each of R.sup.1a, R.sup.1b,
R.sup.3a, and R.sup.3b independently is methyl; ethyl; 1-propyl;
2-propyl; 1-butyl; 1,1-dimethylethyl; cyano; dimethylamino;
methoxy; trifluoromethyl; bromine atom; fluorine atom, or chlorine
atom.
[0118] In some embodiments of the metal-ligand complex of formula
(I) each of R.sup.1a and R.sup.1b is a hydrogen atom and at least
one, and in some embodiments each of R.sup.2a, R.sup.2b, R.sup.3a,
and R.sup.3b independently is methyl; ethyl; 2-propyl;
1,1-dimethylethyl; mono-, di-, or trifluoromethyl; methoxy; ethoxy;
1-methylethoxy; mono-, di-, or trifluoromethoxy; halogen atom;
cyano; nitro; dimethylamino; aziridin-1-yl; or cyclopropyl. In some
embodiments at least one, and in some embodiments each of R.sup.1a
and R.sup.1b is a hydrogen atom and each of R.sup.2a, R.sup.2b,
R.sup.3a, R.sup.3b independently is methyl; ethyl; 1-propyl;
2-propyl; 1-butyl; 1,1-dimethylethyl; cyano; dimethylamino;
methoxy; trifluoromethyl; bromine atom; fluorine atom, or chlorine
atom.
[0119] In some embodiments the metal-ligand complex of formula (I)
and ligand of formula (Q) one of R.sup.1a and R.sup.1b is methyl;
the other of R.sup.1a and R.sup.1b is as in any one of the
preferred embodiments described herein. More preferably in some of
such embodiments each of R.sup.2a and R.sup.2b is a hydrogen atom
and each of R.sup.3a and R.sup.3b independently is as in any one of
the preferred embodiments described herein.
[0120] In some embodiments the metal-ligand complex of formula (I)
and ligand of formula (Q) at least one, and more preferably at
least one of R.sup.1a and R.sup.1b independently is ethyl;
2-propyl; mono-, di-, or trifluoromethyl; methoxy; ethoxy;
1-methylethoxy; mono-, di-, or trifluoromethoxy; halogen atom;
cyano; nitro; dimethylamino; aziridin-1-yl; or cyclopropyl. More
preferably in such embodiments at least one, and more preferably
each of R.sup.2a and R.sup.2b is a hydrogen atom and each of
R.sup.3a and R.sup.3b independently is as in any one of the
preferred embodiments described herein. In some of such embodiments
preferably at least one, and more preferably each of R.sup.1a and
R.sup.1b is a halogen atom or (C.sub.1-C.sub.6)alkyl, and still
more preferably a (C.sub.1-C.sub.4)alkyl, fluorine or chlorine
atom. In some embodiments at least one, and preferably each of
R.sup.1a and R.sup.1b is the fluorine atom. In some embodiments at
least one, and preferably each of R.sup.1a and R.sup.1b is the
chlorine atom. In some embodiments at least one, and preferably
each of R.sup.1a and R.sup.1b is (C.sub.1-C.sub.4)alkyl, and more
preferably methyl.
[0121] In some embodiments R.sup.1a and R.sup.1b are the same as
each other. In other embodiments R.sup.1a and R.sup.1b are
different. In some embodiments R.sup.2a and R.sup.2b are the same
as each other. In other embodiments R.sup.2a and R.sup.2b are
different. In some embodiments R.sup.3a and R.sup.3b are the same
as each other. In other embodiments R.sup.3a and R.sup.3b are
different.
[0122] In some embodiments R.sup.1a and R.sup.1b are the same as
each other and R.sup.3a and R.sup.3b are the same as each other. In
some embodiments R.sup.1a and R.sup.3a are the same as each other
and R.sup.1b and R.sup.3b are the same as each other. In some
embodiments R.sup.1a, R.sup.1b, R.sup.3a, and R.sup.3b are all the
same. In some embodiments R.sup.1a and R.sup.3a are different and
R.sup.1b and R.sup.3b are different. Preferably in such embodiments
each of R.sup.2a and R.sup.2b is a hydrogen atom.
[0123] In some embodiments R.sup.2a and R.sup.2b are the same as
each other and R.sup.3a and R.sup.3b are the same as each other. In
some embodiments R.sup.2a and R.sup.3a are the same as each other
and R.sup.2b and R.sup.3b are the same as each other. In some
embodiments R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b are all the
same. In some embodiments R.sup.2a and R.sup.3a are different and
R.sup.2b and R.sup.3b are different. Preferably in such embodiments
each of R.sup.1a and R.sup.1b is a hydrogen atom.
[0124] In some embodiments of the metal-ligand complex of formula
(I) or the ligand of formula (Q), at least one of R.sup.1a,
R.sup.1b, R.sup.3a, R.sup.3b, R.sup.7c, and R.sup.7d is not methyl.
In some embodiments of the metal-ligand complex of formula (I) or
the ligand of formula (Q) at least one of R.sup.7c, R.sup.7d,
R.sup.3a, and R.sup.3b is not methyl.
[0125] In some embodiments at least one, and in some embodiments
each of R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a, and
R.sup.3b independently is methyl; ethyl; 1-propyl; 2-propyl;
1-butyl; 1,1-dimethylethyl; cyano; dimethylamino; methoxy;
trifluoromethyl; bromine atom; fluorine atom, or chlorine atom.
More preferably R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b, R.sup.3a,
and R.sup.3b are defined as in any one of the Examples described
later.
[0126] Certain R.sup.4a and R.sup.4b are preferred. In some
embodiments each of R.sup.4a and R.sup.4b is a hydrogen atom. In
some embodiments at least one and in some embodiments each of
R.sup.4a and R.sup.4b independently is as defined previously for
R.sup.1a and R.sup.1b, respectively. When R.sup.4a or R.sup.4b
independently is as defined previously for R.sup.1a or R.sup.1b,
respectively, or both, R.sup.4a and R.sup.1a independently may be
the same or different and R.sup.4b and R.sup.1b independently may
be the same or different. In some embodiments at least one, and in
some embodiments each of R.sup.4a and R.sup.4b independently is
methyl; ethyl; 1-propyl; 2-propyl; 1-butyl; 1,1-dimethylethyl;
cyano; dimethylamino; methoxy; trifluoromethyl; bromine atom;
fluorine atom, or chlorine atom.
[0127] Certain of R.sup.6c, R.sup.8c, R.sup.6d, and R.sup.8d are
preferred. In some embodiments each of R.sup.6c, R.sup.8c,
R.sup.6d, and R.sup.8d is a hydrogen atom. In some embodiments one
of R.sup.6c, R.sup.8c, R.sup.6d, and R.sup.8d independently is
hydrocarbyl; heterohydrocarbyl; or halogen atom, and each of the
remainder of R.sup.6c, R.sup.8c, R.sup.6d, and R.sup.8d is a
hydrogen atom. In some embodiments two or more of R.sup.6c,
R.sup.8c, R.sup.6d, and R.sup.8d independently is hydrocarbyl;
heterohydrocarbyl; or halogen atom, and each of the remainder, if
any, of R.sup.6c, R.sup.8c, R.sup.6d, and R.sup.8d is a hydrogen
atom. In some embodiments at least one of R.sup.6c and R.sup.8c or
at least one of R.sup.6d and R.sup.8d, and in some embodiments at
least one of R.sup.6c and R.sup.8c and at least one of R.sup.6d and
R.sup.8d, is fluoro; cyano; methyl; ethyl; isopropyl; 1-butyl; or
tertiary-butyl. More preferably R.sup.6c, R.sup.8c, R.sup.6d, and
R.sup.8d are defined as in any one of the Examples described
later.
[0128] Certain R.sup.7c and R.sup.7d are preferred. In some
embodiments at least one of R.sup.7c and R.sup.7d independently is
hydrocarbyl; heterohydrocarbyl; or halogen atom and the remainder,
if any, of R.sup.7c and R.sup.7d is a hydrogen atom. In some
embodiments each of R.sup.7c and R.sup.7d independently is
hydrocarbyl; heterohydrocarbyl; or halogen atom. Preferably each of
R.sup.7c and R.sup.7d independently is hydrocarbyl or halogen atom.
In some embodiments each of R.sup.7c and R.sup.7d independently is
a halogen atom or alkyl, more preferably a (C.sub.1-C.sub.12)alkyl,
still more preferably a (C.sub.2-C.sub.8)alkyl, and even more
preferably a (C.sub.4-C.sub.8)alkyl. In some embodiments each of
R.sup.7c and R.sup.7d independently is bromo; cyano; ethyl;
isopropyl; 1-butyl; tertiary-butyl; 1,1-dimethylpropan-1-yl;
1,1-dimethylbutan-1-yl; 1,1-dimethylpentan-1-yl;
1,1-dimethylhexan-1-yl; or 2,4,4-trimethylpentan-2yl, and still
more preferably methyl, tertiary-butyl, or
2,4,4-trimethylpentan-2yl (i.e.,
(CH.sub.3).sub.3CCH.sub.2C(CH.sub.3).sub.2--). In some embodiments
R.sup.7c and R.sup.7d are the same as each other. Preferably each
of R.sup.7c and R.sup.7d is 2,4,4-trimethylpentan-2yl. In some
embodiments R.sup.7c and R.sup.7d are different from each other.
More preferably R.sup.7c and R.sup.7d are defined as in any one of
the Examples described later.
[0129] Certain R.sup.5c and R.sup.5d are preferred. In some
embodiments R.sup.5c and R.sup.5d are the same as each other. In
some embodiments R.sup.5c and R.sup.5d are different from each
other.
[0130] In some embodiments at least one, and more preferably each
of R.sup.5c and R.sup.5d independently is (C.sub.6-C.sub.40)aryl.
Preferably the (C.sub.6-C.sub.40)aryl is a (C.sub.6-C.sub.18)aryl
and more preferably (C.sub.6-C.sub.12)aryl. In some embodiments the
(C.sub.6-C.sub.40)aryl is a substituted phenyl and preferably a
2,4-disubstituted phenyl wherein each substituent is R.sup.S,
2,5-disubstituted phenyl wherein each substituent is R.sub.S; or
2,6-disubstituted phenyl wherein each substituent is R.sub.S; and
more preferably wherein each R.sup.S independently is phenyl,
methyl, ethyl, isopropyl, or tertiary-butyl, and still more
preferably 2,6-dimethylphenyl or 2,6-diisopropylphenyl. In some
embodiments the (C.sub.6-C.sub.40)aryl is a 3,5-disubstituted
phenyl wherein each substituent is R.sup.S, and more preferably
wherein each R.sup.S independently is phenyl, methyl, ethyl
isopropyl, or tertiary-butyl, and still more preferably
3,5-di(tertiary-butyl)phenyl or 3,5-diphenylphenyl. In some
embodiments the (C.sub.6-C.sub.40)aryl is a 2,4,6-trisubstituted
phenyl wherein each substituent is R.sup.S, and more preferably
wherein each R.sup.S independently is phenyl, methyl, isopropyl, or
tertiary-butyl; In some embodiments the (C.sub.6-C.sub.40)aryl is a
naphthyl or substituted naphthyl wherein each substituent is
R.sup.S, and more preferably wherein each R.sup.S independently is
phenyl, methyl, ethyl, isopropyl, or tertiary-butyl, and still more
preferably 1-naphthyl, 2-methyl-1-naphthyl, or 2-naphthyl. In some
embodiments the (C.sub.6-C.sub.40)aryl is a
1,2,3,4-tetrahydronaphthyl, and more preferably
1,2,3,4-tetrahydronaphth-5-yl or 1,2,3,4-tetrahydronaphth-6-yl. In
some embodiments the (C.sub.6-C.sub.40)aryl is an anthracenyl, and
more preferably anthracen-9-yl. In some embodiments the
(C.sub.6-C.sub.40)aryl is a 1,2,3,4-tetrahydroanthracenyl, and more
preferably 1,2,3,4-tetrahydroanthracen-9-yl. In some embodiments
the (C.sub.6-C.sub.40)aryl is a
1,2,3,4,5,6,7,8-octahydroanthracenyl, and more preferably
1,2,3,4,5,6,7,8-octahydroanthracen-9-yl, In some embodiments the
(C.sub.6-C.sub.40)aryl is a phenanthrenyl, and more preferably a
phenanthren-9-yl. In some embodiments the (C.sub.6-C.sub.40)aryl is
a 1,2,3,4,5,6,7,8-octahydrophenanthrenyl, and more preferably
1,2,3,4,5,6,7,8-octahydrophenanthren-9-yl. As mentioned before,
each of the aforementioned (C.sub.6-C.sub.40)aryl independently is
unsubstituted or substituted by one or more substituents R.sup.S.
In some embodiments the (C.sub.6-C.sub.40)aryl is unsubstituted.
Preferred unsubstituted (C.sub.6-C.sub.40)aryl is unsubstituted
inden-6-yl; 2,3-dihydro-1H-inden-6-yl; naphthalene-2-yl; or
1,2,3,4-tetrahydronaphthalen-6-yl; and more preferably
unsubstituted naphthalen-1-yl; 1,2,3,4-tetrahydronaphthalen-5-yl;
anthracen-9-yl; 1,2,3,4-tetrahydroanthracen-9-yl; or
1,2,3,4,5,6,7,8-octahydroanthracen-9-yl. As mentioned for
(C.sub.6-C.sub.40)aryl before, each of the aforementioned
(C.sub.1-C.sub.40)aryl independently is unsubstituted or
substituted by one or more substituents R.sup.S. In some
embodiments the (C.sub.6-C.sub.40)aryl is substituted by from 1 to
4 R.sup.S, wherein R.sup.S is as described previously. Preferably
there are 1 or 2 R.sup.S substituents in each substituted
(C.sub.6-C.sub.40, and more preferably 2 R.sup.S substituents in
each substituted phenyl. Preferably each R.sup.S of the substituted
(C.sub.6-C.sub.40)aryl of R.sup.5c and R.sup.5d independently is an
unsubstituted (C.sub.3-C.sub.10)hydrocarbyl, more preferably an
unsubstituted (C.sub.4-C.sub.8)hydrocarbyl, still more preferably
phenyl or an unsubstituted (C.sub.4-C.sub.10)alkyl, and even more
preferably an unsubstituted tertiary (C.sub.4-C.sub.8)alkyl (e.g.,
tertiary-butyl or tertiary-octyl (i.e., 1,1-dimethylhexyl)).
Examples of preferred substituted (C.sub.6-C.sub.40)aryl are a
2,6-disubstituted-phenyl having same substituent R.sup.S (e.g.,
2,6-dimethylphenyl; 2,6-diethylphenyl;
2,6-bis(1-methylethyl)phenyl; and 2,6-diphenyl-phenyl); a
3,5-disubstituted-phenyl having same substituent R.sup.S (e.g.,
3,5-dimethylphenyl; 3,5-bis(trifluoromethyl)phenyl;
3,5-bis(1-methylethyl)phenyl; and 3,5-bis(1,1-dimethylethyl)phenyl;
and 3,5-diphenyl-phenyl); 2,4,6-trisubstituted-phenyl having same
substituent R.sup.S (e.g., 2,4,6-trimethylphenyl; and
2,4,6-tris(1-methylethyl)phenyl);
1-methyl-2,3-dihydro-1H-inden-6-yl;
1,1-dimethyl-2,3-dihydro-1H-inden-6-yl;
1-methyl-1,2,3,4-tetrahydronaphthalen-5-yl; and
1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-5-yl.
[0131] In some embodiments at least one, and more preferably each
of R.sup.5c and R.sup.5d independently is heteroaryl. Preferably
the heteroaryl has at least one nitrogen atom-containing aromatic
ring. More preferably the heteroaryl is a pyridinyl, indolyl,
indolinyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl,
1,2,3,4-tetrahydroisoquinolinyl, carbazolyl,
1,2,3,4-tetrahydrocarbazolyl, or
1,2,3,4,5,6,7,8-octahydrocarbazolyl. In some embodiments the
heteroaryl is carbazolyl or a substituted carbazolyl, preferably a
2,7-disubstituted carbazolyl or 3,6-disubstituted carbazolyl, and
more preferably 2,7-disubstituted 9H-carbazol-9-yl or
3,6-disubstituted 9H-carbazol-9-yl, wherein each substituent is
R.sup.S, more preferably wherein each R.sup.S independently is
phenyl, methyl, ethyl, isopropyl, or tertiary-butyl, still more
preferably 3,6-di(tertiary-butyl)-carbazolyl,
3,6-di(tertiary-octyl)-carbazolyl, 3,6-diphenylcarbazolyl, or
3,6-bis(2,4,6-trimethylphenyl)-carbazolyl, and more preferably
3,6-di(tertiary-butyl)-carbazol-9-yl,
3,6-di(tertiary-octyl)-carbazol-9-yl, 3,6-diphenylcarbazol-9-yl, or
3,6-bis(2,4,6-trimethylphenyl)-carbazol-9-yl. Examples of
2,7-disubstituted carbazolyl are the foregoing 3,6-disubstituted
carbazolyl where the 3,6-substituents are moved to 2,7-positions,
respectively. Tertiary-octyl is 1,1-dimethylhexyl. In some
embodiments the heteroaryl is 1,2,3,4-tetrahydrocarbazolyl,
preferably a 1,2,3,4-tetrahydrocarbazol-9-yl. As mentioned before
for heteroaryl, each of the aforementioned heteroaryl independently
is unsubstituted or substituted by one or more substituents
R.sup.S. Preferably each of the indolyl, indolinyl, and tetrahydro-
and octahydro-containing heteroaryl is bonded via its ring nitrogen
atom to the phenyl rings bearing R.sup.5c or R.sup.5d in formula
(I). In some embodiments the heteroaryl is unsubstituted. Preferred
unsubstituted heteroaryl is unsubstituted quinolin-4-yl,
quinolin-5-yl, or quinolin-8-yl, (the quinolinyl N being at
position 1); 1,2,3,4-tetrahydroquinolin-1-yl (the
tetrahydroquinolinyl N being at position 1); isoquinolin-1-yl,
isoquinolin-4-yl, isoquinolin-5-yl, or isoquinolin-8-yl (the
isoquinolinyl N being at position 2);
1,2,3,4-tetrahydroisoquinolin-2-yl (the tetrahydroisoquinolinyl N
being at position 2); 1H-indol-1-yl (the indolyl N being at
position 1); 1H-indolin-1-yl (the indolinyl N being at position 1);
9H-carbazol-9-yl (the carbazolyl N being at position 9), which may
also be named as a dibenzo-1H-pyrrole-1-yl;
1,2,3,4-tetrahydrocarbazolyl-9-yl (the tetrahydrocarbazolyl N being
at position 9); or 1,2,3,4,5,6,7,8-octahydrocarbazolyl-9-yl (the
octahydrocarbazolyl N being at position 9). In some embodiments the
heteroaryl is substituted by from 1 to 4 R.sup.S. Preferably there
are 1 or 2 R.sup.S substituents in each substituted heteroaryl.
Preferably each R.sup.S of the substituted heteroaryl of R.sup.5c
and R.sup.5d independently is an unsubstituted
(C.sub.3-C.sub.10)hydrocarbyl, more preferably an unsubstituted
(C.sub.4-C.sub.8)hydrocarbyl, still more preferably phenyl or an
unsubstituted (C.sub.4-C.sub.10)alkyl, and even more preferably an
unsubstituted tertiary (C.sub.4-C.sub.8)alkyl (e.g., tertiary-butyl
or tertiary-octyl (i.e., 1,1-dimethylhexyl)). Preferably the
substituted heteroaryl is a 2,7-disubstituted quinolin-4-yl,
2,7-disubstituted quinolin-5-yl, or 3,6-disubstituted
quinolin-8-yl; 3,6-disubstituted 1,2,3,4-tetrahydroquinolin-1-yl;
4-monosubstituted isoquinolin-5-yl; 2-monosubstituted
1,2,3,4-tetrahydroisoquinolin-2-yl; 3-monosubstituted
1H-indol-1-yl; 3-monosubstituted 1H-indolin-1-yl; 2,7-disubstituted
9H-carbazol-9-yl; 3,6-disubstituted 9H-carbazol-9-yl;
3,6-disubstituted 1,2,3,4-tetrahydrocarbazolyl-9-yl; or
3,6-disubstituted 1,2,3,4,5,6,7,8-octahydrocarbazolyl-9-yl.
Examples of preferred substituted heteroaryl are
4.6-bis(1,1-dimethylethyl)pyridine-2-yl; 4,6-diphenylpyridin-2-yl;
3-phenyl-1H-indol-1-yl; 3-(1,1-dimethylethyl)-1H-indol-1-yl;
3,6-diphenyl-9H-carbazol-9-yl;
3,6-bis[2',4',6'-tris(1,1-dimethylphenyl)]-9H-carbazol-9-yl; and
more preferably each of R.sup.5c and R.sup.5d is
3,6-bis(1,1-dimethylethyl)-9H-carbazol-9-yl. The term "tertiary
butyl" means 1,1-dimethylethyl. More preferably R.sup.5C and
R.sup.5d are defined as in any one of the Examples described
later.
[0132] In some embodiments the aforementioned steric interactions
are those between R.sup.5c and R.sup.1a and between R.sup.5d and
R.sup.1b wherein each of R.sup.1a and R.sup.1b is not a hydrogen
atom and is otherwise as described in any one of the preferred
embodiments. In some embodiments the aforementioned valuable steric
interactions are those between R.sup.5c and R.sup.2a and between
R.sup.5d and R.sup.2b wherein each of R.sup.2a and R.sup.2b is not
a hydrogen atom and is otherwise as described in any one of the
preferred embodiments. Preferably each of R.sup.2a and R.sup.2b
independently has a sufficiently high degree of steric bulk such
that volumes of R.sup.2a and R.sup.2b independently are equal to or
greater than volume of ethyl; more preferably equal to or greater
than volume of 2-propyl; and still more preferably equal to or
greater than volume of 1,1-dimethylethyl. In some embodiments
wherein each of R.sup.1a and R.sup.1b is a hydrogen atom, at least
one and preferably both of R.sup.2a and R.sup.2b independently is
(C.sub.2-C.sub.40)hydrocarbyl or a chlorine atom.
[0133] In some embodiments at least one of R.sup.1a, R.sup.2a, and
R.sup.3a independently is different than the respective one of
R.sup.1b, R.sup.2b, and R.sup.3b. In other embodiments at least one
of R.sup.1b, R.sup.2a, R.sup.3a, R.sup.4a, R.sup.5d, R.sup.6d,
R.sup.7d, R.sup.8d independently is different than the respective
one of R.sup.1b, R.sup.2b, R.sup.3b, R.sup.4b, R.sup.5c, R.sup.6c,
R.sup.7c, and R.sup.8c. In such other embodiments, a
two-dimensional representation of such a metal-ligand complex of
formula (I) can be characterized as being C1-symmetric,
[0134] More preferably, each of R.sup.1a and R.sup.1b are the same,
each of R.sup.2a and R.sup.2b are the same, and each of R.sup.3a
and R.sup.3b are the same. Still more preferably, each of R.sup.1a,
R.sup.2a, R.sup.3a, R.sup.4a, R.sup.5d, R.sup.6d, R.sup.7d, and
R.sup.8d independently is the same as the respective one of
R.sup.1b, R.sup.2b, R.sup.3b, R.sup.4b, R.sup.5c, R.sup.6c,
R.sup.7c, and R.sup.8c. In such still more preferred embodiments, a
two-dimensional representation of such a metal-ligand complex of
formula (I) can be characterized as being C2-symmetric,
[0135] In some embodiments the metal-ligand complex of formula (I)
each Z is O, each of R.sup.2a and R.sup.2b is a hydrogen atom, and
each of R.sup.5c and R.sup.5d independently is the heteroaryl. More
preferred in such embodiments is a metal-ligand complex of any one
of formulas (Ia) to (Ie):
##STR00006## ##STR00007##
wherein M, X, R.sup.1a, R.sup.1b, R.sup.3a, R.sup.3b, R.sup.7c,
R.sup.7d, and L are as defined previously and each R.sup.55 and
R.sup.65 is as defined previously. Preferably each R.sup.55 and
R.sup.65 independently is a hydrogen atom or an unsubstituted
(C.sub.1-C.sub.12)alkyl.
[0136] In some embodiments the metal-ligand complex of formula (I)
each Z is O, each of R.sup.1a, and R.sup.1b is a hydrogen atom, and
each of R.sup.5c and R.sup.5d independently is the heteroaryl. More
preferred in such embodiments is a metal-ligand complex of any one
of formulas (If) to (Ij):
##STR00008## ##STR00009##
wherein M, X, R.sup.2a, R.sup.2b, R.sup.3a, R.sup.3b, R.sup.7c,
R.sup.7d, and L are as defined previously and each R.sup.55 and
R.sup.65 is as defined previously. Preferably each R.sup.55 and
R.sup.65 independently is a hydrogen atom or an unsubstituted
(C.sub.1-C.sub.12)alkyl.
[0137] In some embodiments the metal-ligand complex of formula (I)
each Z is O, each of R.sup.2a and R.sup.2b is a hydrogen atom, and
each of R.sup.5c and R.sup.5d independently is the
(C.sub.6-C.sub.40)aryl. More preferred in such embodiments is a
metal-ligand complex of any one of formulas (Ik) to (Io):
##STR00010## ##STR00011##
wherein M, X, R.sup.1a, R.sup.1b, R.sup.3a, R.sup.3b, R.sup.7c,
R.sup.7d, and L are as defined previously and each R.sup.55 and
R.sup.65 is as defined previously. Preferably each R.sup.55 and
R.sup.65 independently is a hydrogen atom or an unsubstituted
(C.sub.1-C.sub.12)alkyl.
[0138] In some embodiments the metal-ligand complex of formula (I)
each Z is O, each of R.sup.3a and R.sup.3b is a hydrogen atom, and
each of R.sup.5c and R.sup.5d independently is the heteroaryl. More
preferred in such embodiments is a metal-ligand complex of any one
of formulas (Ip) to (Iq):
##STR00012##
wherein M, X, R.sup.7c, R.sup.7d, and L are as defined previously
and each R.sup.55 and R.sup.65 is as defined previously. Preferably
each R.sup.55 and R.sup.65 independently is a hydrogen atom or an
unsubstituted (C.sub.1-C.sub.12)alkyl. The metal-ligand complex of
formula (Ip) is more preferred.
[0139] As mentioned above for the metal-ligand complex of any one
of formulas (Ia) to (Iq), the M, X, L, R.sup.1a, R.sup.2a,
R.sup.3a, R.sup.1b, R.sup.2b, R.sup.3b, R.sup.7c, and R.sup.7d, as
the case may be, are as defined for the same of formula (I) (i.e.,
as M, X, L, R.sup.1a, R.sup.2a, R.sup.3a, R.sup.1b, R.sup.2b,
R.sup.3b, R.sup.7c, and R.sup.7d of formula (I)). Preferably M is
hafnium or zirconium, and more preferably hafnium. Preferably each
X is a monodentate ligand. In some embodiments of the metal-ligand
complex of any one of formulas (Ia) to (Iq), n is 2 or 3 and at
least two X independently are monoanionic monodentate ligands and a
third X, if present, is a neutral monodentate ligand. In some
embodiments L is --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH(CH.sub.3)CH.sub.2CH(CH.sub.3)--,
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
1,2-bis(methylene)cyclohexane, or
--CH.sub.2Si(CH.sub.3).sub.2CH.sub.2--. In some embodiments each of
R.sup.1a, R.sup.2a, R.sup.3a, R.sup.1b, R.sup.2b, R.sup.3b
independently is hydrogen atom, methyl; ethyl; 2-propyl;
1,1-dimethylethyl; mono-, di-, or trifluoromethyl; methoxy; ethoxy;
1-methylethoxy; mono-, di-, or trifluoromethoxy; halogen atom;
cyano; nitro; dimethylamino; aziridin-1-yl; or cyclopropyl, wherein
at least one of R.sup.1a, R.sup.2a, and R.sup.3a independently is
not the hydrogen atom and at least one of R.sup.1b, R.sup.2b, and
R.sup.3b independently is not the hydrogen atom. In some
embodiments each of R.sup.7c and R.sup.7d independently is
(C.sub.4-C.sub.8)alkyl. In some embodiments of the metal-ligand
complex of any one of formulas (Ia) to (Iq), R.sup.1b, R.sup.2a,
R.sup.2b, R.sup.3a, and R.sup.3b, where present, are not hydrogen
and otherwise, R.sup.2a, R.sup.2b, R.sup.3a, and R.sup.3b
independently are as respectively defined for said formula.
[0140] In some embodiments the metal-ligand complex of formula (I)
is the metal-ligand complex of any one of the formulas (Ia) to (Iq)
except each Z that is O is replaced by a Z that is S. In some
embodiments the metal-ligand complex of formula (I) is the
metal-ligand complex of any one of the formulas (Ia) to (Iq) except
each Z that is O is replaced by a Z that is Nhydrocarbyl. In some
embodiments the metal-ligand complex of formula (I) is the
metal-ligand complex of any one of the formulas (Ia) to (Iq) except
each Z that is O is replaced by a Z that is Phydrocarbyl.
[0141] In some embodiments the ligand of formula (Q) corresponds to
a demetalated dihydro analog of the metal-ligand complex of
formulas (Ia) to (Iq) (i.e., is a ligand of formula (Qa) to (Qo),
respectively, wherein M and X and n have been deleted and H has
been added to each phenolate oxygen, wherein there are two
phenolate oxygen atoms in formula (I), each phenolate oxygen being
bonded to M via a bond depicted by a straight line "-"). In some
embodiments the invention is the ligand of formula (Q). In some
embodiments the invention is the Group 1 or 2 metal salt of the
ligand of formula (Q). The Group 1 or 2 metal salt includes
monometal salts, bimetal salts, and hemimetal salts. Examples of
the monometal salt are Na(Q-H) and [CaOH](Q-H), wherein "Q-H" means
a monodeprotonated ligand of formula (Q) having a formal charge of
-1. Examples of the bimetal salts are Na.sub.2(Q-2H) and
K.sub.2(Q-2H), wherein "Q-2H" means a doubly deprotonated (i.e.,
demetalated dihydro) ligand of formula (Q) having a formal charge
of -2. Examples of the hemimetal salts are Ca(Q-H).sub.2 and
Mg(Q-H).sub.2.
[0142] The Group 1 or 2 metal salt of the ligand of formula (Q) can
be prepared by conventional means. For example, the Group 1 or 2
metal salt of the ligand of formula (Q) can be prepared by
contacting the ligand of formula (Q) with from one to two mole
equivalents of a corresponding metal base such as, for example, a
metal alkoxide, metal hydroxide, metal bicarbonate, or metal
carbonate, wherein the metal of the metal base is the cation of the
metal of Group 1 or 2. Preferably the contacting is performed in a
polar aprotic solvent (e.g., dimethylformamide, dimethylsulfoxide,
acetone, or a mixture thereof), polar protic solvent (e.g.,
methanol, water, or a mixture thereof), or a mixture thereof.
Alternatively the Group 1 or 2 metal salt can be directly prepared
in situ without going through the conjugate acid that is the ligand
of formula (Q). The Group 1 or 2 metal salt of the ligand of
formula (Q) can be converted back to the ligand of formula (Q)
(i.e., back to its conjugate acid form) by conventional means such
as, for example, acidifying with an acid (e.g., acetic acid or
hydrochloric acid) a solution or mixture of the Group 1 or 2 metal
salt of the ligand of formula (Q) in a polar solvent.
[0143] Syntheses of some of the ligands (e.g., the ligand of
formula (Q)) employed to prepare the metal-ligand complexes of
formula (I) may utilize starting materials, intermediates, or
reaction products that contain more than one reactive functional
group. During chemical reactions, a reactive functional group may
be protected from unwanted side reactions by a protecting group
that renders the reactive functional group substantially inert to
the reaction conditions employed. A protecting group is selectively
introduced onto a starting material or intermediate prior to
carrying out the reaction step for which the protecting group is
needed. Once the protecting group is no longer needed, the
protecting group can be removed. It is well within the ordinary
skill in the art to introduce protecting groups during a synthesis
and then later remove them. Procedures for introducing and removing
protecting groups are known, for example, in Protective Groups in
Organic Synthesis, 3rd ed., Greene T. W. and Wuts P. G.,
Wiley-Interscience, New York, 1999. The following moieties are
examples of protecting groups that may be utilized to protect
amino, hydroxy), or other functional groups: carboxylic acyl groups
such as, for example, formyl, acetyl, and trifluoroacetyl;
alkoxycarbonyl groups such as, for example, ethoxycarbonyl,
tert-butoxycarbonyl (BOC),
.beta.,.beta.,.beta.-trichloroethoxycarbonyl (TCEC), and
.beta.-iodoethoxycarbonyl; aralkyloxycarbonyl groups such as, for
example, benzyloxycarbonyl (CBZ), para-methoxybenzyloxycarbonyl,
and 9-fiuorenylmethyloxycarbonyl (FMOC); trialkylsilyl groups such
as, for example, trimethylsilyl (TMS) and tert-butyldimethylsilyl
(TBDMS); and other groups such as, for example, triphenylmethyl
(trityl), tetrahydropyranyl, vinyloxycarbonyl,
ortho-nitrophenylsulfenyl, diphenylphosphinyl, para-toluenesulfonyl
(Ts), mesyl, trifluoromethanesulfonyl, methoxymethyl (MOM), and
benzyl. Examples of procedures for removing protecting groups
include hydrogenolysis of CBZ groups using, for example, hydrogen
gas at about 3.4 atmospheres in the presence of a hydrogenation
catalyst such as 10% palladium on carbon, acidolysis of BOC or MOM
groups using, for example, hydrogen chloride in dichloromethane or
trifluoroacetic acid (TFA) in dichloromethane, reaction of silyl
groups with fluoride ions, and reductive cleavage of TCEC groups
with zinc metal.
[0144] The invention contemplates preparing the metal-ligand
complex of formula (I) and ligands of formula (Q) by any suitable
method. The method of preparation is not critical. Preferably the
method employs a convergent synthesis approach involving coupling
together of two primary intermediates. Preferred illustrative
procedures are described below and shown in FIGS. 1 to 4.
[0145] An illustrative procedure for preparing a first primary
intermediate of formula useful in the convergent synthesis is shown
in Scheme 1 in FIG. 1. In Scheme 1, the first primary intermediate
is of formula (a5). The preparation of the first primary
intermediate of formula (a5) starts with an electrophilic aromatic
substitution reaction of phenol (a1) with a source of a leaving
group LG, wherein LG is, for example, Br or I, to give
functionalized phenol (a2). Depending on particular R.sup.4
employed in Scheme 1, phenol (a1) is available from commercial
suppliers or can be readily prepared by a person of ordinary skill
in the art. The source of the leaving group LG-Y can be, for
example, Br.sub.2, N-bromosuccinimide (NBS), or I.sub.2. If desired
the Br.sub.2 and I.sub.2 can be prepared in situ such as by a
procedure described later in certain Preparations. The oxygen of
functionalized phenol (a2) can then be protected with a hydroxyl
protecting group, PG, such as, for example, a methoxymethyl or
tetrahydropyran-2-ylmethyl so as to form protected phenol (a3),
which also has the leaving group LG. Protected phenol (a3) can be
coupled with a source of R.sup.5 (e.g., source of the hydrocarbyl
or heterohydrocarbyl) such as, for example, R.sup.5--H (a4) via an
aryl coupling reaction so as to prepare first primary intermediate
(a5). Such aryl coupling reactions are known for a variety of types
of source of R.sup.5 and include copper-mediated nitrogen arylation
reactions where the H in R.sup.5--H (a4) is bonded to a nitrogen
atom of R.sup.5, especially a nitrogen atom of a heteroaryl group;
and palladium-mediated carbon arylation reactions where the H in
R.sup.5--H (a4) is bonded to an aromatic, alkenyl, or alkynyl
carbon atom of R.sup.5. The reactions described in Scheme 1
preferably are carried out under a substantially inert gas
atmosphere in an anhydrous aprotic solvent such as, for example,
diethyl ether, toluene, xylenes, tetrahydrofuran, diethylene glycol
dimethyl ether, or a combination thereof and at a temperature in a
range of from about -78.degree. C. to about 200.degree. C.
Preferably, the reactions are carried out at atmospheric
pressure.
[0146] An illustrative procedure for preparing a second primary
intermediate useful in the convergent synthesis is shown in Scheme
2 in FIG. 2. In Scheme 2, the second primary intermediate is of
formula (b4). The preparation of the second primary intermediate of
formula (b4) starts with an electrophilic aromatic substitution
reaction of phenol (b1) with a source of a leaving group LG,
wherein LG is, for example, Br or I, to give functionalized phenol
(b2). The source of the leaving group LG-Y can be the same as
described previously for Scheme 1. Depending on particular R.sup.1,
R.sup.2, and R.sup.3 employed in Scheme 2, phenol (b1) is available
from commercial suppliers or can be readily prepared by a person of
ordinary skill in the art. Two mole equivalents (mole equiv.), more
or less, of functionalized phenol (b2) can then be reacted with a
source of linker L, wherein the source is LG.sup.L-L-LG.sup.L (b3),
wherein L is as defined for formula (I), to give second primary
intermediate (b4). LG.sup.L are leaving groups suitable for be
displaced in a nucleophilic substitution reaction by a phenol or
phenolate anion. Examples of suitable LG.sup.L are bromide, iodide,
trifluoromethanesulfonate, tosylate, and trifluoroacetate. The
reactions described in Scheme 2 preferably are carried out under a
substantially inert gas atmosphere in an anhydrous aprotic solvent
such as, for example, diethyl ether, toluene, xylenes,
tetrahydrofuran, diethylene glycol dimethyl ether, or a combination
thereof and at a temperature in a range of from about -78.degree.
C. to about 200.degree. C. Preparation of second primary
intermediate (b4) can also be carried out in polar organic solvents
such as, for example, acetone, ethyl acetate, acetonitrile,
ethanol, a mixture thereof, and water-containing mixtures thereof.
Preferably, the reactions are carried out at atmospheric
pressure.
[0147] An illustrative procedure for preparing the ligand of
formula (Q) from the first and second primary intermediates is
shown in Scheme 3 in FIG. 3. In Scheme 3, the preparation of the
ligand of formula (Q) starts with a double Suzuki coupling of first
primary intermediate (a5) (prepared as shown in Scheme 1) with
second primary intermediate (b4) (prepared as shown in Scheme 2) to
give a doubly PG-protected analog of ligand of formula (Q) (not
shown), followed by double deprotection of the doubly PG-protected
analog of ligand of formula (Q) that removes both protecting groups
PG therefrom to give the ligand of formula (Q). The reactions
described in Scheme 3 preferably are carried out under a
substantially inert gas atmosphere in an anhydrous aprotic solvent
such as, for example, diethyl ether, toluene, xylenes,
tetrahydrofuran, diethylene glycol dimethyl ether, or a combination
thereof and at a temperature in a range of from about -78.degree.
C. to about 200.degree. C. The double-deprotection reaction can
also be carried out in polar organic solvents such as, for example,
acetic acid, acetone, ethyl acetate, acetonitrile, ethanol, a
mixture thereof, and water-containing mixtures thereof and
preferably further employs a deprotecting agent such as, for
example, an acid (e.g., HCl in ethanol or trifluoroacetic acid in
methylene chloride), a hydrogenolysis reaction (e.g., when PG is,
for example, benzyl or CBZ) employing hydrogen gas and a palladium
catalyst. Preferably, the reactions are carried out at atmospheric
pressure.
[0148] An illustrative procedure for preparing the metal-ligand
complex of formula (I) from the ligand of formula (Q) is shown in
Scheme 4 in FIG. 4. In Scheme 4, the preparation of the
metal-ligand complex of formula (I) involves reacting the ligand of
formula (Q) (prepared as shown in Scheme 3) with a source or
sources of M and X as shown, for example, in Options A to D. In
option A, the compound of formula (Q) is doubly deprotonated with a
non-nucleophilic base to give bisphenolate in situ (not shown),
which is then allowed to react with a metal halide such as
M(Cl).sub.4, wherein M is Zr, Hf, or Ti, followed by reaction of
the resulting metal-ligand complex with a organometallic compound
such as, for example, an organolithium (X--Li) or Grignard reagent
(X--MgBr) (or organosodium (X--Na) or organopotassium (X--K)),
wherein X is as defined above to give the compound of formula (I).
Alternatively in option B, the compound of formula (Q) reacts with
a metal-amido compound M(NR.sup.KR.sup.L).sub.4 wherein R.sup.K and
R.sup.L are as defined previously for formula (I) to give an
intermediate in situ (not shown), which then reacts with the
organometallic compound X--Li or X--MgBr (e.g., organolithium or
Grignard reagent) to give the compound of formula (I). In yet
another option C, the compound of formula (Q) reacts with an
organometallic compound M(X).sub.4 to give the compound of formula
(I). In yet another alternative option D, the compound of formula
(Q) reacts with the metal halide such as M(Cl).sub.4, followed by
reaction of the resulting metal-ligand complex with 4 mole
equivalents of an organometallic compound X--Li or X--MgBr such as,
for example, methyl lithium or methyl magnesium bromide to give the
compound of formula (I). The reactions described in Scheme 4
preferably are carried out under a substantially inert gas
atmosphere in an anhydrous aprotic solvent such as, for example,
toluene, xylenes, tetrahydrofuran, diethylene glycol dimethyl
ether, or a combination thereof and at a temperature in a range of
from about -78.degree. C. to about 200.degree. C. Preferably, the
reactions are carried out at atmospheric pressure.
[0149] The invention contemplates procedures for preparing the
metal-ligand complex of formula (I) and ligands of formula (Q)
other than the previously described procedures illustrated in FIGS.
1 to 4. Such other procedures would be readily known to one of
ordinary skill in the art in view of the teachings described
herein. Examples of such other procedures are those readily adapted
from procedures in U.S. Pat. No. 7,060,848 B2.
[0150] Turning to the invention catalyst, as mentioned previously,
the invention process employs catalytic amounts of the invention
catalyst. When more than one catalyst is employed in the invention
process, each catalyst independently will be employed in a
catalytic amount. The term "catalytic amount" means less than a
stoichiometric quantity based on number of moles of a
product-limiting stoichiometric reactant employed in the invention
process. The catalytic amount is also equal to or greater than a
minimum amount of the metal-ligand complex of formula (I) that is
necessary for at least some product of the catalyzed reaction to be
formed and detected (e.g., by mass spectrometry). The minimum
catalytic amount preferably is 0.0001 mole percent of the number of
moles of a product-limiting stoichiometric reactant. In the
invention process the product-limiting stoichiometric reactant for
the invention catalyst typically will be ethylene. Preferably, the
catalytic amount of the metal-ligand complex of formula (I) used to
prepare the invention catalyst is from 0.001 mol % to 50 mol % of
the moles of ethylene or (C.sub.3-C.sub.40)alpha-olefin, whichever
is lower. More preferably, the catalytic amount of the metal-ligand
complex of formula (I) is at least 0.01 mol %, still more
preferably at least 0.05 mol %, and even more preferably at least
0.1 mol %. Also more preferably, the catalytic amount of the
metal-ligand complex of formula (I) is 40 mol % or less, and still
more preferably 35 mol % or less.
[0151] A particularly preferred invention catalyst is one that can
achieve a high selectivity for polymerizing ethylene in the
presence of the (C.sub.3-C.sub.40)alpha-olefin in the invention
process, wherein the high selectivity is characterized by the
reactivity ratio r.sub.1 described previously. More preferably for
the invention process, the reactivity ratio r.sub.1 is greater than
30, still more preferably greater than 39 or 40, still more
preferably greater than 50, even more preferably greater than 60,
even more preferably greater than 80, and yet more preferably
greater than 90. When the reactivity ratio r.sub.1 for the
invention process approaches infinity, incorporation of the
alpha-olefin into (or onto) the rich polyethylene produced thereby
approaches 0 mole percent (mol %). In some embodiments, the rich
polyethylene or rich polyethylene segment of the poly(ethylene
alpha-olefin) copolymer is characterized as having 6 mol % or less,
more preferably less than 3 mol %, and still more preferably 2.3
mol % or less of the residual of the alpha-olefin covalently
incorporated therein. The mol % is characterized as having at least
0.01 mol %, in other embodiments at least 0.1 mol %, and in still
other embodiments at least 1.0 mol % of the residual of the
(C.sub.3-C.sub.40) alpha-olefin covalently incorporated therein.
Said mol % are preferably determined by nuclear magnetic
spectroscopy (NMR) spectroscopy as described later, but in some
embodiments may alternatively be determined by the FT-IR
spectroscopy as described later. Preferably, the residuals of the
alpha-olefin and ethylene are approximately randomly distributed in
the soft segment of the poly(ethylene alpha-olefin) block
copolymer.
[0152] Preferably the invention catalyst is characterized as having
a minimum catalyst efficiency or higher. The catalyst efficiency is
calculated by dividing the number of grams of rich polyethylene, or
poly(ethylene alpha-olefin) copolymer, prepared by the number of
grams of metal(M) in ingredient (a) (i.e., M in metal-ligand
complex of formula (I)) employed (i.e., catalyst efficiency=g PE
prepared/g M in metal-ligand complex of formula (I) employed).
Preferably when the catalyst efficiency is determined employing
ethylene and 1-octene as described later at a polymerization
reaction temperature of 170.degree. C. and 0.10 micromole (.mu.mol)
of the metal-ligand complex of formula (I), 0.12 .mu.mol of the
activating co-catalyst, bis(octadecyl)methylammonium
tetrakis(pentafluorophenyl)borate
([HNMe(C.sub.18H.sub.37).sub.2][B(C.sub.6F.sub.5).sub.4],
abbreviated as BOMATPB, or, still more preferably a mixture
comprising BOMATPB, wherein the mixture is designated herein as
"BOMATPB.sup.mix" and is derived from
bis(hydrogenated-tallowalkyl)methylamine, wherein the mixture is
prepared according to a procedure of Example 2 of U.S. Pat. No.
6,121,185 (e.g., Preparation D)), and 1.0 .mu.mol of another
activating co-catalyst that is a triisobutylaluminum-modified
methylalumoxane-3A (MMAO-3A), hydrogen gas, and a mixed alkanes
solvent, according to the experimental procedure described later.
The bis(hydrogenated-tallowalkyl)methylamine is obtained from Akzo
Nobel under the trade name ARMEEN M2HT. BOMATPB.sup.mix is
preferred over BOMATPB for practical reasons as it is cheaper to
manufacture than is BOMATPB. Number of moles of BOMATPB.sup.mix is
calculated by assuming the BOMATPB.sup.mix is 100% BOMATPB. The
BOMATPB can be prepared as described in Example 1 of U.S. Pat. No.
6,121,185 (e.g., Preparation A). Using such a process preferably
the catalyst efficiency is greater than 740,000, more preferably
greater than 960,000, still more preferably greater than 1,480,000,
and even more preferably greater than 1,900,000. Preferably when
the catalyst efficiency is determined employing ethylene and
1-octene as described later at a polymerization reaction
temperature of 170.degree. C. and 0.08 .mu.mol of the metal-ligand
complex of formula (I), 0.096 .mu.mol of the BOMATPB or
BOMATPB.sup.mix, and 0.8 .mu.mol of MMAO-3A, the catalyst
efficiency is greater than 1,1,480,000. Preferably when the
catalyst efficiency is determined employing ethylene and 1-octene
as described later at a polymerization reaction temperature of
170.degree. C. and 0.075 .mu.mol of the metal-ligand complex of
formula (I), 0.09 .mu.mol of the BOMATPB or BOMATPB.sup.mix, and
0.75 .mu.mol of MMAO-3A, the catalyst efficiency is greater than
970,000, more preferably greater than 1,060,000, and still more
preferably greater than 1,090,000. Preferably when the catalyst
efficiency is determined employing ethylene and 1-octene as
described later at a polymerization reaction temperature of
170.degree. C. and 0.05 .mu.mol of the metal-ligand complex of
formula (I), 0.06 .mu.mol of the BOMATPB or BOMATPB.sup.mix, and
0.5 .mu.mol of MMAO-3A, the catalyst efficiency is greater than
920,000, more preferably greater than 940,000, and still more
preferably greater than 2,900,000. More preferably the catalyst
efficiency is as defined as in any one of the Examples described
later.
[0153] In some embodiments, the invention catalyst, invention
catalyst system or composition, or both further comprises one or
more solvents (e.g., as in a solvated form of the invention
catalyst), diluents (described later), or a combination thereof, as
described herein. In other embodiments, the invention catalyst
still further comprises a dispersant, e.g., an elastomer,
preferably dissolved in the diluent. In these embodiments, the
invention catalyst preferably comprises a homogeneous catalyst.
[0154] In some embodiments, the each olefin polymerization catalyst
is rendered catalytically active by contacting it to, or reacting
it with, a cocatalyst (sometimes referred to as an activating
cocatalyst or co-catalyst) or by using an activating technique such
as those that are known in the art for use with metal (e.g., Group
4) olefin polymerization reactions. Where there are two or more
such catalysts, they can be activated by the same or different
cocatalyst or same or different activating technique. Many
cocatalysts and activating techniques have been previously taught
with respect to different metal-ligand complexes in the following
USPNs: U.S. Pat. No. 5,064,802; U.S. Pat. No. 5,153,157; U.S. Pat.
No. 5,296,433; U.S. Pat. No. 5,321,106; U.S. Pat. No. 5,350,723;
U.S. Pat. No. 5,425,872; U.S. Pat. No. 5,625,087; U.S. Pat. No.
5,721,185; U.S. Pat. No. 5,783,512; U.S. Pat. No. 5,883,204; U.S.
Pat. No. 5,919,983; U.S. Pat. No. 6,696,379; and U.S. Pat. No.
7,163,907. Preferred cocatalysts (activating co-catalysts) for use
herein include alkyl aluminums; polymeric or oligomeric alumoxanes
(also known as aluminoxanes); neutral Lewis acids; and
non-polymeric, non-coordinating, ion-forming compounds (including
the use of such compounds under oxidizing conditions). A suitable
activating technique is bulk electrolysis (explained in more detail
hereinafter). Combinations of one or more of the foregoing
cocatalysts and techniques are also contemplated. The term "alkyl
aluminum" means a monoalkyl aluminum dihydride or monoalkylaluminum
dihalide, a dialkyl aluminum hydride or dialkyl aluminum halide, or
a trialkylaluminum. Preferably the alkyl of the foregoing
alkyl-aluminums is from 1 to 10 carbon atoms. Triethylaluminum is
more preferred. Aluminoxanes and their preparations are known at,
for example, U.S. Pat. No. 6,103,657. Examples of preferred
polymeric or oligomeric alumoxanes are methylalumoxane,
triisobutylaluminum-modified methylalumoxane, and
isobutylalumoxane. Other preferred cocatalysts are
tri((C.sub.6-C.sub.18)aryl)boron compounds and halogenated
(including perhalogenated) derivatives thereof, (e.g.,
tris(pentafluorophenyl)borane, trityl tetrafluoroborate, or, more
preferably the BOMATPB or BOMATPB.sup.mix)). In some embodiments at
least two of the cocatalysts are used in combination with each
other.
[0155] The ratio of total number of moles of one or more
metal-ligand complexes of formula (I) to total number of moles of
one or more of the activating co-catalysts is from 1:10,000 to
100:1. Preferably, the ratio is at least 1:5000, more preferably at
least 1:1000; and 10:1 or less, more preferably 1:1 or less. When
an alumoxane alone is used as the activating co-catalyst,
preferably the number of moles of the alumoxane that are employed
is at least 100 times the number of moles of the metal-ligand
complex of formula (I). When tris(pentafluorophenyl)borane alone is
used as the activating co-catalyst, preferably the number of moles
of the tris(pentafluorophenyl)borane that are employed to the total
number of moles of one or more metal-ligand complexes of formula
(I) form 0.5:1 to 10:1, more preferably from 1:1 to 6:1, still more
preferably from 1:1 to 5:1. The remaining activating co-catalysts
are generally employed in approximately mole quantities equal to
the total mole quantities of one or more metal-ligand complexes of
formula (I).
[0156] As mentioned before, in some embodiments the invention
catalyst further is employed in the invention process with the
molecular weight control agent. In these molecular weight control
embodiments of the invention process the molecular weight control
agent is an ingredient (e) and the process gives the molecular
weight-controlled rich polyethylene. Examples of molecular weight
control agents are trialkyl aluminum compounds or other chain
shuttling agents, or, preferably hydrogen (H.sub.2).
[0157] As mentioned before, in some embodiments the invention
catalyst is employed with the combination of the chain shuttling
agent and the promiscuous olefin polymerization catalyst. In these
chain shuttling embodiments of the invention process the chain
shuttling agent (CSA) is an ingredient (e) and the promiscuous
olefin polymerization catalyst is an ingredient (f). If desired, in
some embodiments the molecular weight control agent can also be
employed as another ingredient (e). The chain shuttling embodiments
of the invention process give a poly(ethylene alpha-olefin) block
copolymer. The invention catalyst, where it is employed in the
chain shuttling embodiments of the invention process, gives at
least one polyethylene hard segment of the poly(ethylene
alpha-olefin) block copolymer in the presence of the alpha-olefin
and the promiscuous olefin polymerization catalyst gives at least
one soft segment of the poly(ethylene alpha-olefin) block
copolymer, the soft segment comprising residuals of ethylene and
the alpha-olefin. The contacting step comprises a continuous
polymerization process that is performed under olefin polymerizing
conditions and prepares a poly(ethylene alpha-olefin) block
copolymer in one polymerization reactor, the poly(ethylene
alpha-olefin) block copolymer comprising a segment rich in
polyethylene (a hard segment) characterizable by a high melting
temperature (T.sub.m>100 degrees Celsius) and a segment rich in
residuals from the alpha-olefin and ethylene (a soft segment).
Preferably the alpha-olefin employed in the chain shuttling
embodiments of the invention process is a
(C.sub.3-C.sub.40)alpha-olefin.
[0158] Chain shuttling agents are known. As used herein, the term
"chain shuttling agent" means a molecule characterizable, without
limitation, as functioning in the chain shuttling embodiments of
the invention process in such a way that polymer chains are
transferred between two distinct catalysts with different monomer
selectivities in a single polymerization reactor. That is, the
chain shuttling agent (CSA) is a molecule characterizable, without
limitation, as functioning in such a way that during the continuous
process polymer chains are transferred between the catalyst
comprising a mixture or reaction product of ingredients (a) and (b)
and the promiscuous olefin polymerization catalyst. Typically,
chain shuttling agents comprise a first metal that is Al, B, or Ga,
the first metal being in a formal oxidation state of +3; or a
second metal that is Zn or Mg, the second metal being in a formal
oxidation state of +2. Preferred chain shuttling agents are
(C.sub.1-C.sub.12)hydrocarbyl substituted gallium or zinc compounds
(e.g., diethyl zinc) as described in US 2008/0269412 A1. Other
suitable chain shuttling agents are described in US 2009/0186985
A1; U.S. Pat. No. 7,355,089 B2 and each of its US patent family
members; US 2008/0262175 A1; US 2008/0269412 A1; U.S. Pat. No.
7,858,707 B2; and US 2008/0275189 A1.
[0159] In some embodiments, when preparing the poly(ethylene
alpha-olefin) block copolymer according to the immediately
aforementioned embodiments of the invention process, the process
employs a catalyst system comprising a mixture or reaction product
of: (A) a first olefin polymerization catalyst, the first olefin
polymerization catalyst being characterized as having a high
comonomer incorporation index (described later, e.g., a comonomer
incorporation index of 15 mole percent of comonomer or higher); (B)
a second olefin polymerization catalyst, the second olefin
polymerization catalyst being characterized as having a comonomer
incorporation index that is less than 90 percent of the comonomer
incorporation index of the first olefin polymerization catalyst;
and (C) a chain shuttling agent; wherein the second olefin
polymerization catalyst comprises the invention catalyst as
described in the first embodiment.
[0160] The "first olefin polymerization catalyst" is
interchangeably referred to herein as "Catalyst (A)." In some
embodiments, the first olefin polymerization catalyst (Catalyst
(A)) means the aforementioned "promiscuous olefin polymerization
catalyst." The "second olefin polymerization catalyst" is
interchangeably referred to herein as "Catalyst (B)." The first and
second olefin polymerization catalysts (i.e., Catalyst (A)_and
Catalyst (B)) have different ethylene and
(C.sub.3-C.sub.40)alpha-olefin selectivities.
[0161] In some embodiments more than one Catalysts (B), more than
one Catalysts (A), or both independently can be employed in the
invention process, including the chain shuttling embodiments of the
invention process. More preferably, the invention catalyst that
comprises a mixture or reaction product of the ingredients (a) and
(b) as described in the first embodiment is a Catalyst (B), but not
Catalyst (A). Preferably, the comonomer incorporation index of
Catalyst (B) is less than 50 percent and more preferably less than
5 percent of the comonomer incorporation index of Catalyst (A).
Preferably, the comonomer incorporation index for Catalyst (A) is
greater than 20 mol %, more preferably greater than 30 mol %, and
still more preferably greater than 40 mol % incorporation of
comonomer.
[0162] The invention catalyst is employed in the invention process
to selectively polymerize ethylene. Other catalysts (e.g., the
promiscuous olefin polymerization catalyst) may also be employed to
polymerize at least one other polymerizable olefin. Promiscuous
olefin polymerization catalysts are known. The promiscuous olefin
polymerization catalyst (ingredient (f)) is a catalyst useful for
copolymerizing ethylene and the (C.sub.3-C.sub.40)alpha-olefin and
is characterizable as having a reactivity ratio r.sub.1 of less
than 20 (r.sub.1<20), and preferably r.sub.1<14 wherein
reactivity ratio r.sub.1 is as defined previously.
[0163] Preferably the Catalyst (A) of the catalyst system and the
promiscuous olefin polymerization catalyst independently is a
non-invention Catalyst (A) described in US 2004/0220050 A1; US
2006/0199930 A1; US 2007/0167578 A1; US 2008/0275189 A1; US
2008/0311812 A1; U.S. Pat. No. 7,355,089 B2; or WO 2009/012215 A2.
More preferred are the catalysts described in US 2007/0167578 A1,
paragraphs numbered [0138] to [0476]. Also in some of such
embodiments, the catalyst system further comprises a non-invention
Catalyst (B) (i.e., a Catalyst (B) that is other than the invention
catalyst that comprises a mixture or reaction product of the
ingredients (a) and (b), wherein ingredients (a) and (b) are as
described previously for the first embodiment), the non-invention
Catalyst (B) being a Catalyst (B) described in US 2004/0220050 A1;
US 2006/0199930 A1; US 2007/0167578 A1; US 2008/0275189 A1; US
2008/0311812 A1; U.S. Pat. No. 7,355,089 B2; or WO 2009/012215
A2.
[0164] Representative non-invention Catalysts (A) and (B) is
Catalyst (A1) is
[N-(2,6-di(1-methylethyl)phenyl)amido)(2-isopropylphenyl)(.alpha.-naph-
thalen-2-diyl(6-pyridin-2-diyl)methane)]hafnium dimethyl, prepared
according Example 1 of US 2004/0220050 A1, and having the
structure:
##STR00013##
[0165] In some embodiments, the amount of the
(C.sub.3-C.sub.40)alpha-olefin comonomer incorporated into a
polyolefin such as the rich polyethylene or a segment of a
polyolefin copolymer such as the rich polyethylene segment of the
of the poly(ethylene alpha-olefin) copolymer (e.g., the hard and
soft segments of the poly(ethylene alpha-olefin) block copolymer)
is characterized by the aforementioned comonomer incorporation
index. As used herein, the term, "comonomer incorporation index",
refers to the mole percent of residuals of comonomer incorporated
into an ethylene/comonomer copolymer, or ethylene-derived hard
segment thereof, prepared under representative olefin
polymerization conditions (described later herein), ideally under
steady-state, continuous solution polymerization conditions in a
hydrocarbon diluent at 100.degree. C., 4.5 megapascals (MPa)
ethylene pressure (reactor pressure), greater than 92 percent (more
preferably greater than 95 percent) ethylene conversion, and
greater than 0.01 percent comonomer conversion. The selection of
metal-ligand complexes or catalyst compositions having the greatest
difference in comonomer incorporation indices results in copolymers
from two or more monomers having the largest difference in block or
segment properties, such as density.
[0166] Monomer and comonomer content of the polyolefins prepared by
the invention process may be measured using any suitable technique
such as, for example, infrared (IR) spectroscopy, especially the
aforementioned FT-IR spectroscopy, and nuclear magnetic resonance
(NMR) spectroscopy, with techniques based on NMR spectroscopy being
preferred and carbon-13 NMR spectroscopy being more preferred.
Using carbon-13 NMR spectroscopy, prepare an analysis sample from a
polymer sample of the high density polyethylene or poly(ethylene
alpha-olefin) block copolymer by adding approximately 3 g of a
50/50 mixture of tetrachloroethane-d.sup.2/orthodichlorobenzene to
0.4 g of the polymer sample in a 10 millimeter (mm) NMR tube.
Dissolve and homogenize the polymer sample by heating the tube and
its contents to 150.degree. C. Collect carbon-13 NMR spectroscopy
data using a JEOL Eclipse.TM. 400 MHz spectrometer or a Varian
Unity Plus.TM. 400 MHz spectrometer, corresponding to a carbon-13
resonance frequency of 100.5 MHz. Acquire the carbon-13 data using
4000 transients per data file with a 6 second pulse repetition
delay. To achieve minimum signal-to-noise for quantitative
analysis, add multiple data files together. The spectral width is
25,000 Hz with a minimum file size of 32,000 data points. Analyze
the analysis sample at 130.degree. C. in a 10 mm broad band probe.
Determine the comonomer incorporation with the carbon-13 data using
Randall's triad method (Randall, J. C.; JMS-Rev. Macromol. Chem.
Phys., C29, 201-317 (1989), which is incorporated by reference
herein in its entirety.
[0167] In certain circumstances the comonomer incorporation index
may be determined directly, for example by the use of NMR
spectroscopic techniques described previously or by IR
spectroscopy. If NMR or IR spectroscopic techniques cannot be used,
then any difference in comonomer incorporation is indirectly
determined. For polymers formed from multiple monomers this
indirect determination may be accomplished by various techniques
based on monomer reactivities.
[0168] For copolymers produced by a given catalyst, the relative
amounts of comonomer and monomer in the copolymer and hence the
copolymer composition is determined by relative rates of reaction
of comonomer and monomer. Mathematically the molar ratio of
comonomer to monomer is given by
F 2 F 1 = ( [ comonomer ] [ monomer ] ) polymer = R p 2 R p 1 ( 1 )
##EQU00001##
[0169] Here R.sub.p2 and R.sub.p1 are the rates of polymerization
of comonomer and monomer respectively and F.sub.2 and F.sub.1 are
the mole fractions of each in the copolymer. Because
F.sub.1+F.sub.2=1 we can rearrange this equation to
F 2 = R p 2 R p 1 + R p 2 ( 2 ) ##EQU00002##
[0170] The individual rates of polymerization of comonomer and
monomer are typically complex functions of temperature, catalyst,
and monomer/comonomer concentrations. In the limit as comonomer
concentration in the reaction media drops to zero, R.sub.p2 drops
to zero, F.sub.2 becomes zero and the polymer consists of pure
monomer. In the limiting case of no monomer in the reactor R.sub.p1
becomes zero and F.sub.2 is one (provided the comonomer can
polymerize alone).
[0171] For most homogeneous catalysts the ratio of comonomer to
monomer in the reactor largely determines polymer composition as
determined according to either the Terminal Copolymerization Model
or the Penultimate Copolymerization Model.
[0172] For random copolymers in which the identity of the last
monomer inserted dictates the rate at which subsequent monomers
insert, the terminal copolymerization model is employed. In this
model insertion reactions of the type
M i C * + M j k ij M i M j C * ( 3 ) ##EQU00003##
[0173] where C* represents the catalyst, M.sub.i represents monomer
i, and k.sub.ij is the rate constant having the rate equation
R.sub.p.sub.ij=k.sub.ij[ . . . M.sub.iC*][M.sub.j] (4)
[0174] The comonomer mole fraction (i=2) in the reaction media is
defined by the equation:
f 2 = [ M 2 ] [ M 1 ] + [ M 2 ] ( 5 ) ##EQU00004##
[0175] A simplified equation for comonomer composition can be
derived as disclosed in George Odian, Principles of Polymerization,
Second Edition, John Wiley and Sons, 1970, as follows:
F 2 = r 1 ( 1 - f 2 ) 2 + ( 1 - f 2 ) f 2 r 1 ( 1 - f 2 ) 2 + 2 ( 1
- f 2 ) ) f 2 + r 2 f 2 2 . ( 6 ) ##EQU00005##
[0176] From this equation the mole fraction of comonomer in the
polymer is solely dependent on the mole fraction of comonomer in
the reaction media and two temperature dependent reactivity ratios
defined in terms of the insertion rate constants as:
r 1 = k 11 k 12 r 2 = k 22 k 21 . ( 7 ) ##EQU00006##
[0177] Alternatively, in the penultimate copolymerization model,
the identities of the last two monomers inserted in the growing
polymer chain dictate the rate of subsequent monomer insertion. The
polymerization reactions are of the form
M i M j C * + M k k ijk M i M j M k C * ( 8 ) ##EQU00007##
[0178] and the individual rate equations are:
R.sub.p.sub.ijk=k.sub.ijk[ . . . M.sub.iM.sub.j=C*][M.sub.k]
(9).
[0179] The comonomer content can be calculated (again as disclosed
in George Odian, Supra.) as:
( 1 - F 2 ) F 2 = 1 + r 1 ' X ( r 1 X + 1 ) ( r 1 ' X + 1 ) 1 + r 2
' ( r 2 + X ) X ( r 2 ' + X ) ( 10 ) ##EQU00008##
[0180] where X is defined as:
X = ( 1 - f 2 ) f 2 ( 11 ) ##EQU00009##
[0181] and the reactivity ratios are defined as:
r 1 = k 111 k 112 r 1 ' = k 211 k 212 r 2 = k 222 k 221 r 2 ' = k
122 k 121 . ( 12 ) ##EQU00010##
[0182] For this model as well the polymer composition is a function
only of temperature dependent reactivity ratios and comonomer mole
fraction in the reactor. The same is also true when reverse
comonomer or monomer insertion may occur or in the case of the
interpolymerization of more than two monomers.
[0183] Reactivity ratios for use in the foregoing models may be
predicted using well known theoretical techniques or empirically
derived from actual polymerization data. Suitable theoretical
techniques are disclosed, for example, in B. G. Kyle, Chemical and
Process Thermodynamics, Third Addition, Prentice-Hall, 1999 and in
Redlich-Kwong-Soave (RKS) Equation of State, Chemical Engineering
Science, 1972, pp 1197-1203. Commercially available software
programs may be used to assist in deriving reactivity ratios from
experimentally derived data. One example of such software is Aspen
Plus from Aspen Technology, Inc., Ten Canal Park, Cambridge, Mass.
02141-2201 USA.
[0184] As mentioned before, the invention process employs olefin
polymerizing conditions. In some embodiments, the olefin
polymerizing conditions independently produce the invention
catalyst in situ that is formed by combination or reaction of the
metal-ligand complex of formula (I) and the one or more activating
co-catalysts of ingredient (b). The invention catalyst system
comprises the invention catalyst and at least one other ingredient
of the invention process. Such other ingredients include, but are
not limited to, (i) olefin monomer(s); (ii) another metal-ligand
complex of formula (I); (iii) one or more of non-invention
Catalysts (A); (iv) one or more of non-invention Catalysts (B); (v)
chain shuttling agent; (vi) a catalyst stabilizer (if any); (vii) a
solvent (if any); and (viii) a mixture of any two or more
thereof.
[0185] Olefin polymerizing conditions independently refer to
reaction conditions such as solvent(s), atmosphere(s),
temperature(s), pressure(s), time(s), and the like that are
preferred for giving, after 15 minutes reaction time, at least a 10
percent (%), more preferably at least 20%, and still more
preferably at least 30% reaction yield of the rich polyethylene or
rich polyethylene segment of the poly(ethylene alpha-olefin)
copolymer, from the invention process. In some embodiments the rich
polyethylene segment of the poly(ethylene alpha-olefin) copolymer
is the polyethylene hard segment of a poly(ethylene alpha-olefin)
block copolymer. Preferably, the invention process is independently
are run under an inert atmosphere (e.g., under an inert gas
consisting essentially of, for example, nitrogen gas, argon gas,
helium gas, or a mixture of any two or more thereof). Other
atmospheres are contemplated, however, and these include
sacrificial olefin in the form of a gas and hydrogen gas (e.g., as
a polymerization termination agent). In some aspects, the invention
process independently is run without any solvent, i.e., is a neat
process that is run in a neat mixture of ingredients (a) to (d). In
other aspects, the neat mixture further contains additional
ingredients (e.g., catalyst stabilizer such as triphenylphosphine)
other than solvent(s). In still other aspects, the invention
process is run with a solvent or mixture of two or more solvents,
i.e., is a solvent-based process that is run as a
solvent-containing mixture of ingredients (a) to (d), and at least
one solvent, e.g., an aprotic solvent. Preferably, the neat process
or solvent-based process is run at a temperature of the neat
mixture or solvent-containing mixture of from -20.degree. C. to
about 300.degree. C. In some embodiments, the temperature is at
least 30.degree. C., and more preferably at least 40.degree. C. One
of the advantages of the invention catalysts is that they
functional well at high ethylene polymerization temperatures (e.g.,
more than 130.degree. C.), even in presence of an alpha-olefin and
without incorporating undesired amounts of the alpha-olefin. In
some embodiments, the temperature is at least 100.degree. C. In
some embodiments, the temperature is at least 120.degree. C. In
some embodiments, the temperature is at least 130.degree. C. In
some embodiments, the temperature is at least 150.degree. C. In
some embodiments, the temperature is 200.degree. C. or lower. In
some embodiments, the temperature is 180.degree. C. or lower. In
some embodiments, the temperature is 160.degree. C. or lower. A
convenient temperature is from about 130.degree. C. to about
190.degree. C. (e.g., 150.degree. C. or 170.degree. C. or
190.degree. C.). Preferably the invention process independently is
run under a pressure of from about 0.9 atmospheres (atm) to about
10 atm (i.e., from about 91 kiloPascals (kPa) to about 1010 kPa).
More preferably, the pressure is about 1 atm (i.e., about 101
kPa).
[0186] In some embodiments, polymerizable olefins useful in the
invention process are (C.sub.2-C.sub.40)hydrocarbons consisting of
carbon and hydrogen atoms and containing at least 1, and preferably
no more than 3, and more preferably no more than 2, carbon-carbon
double bonds. In some embodiments, from 1 to 4 hydrogen atoms of
the (C.sub.2-C.sub.40)hydrocarbons are replaced, each by a halogen
atom, preferably fluoro or chloro to give halogen atom-substituted
(C.sub.2-C.sub.40)hydrocarbons as the useful polymerizable olefins.
The (C.sub.2-C.sub.40)hydrocarbons (not halogen atom-substituted)
are preferred. Preferred polymerizable olefins (i.e., olefin
monomers) useful for making the polyolefins are ethylene and
polymerizable (C.sub.3-C.sub.40)olefins. The
(C.sub.3-C.sub.40)olefins include an alpha-olefin, a cyclic olefin,
styrene, and a cyclic or acyclic diene. In some embodiments at
least one of the other polymerizable olefin is the alpha-olefin,
and more preferably a (C.sub.3-C.sub.40)alpha-olefin. In some
embodiments the (C.sub.3-C.sub.40)alpa-oefin is a
(C.sub.4-C.sub.40)alpha-olefin, more preferably a
(C.sub.6-C.sub.40)alpha-olefin, still more preferably a
(C.sub.7-C.sub.40)alpha-olefin, and even more preferably a
(C.sub.8-C.sub.40)alpha-olefin. Preferably, the alpha olefin
comprises the (C.sub.3-C.sub.40) alpha-olefin, more preferably a
branched chain (C.sub.3-C.sub.40)alpha-olefin, still more
preferably a linear-chain (C.sub.3-C.sub.40)alpha-olefin, even more
preferably a linear chain (C.sub.3-C.sub.40)alpha-olefin of formula
(A): CH.sub.2.dbd.CH.sub.2--(CH.sub.2).sub.zCH.sub.3 (A), wherein z
is an integer of from 0 to 40, and yet even more preferably a
linear-chain (C.sub.3-C.sub.40)alpha-olefin that is 1-propene,
1-butene, 1-pentene, 1-hexene, 1-heptene, 1-octene, 1-nonene,
1-decene, 1-undecene, 1-dodecene, 1-tridecene, 1-tetradecene,
1-pentadecene, 1-hexadecene, 1-heptadecene, 1-octadecene, or a
linear chain (C.sub.20-C.sub.24)alpha-olefin. Preferably the cyclic
olefin is a (C.sub.3-C.sub.40)cyclic olefin. Preferably, the cyclic
or acyclic diene is a (C.sub.4-C.sub.40)diene, preferably an
acyclic diene, more preferably an acyclic conjugated
(C.sub.4-C.sub.40)diene, more preferably an acyclic 1,3-conjugated
(C.sub.4-C.sub.40)diene, and still more preferably
1,3-butadiene.
[0187] Polyolefins that can be made by an invention process
include, for example, rich polyethylene and interpolymers that
comprise residuals of ethylene and one or more polymerizable
(C.sub.3-C.sub.40)olefins. Preferred homopolymers are high density
polyethylene. Preferred interpolymers are those prepared by
co-polymerizing a mixture of two or more polymerizable olefins such
as, for example, ethylene/propylene, ethylene/1-butene,
ethylene/1-pentene, ethylene/1-hexene, ethylene/4-methyl-1-pentene,
ethylene/1-octene, ethylene/styrene, ethylene/propylene/butadiene
and other EPDM terpolymers. Preferably, the polyolefin is an
ethylene homopolymer (e.g., a high density polyethylene), an
ethylene/alpha-olefin interpolymer (i.e., poly(ethylene
alpha-olefin) copolymer such as, for example, a poly(ethylene
1-octene)), or an ethylene/alpha-olefin/diene interpolymer (i.e., a
poly(ethylene alpha-olefin diene) terpolymer such as, for example,
a poly(ethylene 1-octene 1,3-butadiene).
[0188] Preferably in the invention process, the mole ratio of
(moles of (C.sub.3-C.sub.40)alpha-olefin)/(moles of ethylene) is
0.1 or higher, more preferably 0.30 or higher, still more
preferably 0.50 or higher, and even more preferably 0.75 or higher
(e.g., 1.0 or higher).
[0189] In another embodiment, the present invention is a
polyolefin, preferably the rich polyethylene (e.g., in an isolated
form or as part of an intermediate mixture with the alpha-olefin)
prepared by the invention process.
[0190] The invention olefin polymerization reactions can be run in
one reactor or multiple reactors, the multiple reactors being two
reactors, or more than two reactors. For example, single reactor,
multiple catalyst processes are useful in the present invention. In
one embodiment, two or more catalysts are introduced into a single
reactor under the olefin polymerization conditions, wherein at
least the first one of the catalysts is an invention catalyst and
each catalyst inherently produces a mixture or blend of different
polyolefin copolymers. The terms "mixture" and "blend" as applied
to the polyolefin copolymers are synonymous. In one embodiment, a
relatively high molecular weight product (M.sub.w from 100,000 to
over 1,000,000, more preferably 200,000 to 500,000) polyolefin is
formed from one of the catalysts while a product of a relatively
low molecular weight (M.sub.w 1,2,000 to 300,000) polyolefin is
formed from another of the catalysts. The two or more catalysts can
have similar or different comonomer incorporation ability,
different molecular weight capability, or a combination thereof.
The resulting mixture or blend of different polyolefin copolymers
will have properties dependent on the ratio of the two or more
catalysts that are employed in the single reactor. Suitable
combinations of polyolefin molecular weight, comonomer
incorporation ability, processes, and ratios of catalysts for such
products are disclosed in U.S. Pat. No. 6,924,342. The invention
catalysts are compatible with other olefin polymerization
catalysts, including Ziegler/Natta catalysts. Due to this
compatibility, the second catalyst composition may comprise another
invention catalyst, a metallocene or other .pi.-bonded ligand group
containing metal-ligand complex (including constrained geometry
metal-ligand complexes), or a polyvalent heteroatom ligand group
containing metal-ligand complex, especially polyvalent pyridylamine
or imidizolylamine based complexes and tetradentate oxygen-ligated
biphenylphenol based Group 4 metal-ligand complexes. Preferably,
the invention catalyst is prepared from and the invention process
employs three or fewer, more preferably two, and still more
preferably one metal-ligand complex of formula (I) per reactor.
[0191] Examples of suitable processes and systems employing
multiple reactors include such processes and systems as are
disclosed in U.S. Pat. No. 3,914,342. The multiple reactors,
preferably two reactors, can be operated in series or in parallel,
with at least one invention catalyst being employed in at least one
of the reactors. In some embodiments one, two, or, when employing
more than two reactors, three or more of the multiple reactors
contain the two or more catalysts described in the immediately
preceding paragraph (single reactor paragraph). Polyolefin products
from these reactors can have similar or different densities. The
final polymer product is a mixture or blend of effluents of
different polyolefin copolymers from the two or more, preferably
two, reactors. The effluents of different polyolefin copolymers are
combined by mixing or blending prior to being subjected to
devolatilization so as to result in a uniform mixing or blending of
the different polyolefin copolymers. In another embodiment, the
molecular weight of the different polyolefin copolymers from the
two or more reactors is nearly the same but the densities vary to
the extent that one of the reactors produces a first polyolefin
copolymer with density in the range of 0.865-0.895, while another
reactor produces a second polyolefin copolymer with a different
density in the range of 0.885-0.950. When two reactors and two
catalysts, at least one of which is an invention catalyst, are
employed, such a dual reactor/dual catalyst invention process
allows for the preparation of a mixture or blend polyolefin
copolymers with tailored properties. In some embodiments employing
the dual reactors, two reactors are connected in series, that is,
the effluent from a first reactor is charged to a second reactor
and, optionally, fresh monomer, solvent and hydrogen is added to
the second reactor. Olefin polymerization conditions are adjusted
in the second reactor so that they are different from the olefin
polymerization conditions that were employed in the first reactor
such that a weight ratio of weight of the polyolefin copolymer
produced in the first reactor to weight of the polyolefin copolymer
produced in the second reactor is ideally in the range of from
20:80 to 80:20. This embodiment of a dual reactor process is
capable of producing a mixture or blend of different polyolefin
copolymers having broadened molecular weight distribution or
polydispersity index (PDI). In addition, in a more preferred
embodiment, the invention process produces a mixture or blend of
different polyolefin copolymers that comprises high and low
molecular weight polyolefin copolymer components, wherein the high
molecular weight polyolefin copolymer component contains higher
quantities of comonomer (lower density) incorporated therein than
quantities of comonomer that are contained in the low molecular
weight polyolefin copolymer component.
[0192] In some embodiments one of the two reactors of the dual
reactor embodiment, including the first of two reactors operating
in series, contains a heterogeneous Ziegler-Natta catalyst or a
chromium containing catalyst, such as one of the numerous such
catalysts known in the art. Examples of Ziegler-Natta catalysts
include, but are not limited to, titanium-based catalysts supported
on MgCl.sub.2, and additionally comprise compounds of aluminum
containing at least one aluminum-alkyl bond. Suitable Ziegler-Natta
catalysts and their preparation include, but are not limited to,
those disclosed in U.S. Pat. Nos. 4,612,300, 4,330,646, and
5,869,575. Suitable chromium based catalysts are those disclosed in
U.S. Pat. Nos. 4,981,927, 4,835,219, 4,564,660, 4,173,548,
3,953,413, and elsewhere. The invention catalyst is contained in
the same or different one of the two reactors.
[0193] The mixture or blend of different polyolefin copolymers and
invention process for preparing same are preferred. Especially
preferred is such a mixture or blend containing the rich
polyethylene or rich polyethylene segment-containing poly(ethylene
alpha-olefin) copolymer produced by the invention process.
[0194] In another embodiment the present invention is the
poly(ethylene alpha-olefin) copolymer prepared by certain
embodiments of the invention process. A particularly valuable type
of poly(ethylene alpha-olefin) copolymer is the aforementioned
poly(ethylene alpha-olefin) block copolymer or, simply, an olefin
block copolymer (OBC). OBCs are characterized as having at least
one so-called "hard segment" or block comprising residuals of
ethylene monomer and at least one so-called "soft segment" or block
comprising residuals of an alpha-olefin (also known as an
alpha-olefin and 1-olefin) monomer. OBCs are available from The Dow
Chemical Company, Midland, Mich., USA under the trade name
INFUSE.TM. Olefin Block Copolymers. INFUSE.TM. Olefin Block
Copolymers are useful in a variety of forms and applications such
as, for example, those listed at www.dow.com/infuse. Part of a
preparation of an OBC involves a process that, among other steps,
selectively polymerizes ethylene in the presence of the
alpha-olefin to form the one or more hard segments of the OBC. More
preferably, the poly(ethylene alpha-olefin) block copolymer is
characterizable as having a melting temperature of greater than 100
degrees Celsius, and more preferably greater than 120.degree. C.,
as determined by Differential Scanning Calorimetry using the
procedure described later.
[0195] The poly(ethylene alpha-olefin) block copolymers comprise
ethylene residuals and one or more copolymerizable .alpha.-olefin
comonomer residuals (i.e., ethylene and one or more copolymerizable
.alpha.-olefin comonomers in polymerized form). The poly(ethylene
alpha-olefin) block copolymers are characterized by multiple blocks
or segments of two or more polymerized monomer units differing in
chemical or physical properties. That is, the
ethylene/.alpha.-olefin interpolymers are block interpolymers,
preferably multi-block interpolymers or copolymers. The terms
"interpolymer" and copolymer" are used interchangeably herein. In
some embodiments a polyolefin block of the copolymer can be
characterized as being a hard or soft block. "Hard" blocks or
segments refer to crystalline or semi-crystalline blocks of
polymerized units in which in some embodiments contain ethylene,
preferably ethylene is present in an amount greater than about 80
mole percent, and preferably greater than 88 mole percent. In other
words, the comonomer content in the hard segments is less than 20
mole percent, and preferably less than 12 weight percent. In some
embodiments, the hard segments comprise all or substantially all
ethylene. Such hard blocks are sometimes referred to herein as
"rich polyethylene" blocks or segments. "Soft" blocks or segments,
on the other hand, refer to blocks of polymerized units in which
the comonomer content is greater than 20 mole percent, preferably
greater than 25 mole percent, up to 100 mole percent. In some
embodiments, the comonomer content in the soft segments can be
greater than 20 mole percent, greater than 25 mole percent, greater
than 30 mole percent, greater than 35 mole percent, greater than 40
mole percent, greater than 45 mole percent, greater than 50 mole
percent, or greater than 60 mole percent. "Soft" blocks or segments
may refer to amorphous blocks or segments or with levels of
crystallinity lower than that of the "hard" blocks or segments
[0196] A preferred poly(olefin monomer-olefin comonomer) block
copolymer is a poly(olefin monomer-olefin comonomer) that is
characterizable as being a multiblock interpolymer having blocks or
segments of two or more polymerized monomer units differing in
chemical or physical properties, and characterizable as being
mesophase separated. Such copolymers are sometimes referred to
herein as "mesophase-separated olefin multiblock interpolymers."
Preferably, each poly(olefin monomer-olefin comonomer)
independently is characterizable as being mesophase separated and
having a PDI of 1.4 or greater.
[0197] In some embodiments, the poly(olefin monomer-olefin
comonomer) block copolymer is an ethylene/alpha-olefin
interpolymer, such as those described in US 2010/0298515 A1,
preferably a block copolymer, which comprises a hard segment and a
soft segment, and is characterized by a M.sub.w/M.sub.n in the
range of from about 1.4 to about 2.8 and (a), (b), (c), (d), (e),
(f), or (g): (a) paragraph [0074] of US 2010/0298515 A1; or (b)
paragraph [0075] of US 2010/0298515 A1; or (c) paragraph [0076] of
US 2010/0298515 A1; or (d) paragraph [0077] of US 2010/0298515 A1;
or (e) paragraph [0078] of US 2010/0298515 A1; or (f) paragraph
[0079] of US 2010/0298515 A1; or (g) paragraph [0107] of US
2010/0298515 A1; wherein the US 2010/0298515 A1 paragraphs
referenced in this paragraph, and their relevant supporting
characterization methods as described in paragraphs [0291] to
[0326] of US 2010/0298515 A1, are incorporated by reference here;
and wherein the ethylene/alpha-olefin block interpolymer is
mesophase separated.
[0198] In some embodiments the poly(olefin monomer-olefin
comonomer) block copolymer is an ethylene/alpha-olefin
interpolymer, such as that described in U.S. Pat. No. 7,355,089 and
US 2006/0199930 A1, wherein the interpolymer is preferably a block
copolymer, and comprises a hard segment and a soft segment, and the
ethylene/alpha-olefin interpolymer (a), (b), (c), (d), (e), (0,
(g), or (h): (a) paragraph [0049] of US 2006/0199930 A1; or (b)
paragraphs [0049] and [0051] of US 2006/0199930 A1; or (c)
paragraph [0053] of US 2006/0199930 A1; or (d) paragraph [0052] of
US 2006/0199930 A1; or (e) paragraph [0056] of US 2006/0199930 A1;
or (f) paragraphs [0047] and [0052] of US 2006/0199930 A1; or (g)
paragraph [0047] of US 2006/0199930 A1; or (h) paragraph [0065] of
US 2006/0199930 A1; wherein the US 2006/0199930 A1 paragraphs
referenced in this paragraph and their relevant supporting
characterization methods as described in paragraphs [0169] to
[0202] of in US 2006/0199930 A1, are incorporated by reference
here.
[0199] Other embodiments comprise polyolefins and processes such as
those described in US 2007/0167315 A1, US 2008/0311812 A1, and US
2007/0167578 A1; and WO 2009/097565.
[0200] In some embodiments a preferred invention process can
achieve a minimum molecular weight distribution or polydispersity
index (PDI) of the polyolefin product produced thereby. In some
embodiments the PDI is greater than 2.4, in other embodiments the
PDI is greater than 4.0, in other embodiments the PDI is greater
than 6.0, and in still other embodiments the PDI is greater than
8.0. In some embodiments the PDI is less than 11. More preferably
the PDI is as defined as in any one of the Examples described
later.
[0201] In some embodiments a preferred invention process can
achieve a productivity ratio of weight of polyolefin produced per
weight of ethylene employed, as determined employing ethylene and
1-octene as described later at a polymerization reaction
temperature of 170.degree. C., wherein the productivity ratio of
the polyolefin produced to ethylene employed is greater than 1.00,
preferably greater than 1.10, more preferably greater than 1.40,
and still more preferably greater than 2.50. More preferably the
productivity ratio is as defined as in any one of the Examples
described later.
Materials, Methods and Preparations
[0202] General Considerations All solvents and reagents are
obtained from commercial sources and used as received unless
indicated otherwise. Purify hexanes solvent through a column of
activated alumina followed by a column of Q5 copper oxide on
alumina (Cu-0226 S is obtained from (Engelhard subsidiary of BASF
Corporation). Purify tetrahydrofuran (THF) and diethyl ether
through columns of activated alumina Synthesize and store all
metal-ligand complexes in a Vacuum Atmospheres inert atmosphere
glove box under a dry nitrogen atmosphere. Record NMR spectra on a
300 megahertz (MHz) Varian INOVA spectrometer. Report chemical
shifts in parts per million (.delta.) versus tetramethylsilane and
referenced to residual protons in a deuterated solvent.
[0203] Determining percent incorporation of 1-octene and polymer
density by FT-IR Spectroscopy: Deposit 140 microliters (.mu.L) of
each polymer solution onto a silica wafer, heat at 140.degree. C.
until the 1,2,4-trichlorobenzne (TCB) evaporates, and analyze using
a Nicolet Nexus 670 FT-IR with 7.1 version software equipped with
an AutoPro auto sampler.
[0204] Gel permeation chromatography (GPC): Determine weight
average molecular weight (M.sub.W) and polydispersity index:
Determine M.sub.W and ratio of M.sub.W/M.sub.n (polydispersity
index or PDI) using a Polymer Labs.TM. 210 high temperature gel
permeation chromatograph. Prepare samples using 13 mg of
polyethylene polymer that is diluted with 16 mL of
1,2,4-trichlorobenzene (stabilized with butylated hydroxy toluene
(BHT)), heat and shake at 160.degree. C. for 2 hours.
[0205] Determining melting and crystallization temperatures and
heat of fusion by Differential Scanning Calorimetry (DSC; DSC 2910,
TA Instruments, Inc.)): First heat samples from room temperature to
180.degree. C. at a heating rate of 10.degree. C. per minute. After
being held at this temperature for 2 to 4 minutes, cool the samples
to -40.degree. C. at a cooling rate of 10.degree. C. per minute;
hold the sample at the cold temperature for 2 to 4 minutes, and
then heat the sample to 160.degree. C.
[0206] Analyzing end groups by proton-nuclear magnetic resonance
(.sup.1H-NMR) spectroscopy using a Varian 600 MHz NMR instrument
and deuterated tetrachloroethane.
[0207] Abbreviations (meanings): r.t. (room temperature); g
(gram(s)); mL (milliliter(s)); .degree. C. (degrees Celsius); mmol
(millimole(s)); MHz (MegaHertz); Hz (Hertz).
[0208] Examples of general synthetic methods are as described in
U.S. Pat. No. 7,060,848 B2.
[0209] Preparation 1: preparation of intermediate,
3,6-bis(1,1-dimethylethyl)-9H-carbazole, (P1).
##STR00014##
[0210] To a 500 mL three-necked round bottom flask equipped with an
over head stirrer, nitrogen gas bubbler, and an addition funnel add
20.02 g (120.8 mmol) of carbazole, 49.82 g (365.5 mmol) of
ZnCl.sub.2, and 300 mL of nitromethane at room temperature. To the
resulting dark brown slurry add 49.82 g (365.5 mmol) of
2-chloro-2-methylpropane (also known as tertiary-butyl chloride or
t-BuCl) dropwise from the addition funnel over the period of 2.5
hours. After completing the addition, stir the resulting slurry for
an additional 18 hours. Pour the reaction mixture into 800 mL of
ice cold water, extract with 3.times.500 mL methylene chloride,
combine and dry the extracts with anhydrous magnesium sulfate,
filter, and concentrate the filtrate first by rotary evaporation
and then by evaporation under high vacuum to remove nitromethane.
Dissolve the resulting residue first in hot methylene chloride (70
mL) followed by hot hexanes (50 mL), allow the resulting solution
to cool to room temperature and then placed it in a refrigerator
overnight. Isolate the solids formed and wash the isolated solids
with cold hexanes and then place them under high vacuum to yield
10.80 g (32.0%) of (P1) as off white crystals.
[0211] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.11 (d, J=1.6 Hz,
2H), 7.75 (s, 1H), 7.48 (dd, J=8.5, 1.9 Hz, 2H), 7.31 (d, J=8.5 Hz,
2H), 1.48 (s, 18H).
[0212] .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 142.17 (s),
137.96 (s), 123.45 (s), 123.28 (s), 116.11 (s), 109.97 (s), 34.73
(s), 32.09 (s).
[0213] Preparation 2: preparation of intermediate,
2-iodo-4-(2,4,4-trimethylpentan-2-yl)phenol, (P2).
##STR00015##
[0214] To a stirred solution of 10.30 g (50.00 mmol) of
4-(2,4,4-trimethylpentan-2-yl)phenol in 125 mL of methanol at
0.degree. C., add 7.48 g (50.00 mmol) of NaI and 2.00 g (50 mmol)
of NaOH. To the resulting mixture add 86 mL of 5% aqueous NaOCl
solution (commercial bleach) over a one hour period. Stir the
resulting slurry for one more hour at 0.degree. C. Then add 30 mL
of aqueous 10% Na.sub.2S.sub.2O.sub.3 solution, and acidify the
resulting reaction mixture with addition of dilute hydrochloric
acid. Extract the resulting mixture with methylene chloride, wash
the resulting organic layer with brine, and dry it over anhydrous
magnesium sulfate. Remove volatiles and purify the resulting
residue by flash chromatography on silica gel eluting with 5 volume
percent (vol %) ethyl acetate in hexanes to yield 11.00 g (66%) of
(P2) as a viscous oil.
[0215] .sup.1H NMR (CDCl.sub.3) .delta. 7.60 (d, J=2.5 Hz, 1H),
7.25 (dd, J=8.5 and 2.2 Hz, 1H), 6.90 (d, J=8.5 Hz, 1H), 5.13 (s,
1H), 1.69 (s, 2H), 1.32 (s, 6H) and 0.74 (s, 9H).
[0216] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 152.21, 144.52,
135.56, 128.03, 114.17, 85.36, 56.92, 38.01, 32.43, 31.90 and
31.64.
[0217] GCMS (m/e): 332 (M.sup.+).
[0218] Preparation 3: preparation of intermediate,
2-iodo-1-(methoxymethoxy)-4-(2,4,4-trimethylpentan-2-yl)benzene,
(P3).
##STR00016##
[0219] (A general procedure for methoxymethyl-ether (MOM-ether
synthesis.) To a stirred solution of
4-(2,4,4-trimethylpentan-2-yl)phenol (P2) (9.50 g, 28.61 mmol,
Preparation 2) and dimethoxymethane (25 mL, 286.2 mmol; DMM) in 150
mL of methylene chloride under the nitrogen atmosphere, add 14.00 g
(99.29 mmol) of P.sub.2O.sub.5 in portions over a period of 1.5
hours. After the final addition, stir the resulting reaction
mixture for another 1.5 hours. Then decant the resulting solution,
and pass the decanted liquid through a small bed of silica gel.
Wash the resulting solution successively with water and brine, and
dry the washed solution over anhydrous magnesium sulfate. Pass the
dried solution through a small bed of silica gel, and remove
solvent to yield 9.90 g (92%) of pure (P3) as a viscous oil.
[0220] .sup.1H NMR (C.sub.6D.sub.6) .delta. 7.88 (d, J=2.2 Hz, 1H),
7.03 (dd, J=2.5 Hz and 8.5 Hz, 1H), 6.89 (d, J=8.8 Hz, 1H), 4.82
(s, 2H), 3.12 (s, 3H), 1.53 (s, 2H), 1.15 (s, 6H) and 0.70 (s,
9H).
[0221] .sup.13C{.sup.1H} NMR (C.sub.6D.sub.6) .delta. 154.47,
145.69, 137.49, 127.40, 114.45, 95.12, 87.32, 56.98, 56.03, 38.11,
32.55.
[0222] Preparation 4: preparation of intermediate,
3,6-di-tert-butyl-9-(2-(methoxymethoxy)-5-(2,4,4-trimethylpentan-2-yl)phe-
nyl)-9H-carbazole, (P4).
##STR00017##
[0223] Heat a mixture of 4.96 g (13.18 mmol) of
2-iodo-1-(methoxymethoxy)-4-(2,4,4-trimethylpentan-2-yl)benzene
(P3), Preparation 3; 3.68 g (13.18 mmol) of 3,6-di-t-butylcarbazole
(P1), Preparation 1; 0.53 g (2.6 mmol) of CuI, 8.42 g (39.54 mmol)
of K.sub.3PO.sub.4, and 0.63 g (4.13 mmol) of
N,N'-dimethylethylenediamine in 25 mL of toluene under nitrogen
atmosphere to reflux and reflux for 24 hours. Cool the reaction
mixture, dilute it with 25 mL of THF, and filter to remove solid.
Concentrate the filtrate to give a solid residue. Crystallize the
solid residue from acetonitrile to yield 5.5 g (90%) of (P4) as
white solid.
[0224] .sup.1H NMR (CDCl.sub.3) .delta. 8.17 (d, J=2.4 Hz, 2H),
7.46 (m, 4H), 7.33 (d, J=7.8 Hz, 1H), 7.09 (d, J=8.6 Hz, 2H), 4.94
(s, 2H), 3.21 (s, 3H), 1.76 (s, 2H), 1.50 (s, 18H), 1.40 (s, 6H)
and 0.83 (s, 9H).
[0225] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 151.37, 144.89,
142.16, 139.87, 127.85, 126.81, 126.63, 123.34, 122.99, 116.34,
116.03, 109.45, 95.13, 57.00, 56.07, 38.25, 34.70, 32.40, 32.07,
31.84, 31.57.
[0226] Preparation 5: preparation of intermediate,
2-(2-iodo-4-(2,4,4-trimethylpentan-2-yl)phenoxy)tetrahydro-2H-pyran,
(P5).
##STR00018##
[0227] To a stirred solution of 4.91 g (14.78 mmol) of
4-(2,4,4-trimethylpentan-2-yl)phenol (P2) and 1.50 g (17.83 mmol)
of 3,4-dihydropyran in 5 mL of methylene chloride at 0.degree. C.
add 0.039 g (0.205 mmol) of para-toluenesulfonic acid monohydrate.
The resulting solution quickly becomes purple. Allow solution to
warm to room temperature, and stir thereat for approximately 10
minutes. Then add 0.018 g (0.178 mmol) of triethylamine, and the
resulting mixture turned yellow. Dilute the mixture with 50 mL of
methylene chloride, and successively wash the diluted mixture with
50 mL each of 1M NaOH, water, and brine. Dry the organic phase with
anhydrous magnesium sulfate, filter, and concentrate to give a
crude material. Purify the crude material by flash chromatography
on silica gel using 5 vol % ethyl acetate in hexanes to yield 5.18
g (93.12%) of (P5) as a golden oil.
[0228] .sup.1H NMR (CDCl.sub.3) .delta. 7.74 (d, J=2.3 Hz, 1H),
7.27 (dd, J=2.3 and 8.6 Hz, 1H), 6.99 (d, J=8.6 Hz, 1H), 5.49 (m,
1H), 3.91 (m, 1H), 3.61 (m, 1H), 2.20-1.60 (m, 6H), 1.69 (s, 2H),
1.34 (s, 6H) and 0.75 (s, 9H).
[0229] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 153.27, 145.49,
136.98, 127.08, 114.44, 96.72, 87.09, 61.69, 56.91, 37.95, 32.33,
31.81, 31.52, 31.44, 30.26, 25.27, 18.36.
[0230] Preparation 6: preparation of intermediate,
3,6-di-tert-butyl-9-(2-(tetrahydro-2H-pyran-2-yloxy)-5-(2,4,4-trimethylpe-
ntan-2-yl)phenyl)-9H-carbazole, (P6).
##STR00019##
[0231] To a 50 mL three necked round bottom flask equipped with a
stir bar and condenser under N.sub.2 atmosphere add 20 mL of dry
toluene, 5.00 g (12.01 mmol) of
2-(2-iodo-4-(2,4,4-trimethylpentan-2-yl)phenoxy)tetrahydro-2H-pyran
(P5), Preparation 5; 3.56 g (12.01 mmol) of 3,6-di-t-butyl
carbazole (P1), Preparation 1; 0.488 g (2.56 mmol) of Cud, 7.71 g
(36.22 mmol) of K.sub.3PO.sub.4, and 0.338 g (3.84 mmol) of
N,N'-dimethylethylenediamine. Reflux the reaction mixture for 48
hours, cool it, filter it through a bed of silica gel, rinse the
silica gel with tetrahydrofuran (THF), and concentrate the organics
to give a crude residue. Crystallize the crude residue using
acetonitrile to yield 4.57 g (67.01%) of (P6) as a white solid.
[0232] .sup.1H NMR (CDCl.sub.3) .delta. 8.13 (t, J=1.71 Hz, 1H),
7.48 (d, J=2.4 Hz, 1H), 7.40 (m, 3H), 7.31 (d, J=8.68 Hz, 1H), 7.14
(d, J=8.68 Hz, 1H), 7.08 (d, J=8.56 Hz, 1H), 5.22 (t, J=2.81 Hz,
1H), 3.72 (td, J=11.12 and 2.8 Hz, 1H), 3.47 (dt, J=11.12 and 3.47
Hz, 1H), 1.75 (s, 2H), 1.474 (s, 9H), 1.472 (s, 9H), 1.394 (s, 3H),
1.391 (s, 3H), 1.37-1.12 (m, 6H) and 0.82 (s, 9H).
[0233] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 150.96, 144.22,
142.07, 140.02, 127.49, 126.60, 126.56, 123.14, 123.12, 122.96,
116.37, 115.88, 115.72, 110.18, 109.52, 97.02, 61.56, 57.03, 38.23,
34.69, 32.41, 32.07, 31.86, 31.72, 31.50, 29.98, 25.06, 17.61.
[0234] Preparation 7: preparation of intermediate,
2,4-difluoro-6-iodophenol, (P7).
##STR00020##
[0235] To a stirred solution of 10 g of 2,4-difluorophenol in 300
mL of methanol at 0.degree. C., add 22.5 g (150.2 millimoles (mmol)
of NaI and 3.08 g (77 mmol) of NaOH. To the resulting mixture add
175 mL of 5% aqueous NaOCl solution (commercial bleach) over a one
hour period. Stir the resulting slurry for one more hour at
0.degree. C. Add 100 mL of 10% aqueous Na.sub.2S.sub.2O.sub.3
solution, and acidify the resulting reaction mixture by adding
dilute hydrochloric acid. Extract the resulting mixture with
methylene chloride, wash the resulting organic layer with brine and
dry it over anhydrous magnesium sulfate. Remove solvent and purify
the residue by flash chromatography using 50 vol % methylene
chloride in hexanes to yield 8.10 g (41.16%) of pure
2,4-difluoro-6-iodophenol (P7) as a white solid.
[0236] .sup.1H NMR (CDCl.sub.3) .delta. 7.24 (m, 1H), 6.90 (m, 1H)
and 5.30 (s, 1H).
[0237] .sup.13C{.sup.1H} NMR (126 MHz, CDCl.sub.3) .delta. 155.88
(dd, J=245.8, 11.1 Hz), 148.90 (dd, J=247.0, 12.4 Hz), 140.77 (d,
J=18.5 Hz), 120.44 (dd, J=24.9, 4.0 Hz), 104.93 (dd, J=26.8, 22.7
Hz), 83.27 (dd, J=10.4, 1.5 Hz).
[0238] .sup.19F NMR (282 MHz) .delta. -118.84 (m), -128.95 (m).
[0239] GCMS (m/e): 256 (M.sup.+).
[0240] Preparation 8: preparation of intermediate,
1,3-bis(2,4-difluoro-6-iodophenoxy)propane, (P8).
##STR00021##
[0241] To a solution of 7.68 g (30 mmol) of
2,4-difluoro-6-iodophenol (P7), Preparation 7 and 3.03 g (15 mmol)
of 1,3-dibromopropane in 125 mL of acetone add 12.42 g (90 mmol) of
potassium carbonate. Reflux the resulting reaction mixture for 48
hours. Cool the reaction mixture to room temperature, filter it,
and extract the resulting filtrate thoroughly with methylene
chloride. Combine methylene chloride extracts and concentrate them
by rotary evaporation. Crystallize the resulting solid from hexanes
to yield 3.4 g (41.1%) of (P8) as a white solid.
[0242] .sup.1H NMR (CDCl.sub.3) .delta. 7.28 (m, 2H), 6.80 (m, 2H),
4.31 (t, J=6.18 Hz, 4H) and 2.33 (quintet, J=6.18 Hz, 2H).
[0243] .sup.13C{.sup.1H} NMR (126 MHz, CDCl.sub.3) .delta. 158.02
(dd, J=249.1, 11.9 Hz), 154.04 (dd, J=253.9, 12.7 Hz), 143.75 (dd,
J=12.4, 4.1 Hz), 121.02 (dd, J=24.5, 3.6 Hz), 105.65 (dd, J=26.3,
23.8 Hz), 91.46 (dd, J=10.4, 2.4 Hz), 71.17 (d, J=4.8 Hz), 30.89
(s).
[0244] .sup.19F NMR (282 MHz, CDCl.sub.3) .delta. -114.45 (m),
-121.09, m).
[0245] GCMS (m/e): 552 (M.sup.+).
[0246] Preparation 9: preparation of intermediate,
2,4-dichloro-6-iodophenol, (P9).
##STR00022##
(t-Butyl hypochlorite Method)
[0247] To a solution of 6.52 g (40 mmol) of 2,4-dichlorophenol and
7.76 g (52 mmol) of sodium iodide in 80 mL of acetonitrile and 16
mL of water at room temperature add 5.64 g (52 mmol) of tert-butyl
hypochlorite dropwise over a period of 30 minutes. Stir the
reaction mixture for 3 hours at ambient temperature. Dilute the
reaction mixture with 200 mL of ethyl acetate. Wash the resulting
organic solution successively with 5% aqueous sodium thiosulfate
solution and brine and dry over anhydrous magnesium sulfate. Remove
the solvent and then crystallize from hexanes to yield 5.9 g (51%)
of (P9) as a slightly colored solid.
[0248] .sup.1H NMR (CDCl.sub.3) .delta. 7.60 (d, J=2.5 Hz, 1H),
7.32 (d, J=2.5 Hz, 1H) and 5.87 (s, 1H). .sup.13C{.sup.1H}NMR
(CDCl.sub.3) .delta. 149.80, 136.86, 129.17, 126.21, 119.12 and
83.21.
[0249] GCMS (m/e): 289 (M.sup.+).
[0250] Preparation 10: preparation of intermediate,
1,3-bis(2,4-dichloro-6-iodophenoxy)propane, (P10).
##STR00023##
[0251] In a manner similar to the preparation of (P8) (Preparation
8) except use (P9) (Preparation 9) instead of (P7), prepare crude
1,3-bis(2,4-dichloro-6-iodophenoxy)propane (P10) from 6.0 g of
2,4-dichloro-6-iodophenol (P9) and purify by crystallization from
acetonitrile to yield 5.20 g (81.37%) of (P10) as a white
solid.
[0252] .sup.1H NMR (CDCl.sub.3) .delta. 7.67 (d, J=2.5 Hz, 2H),
7.38 (d, J=2.5 Hz, 2H), 4.26 (t, J=6.5 Hz, 4H) and 2.47 (quintet,
J=6.5 Hz, 2H).
[0253] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 153.75, 137.08,
130.43, 130.23, 127.89, 92.82, 70.79 and 31.00.
[0254] Preparation 11: preparation of intermediate,
2-iodo-4-chloro-6-methylphenol, (P11).
##STR00024##
[0255] To a stirred solution of 5.00 g (35.00 mmol) of
2-methyl-4-chlorophenol (available from Aldrich Chemical Company)
in 100 mL of methanol at 0.degree. C., add 6.83 g (45.57 mmol) of
NaI and 1.40 g (35.00 mmol) of NaOH. To the resulting mixture add
65 mL of 5% aqueous NaOCl solution (commercial bleach) over one
hour period. The resulting slurry is stirred for one more hour at
0.degree. C. After the addition of 20 mL of 10%
Na.sub.2S.sub.2O.sub.3 solution, the reaction mixture is acidified
by dilute hydrochloric acid. The mixture is extracted with
methylene chloride. The organic layer is washed with brine and
dried over anhydrous magnesium sulfate. Removal of the solvent
followed by purification by recrystallization from hexanes gives
3.80 g (40.5%) of (P11) as white solid.
[0256] .sup.1H NMR (CDCl.sub.3) .delta. 7.43 (dd, J=0.55 and 2.5
Hz, 1H), 7.06 (d, J=2.5 Hz, 1H), 5.23 (s, 1H) and 2.26 (s, 3H).
[0257] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 151.70, 134.28,
131.11, 125.88, 125.55, 85.34 and 17.22.
[0258] GCMS (m/e): 268 (M.sup.+).
[0259] Preparation 12: preparation of intermediate,
1,3-bis(4-chloro-2-iodo-6-methylphenoxy)propane, (P12).
##STR00025##
[0260] To a solution of 3.50 g (13.05 mmol) of
2-iodo-4-chloro-6-methylphenol (P11) (Preparation 11) and 1.32 g
(6.53 mmol) of 1,3-dibromopropane in 75 mL of acetone add 5.40 g
(39.1 mmol) of K.sub.2CO.sub.3. Reflux the reaction mixture for 36
hours. Cool the reaction mixture to room temperature, filter it,
and the concentrate the resulting filtrate by rotary evaporation.
The residue thus obtained is crystallized from acetonitrile to
obtain 2.80 g (74.3%) of the bridge compound as white solid.
[0261] .sup.1H NMR (CDCl.sub.3) .delta. 7.59 (d, J=2.4 Hz, 2H),
7.14 (d, J=2.4 Hz, 2H), 4.09 (t, J=6.5 Hz, 4H), 2.44 (quintet,
J=6.5 Hz, 2H) and 2.32 (s, 6H).
[0262] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta.156.01, 136.21,
133.26, 131.32, 129.81, 92.24, 70.07, 31.05, 17.20.
[0263] GCMS (m/e): 577 (M.sup.+).
[0264] Preparations 13a to 13d: preparation of intermediates,
2,4-dimethyl-6-iodophenol (P13a); 4-chloro-2-ethyl-6-iodophenol,
(P13b); 4-fluoro-6-iodo-2-methylphenol, (P13c), and
4-fluoro-6-iodo-2-trifluoromethylphenol, (P13d).
##STR00026##
[0265] In separate reactions, each run in a manner similar to the
preparation of (P2) (Preparation 2), except use 2,4-dimethylphenol;
4-chloro-2-ethylphenol; 4-fluoro-2-methylphenol; or
4-fluoro-2-trifluoromethylphenol instead of the
4-(2,4,4-trimethylpentan-2-yl)phenol, respectively, prepare crude
(P13a) to (P13d). Purify each of crude (P13a) to (P13d) by
crystallization to respectively obtain each of purified (P13a) to
(P13d) as a solid.
[0266] Preparations 14a to 14d: preparation of intermediates,
1,3-bis(2,4-dimethyl-6-iodophenoxy)propane, (P14a);
1,3-bis(4-chloro-2-ethyl-6-iodophenoxy)propane, (P14b);
1,3-bis(4-fluoro-6-iodo-2-methylphenoxy)propane, (P14c); and
1,3-bis(4-fluoro-6-iodo-2-trifluoromethylphenoxy)propane,
(P14d).
##STR00027##
[0267] In separate reactions, each run in a manner similar to the
preparation of (P8) (Preparation 8), except use
2,4-dimethyl-6-iodophenol (P13a); 4-chloro-2-ethyl-6-iodophenol,
(P13b); 4-fluoro-6-iodo-2-methylphenol, (P13c), or
4-fluoro-6-iodo-2-trifluoromethylphenol, (P13d) instead of (P7),
respectively prepare crude
1,3-bis(2,4-dimethyl-6-iodophenoxy)propane, (P14a);
1,3-bis(4-chloro-2-ethyl-6-iodophenoxy)propane, (P14b);
1,3-bis(4-fluoro-6-iodo-2-methylphenoxy)propane, (P14c); and
1,3-bis(4-fluoro-6-iodo-2-trifluoromethylphenoxy)propane, (P14d).
Purify each of crude (P14a), (P14b), (P14c), and (P14d) by
crystallization from acetonitrile to respectively yield each of
purified (P14a), (P14b), (P14c), or (P14d) as a solid.
[0268] Preparations 15a and 15b: preparation of intermediates,
1,4-bis(4-chloro-2-iodo-6-methylphenoxy)butane, (P15a); and
1,2-bis(4-chloro-2-iodo-6-methylphenoxy)ethane, (P15b).
##STR00028##
[0269] In separate reactions and in a manner similar to the
preparation of (P8) (Preparation 8) except use (P11) (Preparation
11) instead of (P7) and either 1,4-dibromobutane or
1,2-di(para-tosyloxy)ethane instead of 1,3-dibromopentane,
respectively prepare each of crude
1,4-bis(4-chloro-2-iodo-6-methylphenoxy)butane, (P15a); and
1,2-bis(4-chloro-2-iodo-6-methylphenoxy)ethane, (P15b) and purify
each of crude (P15a) and (P15b) by crystallization from
acetonitrile to yield each of purified (P15a) or (P15b) as a
solid.
[0270] Preparation 16: Preparation of
9-(2-(methoxymethoxy)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-carbazole
##STR00029##
[0271] To 30 mL of dry toluene add
2-iodo-1-(methoxymethoxy)-4-(2,4,4-trimethylpentan-2-yl)benzene
(1.50 g, 3.986 mmol), carbazole (0.633 g, 3.786 mmol),
K.sub.3PO.sub.4 (1.71 g, 8.034 mmol), CuI (0.158 g, 0.830 mmol) and
trans-N,N-dimethylcyclohexane-1,2-diamine (0.158 g, 1.111 mmol).
Reflux the reaction mixture for 48 hours, cool, filter, and
concentrate to give material. Purify material by flash
chromatography using 3% ethyl acetate in hexanes to give 0.49 g
(29.6%) of
9-(2-(methoxymethoxy)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-carbazole
as off-white powder. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.19-8.14 (m, 2H), 7.50-7.25 (m, 7H), 7.19-7.13 (m, 2H), 4.93 (s,
2H), 3.16 (s, 3H), 1.76 (s, 2H), 1.40 (s, 6H), 0.82 (s, 9H).
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 151.41 (s), 144.96 (s),
141.46 (s), 127.95 (s), 127.19 (s), 126.13 (s), 125.68 (s), 123.11
(s), 120.13 (s), 119.39 (s), 116.20 (s), 110.05 (s), 94.99 (s),
56.99 (s), 56.06 (s), 38.27 (s), 32.40 (s), 31.85 (s), 31.58
(s);
[0272] MS m/e 416 (M+Na).sup.+.
[0273] Preparation 17: Preparation of
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetrame-
thyl-1,3,2-dioxaborolan-2-yl)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-car-
bazole
##STR00030##
[0274] To a stirred solution of 2.5 g (4.4 mmol) of (P6) in 40 mL
of THF at 0.degree. C. under nitrogen atmosphere 2.8 mL (7.0 mmol)
of n-butyl lithium (2.5 M solution in hexanes) add over a period of
5 minutes. Stir solution at 0.degree. C. for 3 hours. Add
2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.44 mL, 7.0
mmol), and continue stirring at 0.degree. C. for 1 more hour.
Slowly warm the reaction mixture to room temperature and stir for
18 hours. Concentrate the reaction mixture to dryness by rotary
evaporation, and add 100 mL of ice cold water. Extract mixture with
methylene chloride, wash the organic layer with brine, dry over
anhydrous magnesium sulfate, remove the solvent, and crystallize
residue from acetonitrile to give 2.4 g (78.6%) of
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetr-
amethyl-1,3,2-dioxaborolan-2-yl)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H--
carbazole as white solid. .sup.1H NMR (CDCl.sub.3) .delta.
8.30-7.96 (m, 2H), 7.81 (d, J=2.5 Hz, 1H), 7.58-7.32 (m, 3H), 7.14
(d, J=8.6 Hz, 2H), 4.85 (d, J=2.8 Hz, 1H), 2.76 (td, J=11.0, 2.7
Hz, 1H), 2.59 (dd, J=7.9, 3.5 Hz, 1H), 1.73 (s, 2H), 1.67-0.87 (m,
6H), 1.46 (s, 9H), 1.45 (s, 9H), 1.38 (s, 9H), 1.37 (s, 9H), 0.78
(s, 9H); .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 156.25, 145.86,
142.05, 142.01, 139.79, 139.78, 133.82, 130.61, 129.72, 123.39,
123.37, 123.05, 115.59, 115.55, 110.20, 110.11, 101.41, 83.64,
61.20, 56.95, 38.37, 34.68, 32.42, 32.08, 31.90, 31.45, 29.97,
25.06, 25.04, 24.79, 18.16. MS m/e 716.38 (M+Na).
[0275] Preparation 18: Preparation of
4-chloro-2-fluoro-6-iodophenol.
##STR00031##
[0276] Replicate Preparation 7 except use 4-chloro-2-fluorophenol
to give crude compound. Crystallize from hexanes to afford 3.85 g
(42%) of 4-chloro-2-fluoro-6-iodophenol as white crystals. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.46 (t, J=2.1 Hz, 1H), 7.11 (dd,
J=9.8, 2.4 Hz, 1H), 5.46 (s, 1H). .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 150.27 (s), 147.81 (s), 142.98 (d, J=14.4 Hz),
133.22 (d, J=3.8 Hz), 126.08 (d, J=9.3 Hz), 117.07 (s), 116.85 (s),
84.29 (d, J=1.1 Hz). .sup.19F NMR (376 MHz, CDCl.sub.3) .delta.
-131.45 (dd, J=9.8, 1.8 Hz). GCMS (m/e): 272 (M.sup.+).
[0277] Preparation 19: Preparation of 1,3-propanediol
bis(4-methylbenzenesulfonate).
##STR00032##
[0278] To a solution of 116.36 g (610.37 mmol) of tosyl chloride in
200 mL of anhydrous pyridine add 19.26 g (253.09 mmol) of
1,3-propanediol in 50 mL of anhydrous pyridine dropwise over the
period of two hours at 0-10.degree. C. Stir the reaction mixture
for an additional four hours, then pour it into 500 mL of ice cold
water. Collect the white precipitate that forms by filtration, wash
filter cake with water, dilute aqueous sulfuric acid (10 wt. %),
dilute aqueous sodium carbonate (1M), and again with water.
Crystallize the wet product from acetone to afford 80.68 g (83%) of
1,3-propanediol bis(4-methylbenzenesulfonate) as off white powder.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.77-7.69 (m, 4H),
7.37-7.30 (m, 4H), 4.05 (t, J=6.0 Hz, 4H), 2.44 (s, 6H), 1.99 (p,
J=6.0 Hz, 2H). .sup.13C{.sup.1H} NMR (101 MHz, CDCl.sub.3) .delta.
145.01, 132.65, 129.92, 127.84, 65.83, 28.67, 21.61. MS (m/e): 408
(M+Na).
[0279] Preparation 20: Preparation of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane.
##STR00033##
[0280] To a stirred solution of 3.21 g (11.78 mmol) of
2-iodo-4-chloro-6-fluorophenol and 2.28 g (5.95 mmol) of
1,3-propanediol bis(4-methylbenzenesulfonate) in 50 mL of DMF add
3.31 g (23.94 mmol) of potassium carbonate. Reflux the reaction
mixture for 30 minutes, cool to room temperature, concentrate to
dryness, and take up the residue in 50/50 methylene chloride and
water. Extract into methylene chloride, and wash the organic
solution with 2N NaOH then brine, dry over anhydrous magnesium
sulfate, filter through a pad of silica gel, and concentrate by
rotary evaporation. Purify the resulting crude product by
crystallization from acetonitrile to yield 1.94 g (56%) of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane as white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.52 (d, J=1.7 Hz, 2H),
7.10 (dd, J=10.6, 2.3 Hz, 2H), 4.36 (t, J=5.9 Hz, 4H), 2.31 (p,
J=6.0 Hz, 2H). .sup.13C{.sup.1H} NMR (101 MHz, CDCl.sub.3) .delta.
153.75 (d, J=254.8 z Hz), 145.81 (d, J=12.0 Hz), 133.77 (d, J=3.6
Hz), 129.32 (d, J=10.1 Hz), 117.98 (d, J=23.4 Hz), 92.07 (d, J=2.1
Hz), 71.01 (d, J=6.1 Hz), 30.89 (s). .sup.19F NMR (376 MHz,
CDCl.sub.3) .delta. -123.93 (d, J=10.5 Hz). GCMS (m/e): 584
(M.sup.+).
[0281] Preparation 21: Preparation of
4-chloro-2-(hydroxypropan-2-yl)phenol.
##STR00034##
[0282] Cool 4-chloro-2-hydroxyacetophenone (4.992 g, 29.26 mmol)
and 85 mL of dried THF in a dried flask to 0-10.degree. C., and add
dropwise 90 mL of 1 M methyl magnesium bromide (90 mmol). Keep the
reaction cold, and stir for 4 hours before quenching with saturated
NH.sub.4Cl and an equivalent volume of water. Separate the mixture,
and extract the aqueous phase with diethyl ether. Wash the combined
organic phases with water then brine, dry with calcium chloride,
filter, and concentrate to give a golden oil of crude compound,
which is crystallized using hexanes to give 4.48 g (82%) of
4-chloro-2-(hydroxypropan-2-yl)phenol as off white needles. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.92 (s, 1H), 7.09 (dd, J=8.6,
2.6 Hz, 1H), 7.02 (d, J=2.6 Hz, 1H), 6.77 (d, J=8.6 Hz, 1H), 2.51
(s, 1H), 1.64 (s, 6H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
154.13, 132.28, 128.63, 125.27, 124.24, 118.83, 75.89, 30.26. MS:
m/e 186.
[0283] Preparation 22: Preparation of
4-chloro-2-isopropylphenol.
##STR00035##
[0284] To a -10.degree. C. solution of
4-chloro-2-(hydroxypropan-2-yl)phenol (6.00 g, 32.15 mmol) in 100
mL of methylene chloride add triethylsilane (31.0 mL, 194.08 mmol)
and boron trifluoride diethyl etherate (66 mL, 520.82 mmol)
dropwise over a period of 10 minutes. Keep the reaction mixture
cold and stir for an additional hour before quenching with aqueous
sodium bicarbonate. Separate the mixture, and extract the aqueous
phase with methylene chloride. Wash combined organic phases with
aqueous sodium bicarbonate and brine, dry over anhydrous magnesium
sulfate, filter, and concentrate to give a purple oil. Purify by
flash chromatography using 25% ethyl acetate in hexanes to give
4.37 g (80%) of pure 4-chloro-2-isopropylphenol as a clear oil.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.15 (d, J=2.6 Hz, 1H),
7.01 (dd, J=8.5, 2.6 Hz, 1H), 6.66 (d, J=8.5 Hz, 1H), 4.77 (s, 1H),
3.17 (sept, 1H), 1.24 (d, J=6.9 Hz, 6H). .sup.3C NMR (101 MHz,
CDCl.sub.3) .delta. 151.26, 136.37, 126.56, 126.36, 125.81, 116.46,
27.14, 22.33. MS: m/e 171.
[0285] Preparation 23: Preparation of
4-chloro-2-iodo-6-isopropylphenol.
##STR00036##
[0286] Replicate Preparation 7 except use
4-chloro-2-isopropylphenol to give 3.90 g (86%) of pure
4-chloro-2-iodo-6-isopropylphenol as a dark red oil. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.45 (d, J=2.5 Hz, 1H), 7.13 (d,
J=2.5 Hz, 1H), 5.26 (s, 1H), 3.27 (sept, 1H), 1.21 (d, J=6.9 Hz,
6H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 150.76, 136.49,
134.10, 127.23, 126.16, 86.25, 28.58, 22.18. MS: m/e 297.
[0287] Preparation 24: Preparation of
1,3-bis(4-chloro-2-iodo-6-isopropylphenoxy)propane.
##STR00037##
[0288] Replicate Preparation 8 except use
4-chloro-2-iodo-6-isopropylphenol to give 2.87 g (77%) of pure
1,3-bis(4-chloro-2-iodo-6-isopropylphenoxy)propane as white powder.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.60 (d, J=2.5 Hz, 2H),
7.20 (d, J=2.4 Hz, 2H), 4.09 (t, J=6.4 Hz, 4H), 3.32 (sept, 2H),
2.47 (p, J=6.4 Hz, 2H), 1.22 (d, J=6.9 Hz, 12H). .sup.13C NMR (101
MHz, CDCl.sub.3) .delta. 154.73, 144.29, 136.10, 130.49, 127.29,
92.53, 71.27, 31.15, 27.79, 23.69. MS: m/e 632.
[0289] Preparation 25: Preparation of
2-(3-bromopropoxy)-5-chloro-1-iodo-3-methylbenzene.
##STR00038##
[0290] To a solution of 9.37 g (34.90 mmol) of (P11) and 9.78 g
(70.76 mmol) of potassium carbonate in 240 mL of acetone add 70 mL
of 1,3-dibromopropane. Reflux overnight, filter, then concentrate,
resulting in a brown oil, which is purified by flash chromatography
using 2% ethyl acetate in hexanes to give 11.61 g (85%) of
2-(3-bromopropoxy)-5-chloro-1-iodo-3-methylbenzene as a clear oil.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.60-7.55 (m, 1H),
7.16-7.10 (m, 1H), 3.94 (t, J=5.8 Hz, 2H), 3.70 (t, J=6.5 Hz, 2H),
2.38 (p, J=6.1 Hz, 2H), 2.31 (s, 3H). .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 155.43 (s), 136.18 (s), 133.31 (s), 131.33 (s),
129.94 (s), 92.16 (s), 69.97 (s), 33.25 (s), 30.02 (s), 17.03 (s).
GCMS (m/e): 390 (M.sup.+).
[0291] Preparation 26: Preparation of
5-chloro-2-(3-(4-chloro-2-iodophenoxy)propoxy)-1-iodo-3-methylbenzene.
##STR00039##
[0292] In 70 mL of acetone combine 4.08 g (10.48 mmol) of
2-(3-bromopropoxy)-5-chloro-1-iodo-3-methylbenzene, 2.67 g (10.49
mmol) of 2-iodo-4-chlorophenol (Prepared in a manner similar to
Preparation 7) and 3.06 g (22.14 mmol) of potassium carbonate.
Reflux overnight, filter, cool and concentrate to give an off white
solid, which is crystallized using acetonitrile to yield 5.18 g
(88%) of
5-chloro-2-(3-(4-chloro-2-iodophenoxy)propoxy)-1-iodo-3-methylbenzene
as a white powder. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.74
(d, J=2.5 Hz, 1H), 7.58 (d, J=2.4 Hz, 1H), 7.31-7.23 (m, 1H),
7.16-7.10 (m, 1H), 6.76 (d, J=8.8 Hz, 1H), 4.28 (t, J=5.8 Hz, 2H),
4.09 (t, J=6.0 Hz, 2H), 2.36 (p, J=5.9 Hz, 2H), 2.26 (s, 3H).
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 156.17, 155.57, 138.56,
136.17, 133.37, 131.34, 129.89, 129.24, 126.36, 112.21, 92.21,
86.64, 68.85, 65.57, 29.85, 17.02. GCMS (m/e): 562 (M.sup.+).
[0293] Preparation 27: Preparation of
2-(4-methoxyphenoxy)tetrahydro-2H-pyran: in a manner similar to
Preparation 5 stir 4-methoxyphenol (0.161 mol),
3,4-dihydro-2H-pyran (0.193 mol), CH.sub.2Cl.sub.2 (50 mL), p-TsOH
(0.161 mol) at 0.degree. C. for 10 minutes, then add triethylamine
(1.77 mol). Evaporate, add diethyl ether (Et.sub.2O), and
extractively work up to give 33.5 g (100%) of
2-(4-methoxyphenoxy)tetrahydro-2H-pyran as a yellow oil. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.06-6.95 (m, 2H), 6.89-6.77 (m,
2H), 5.31 (t, J=3.3 Hz, 1H), 4.00-3.89 (m, 1H), 3.78 (s, 3H),
3.64-3.56 (m, 1H), 2.07-1.93 (m, 1H), 1.88-1.83 (m, 2H), 1.65 (m,
3H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 154.49, 151.09,
117.78, 114.49, 97.31, 62.11, 55.67, 30.50, 25.27, 18.95.
[0294] Preparation 28: Preparation of
2-(4-methoxy-2-methyl-phenoxy)tetrahydro-2H-pyran:
##STR00040##
Dissolve 2-(4-methoxyphenoxy)tetrahydro-2H-pyran (20 g, 96 mmol,
Preparation 27) in 200 mL anhydrous THF at 0.degree. C. under
nitrogen atmosphere. Add n-butyl lithium (n-BuLi) (78 mL, 1.6 M in
hexanes, 125 mmol) dropwise via an additional funnel. Stir the
resulting mixture at 0.degree. C. for 3 hours. Add CH.sub.3I (7.8
mL, 125 mmol) in one batch. After 10 minutes add water. Rotary
evaporate off volatiles, extract residue with Et.sub.2O and dry to
give 21.3 g (100%) of
2-(4-methoxy-2-methyl-phenoxy)tetrahydro-2H-pyran as a yellow oil
(21.3 g, 100%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.03 (d,
J=8.8 Hz, 1H), 6.75 (d, J=3.0 Hz, 1H), 6.68 (dd, J=8.8, 3.1 Hz,
1H), 5.30 (t, J=3.3 Hz, 1H), 3.96 (ddd, J=12.0, 9.2, 3.1 Hz, 1H),
3.78 (s, 3H), 3.67-3.56 (m, 1H), 2.28 (s, 3H), 2.10-1.96 (m, 1H),
1.94-1.83 (m, 2H), 1.67 (m, 3H). .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 154.14, 149.33, 128.78, 116.55, 115.79, 111.08, 97.20,
62.15, 55.56, 30.73, 25.38, 19.14, 16.55.
[0295] Preparation 29: Preparation of
2-iodo-4-methoxy-6-methylphenol: Dissolve
2-(4-methoxy-2-methylphenoxy)tetrahydro-2H-pyran (5 g, 22 mmol,
Preparation 28) in 60 mL anhydrous THF at 0.degree. C. under
nitrogen atmosphere. Add n-BuLi (22.5 mL, 36 mmol, 1.6 M in
Hexanes) dropwise. Stir the resulting mixture at 0.degree. C. for 3
hours. Add I.sub.2 (7.4 g, 29 mmol). After 10 minutes add water.
Extract the quenchate with Et.sub.2O, wash using 10%
Na.sub.2S.sub.2O.sub.3 (aqueous), and rotary evaporate off
volatiles. Add methanol (10 mL), THF (10 mL) and one drop of
concentrated HCl (aqueous). Heat the resulting solution at reflux
for 2 hours, rotary evaporate, and purify the resulting dark brown
oil by flash chromatography using hexanes:EtOAc (95:5) as the
eluent to give 3.0 g (47%) of 2-iodo-4-methoxy-6-methylphenol as a
white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.03 (d,
J=2.9 Hz, 1H), 6.73 (d, J=2.9 Hz, 1H), 4.94 (s, 1H), 3.75 (s, 3H),
2.30 (s, 3H).
[0296] Preparation 30: Preparation of
1,3-bis(2-iodo-4-methoxy-6-methylphenoxy)propane:
##STR00041##
Add 2-iodo-4-methoxy-6-methylphenol (1.0 g, 3.79 mmol, Preparation
29), propane-1,3-ditosylate (0.728 g, 1.89 mmol), and NaOH (0.454
g, 11.36 mmol) to 20 mL anhydrous dimethylformamide (DMF) under
nitrogen atmosphere. Heat the resulting mixture to reflux for 2
hours. Partition between water and Et.sub.2O, and wash organic
layer with water to remove DMF. Rotary evaporate Et2O layer, and
purify residue by flash chromatography using Hexanes:EtOAc (95:5)
as the eluent to give 0.82 g (75%) of
1,3-bis(2-iodo-4-methoxy-6-methylphenoxy)propane as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.15 (d, J=2.5 Hz, 2H),
6.73 (d, J=2.5 Hz, 2H), 4.09 (t, J=6.4 Hz, 4H), 3.77 (s, 6H),
2.53-2.39 (m, 2H), 2.35 (s, 6H). .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 156.16, 151.16, 132.46, 121.44, 117.32, 92.07, 70.30,
55.70, 31.14, 17.61.
[0297] Preparation 31: Preparation of
2-(2,3-dimethylphenoxy)tetrahydro-2H-pyran: in a manner similar to
Preparation 27 except use 2,3-Dimethylphenol (20 g, 0.164 mol),
1,2-dihyropyran (17.9 mL, 0.196 mol), p-toluenesulfonic acid (1.64
mmol), and triethylamine (1.80 mmol) to give 33.0 g (100%) of
2-(2,3-dimethylphenoxy)tetrahydro-2H-pyran as a yellow oil. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 7.02 (t, J=7.8 Hz, 1H), 6.94 (d,
J=8.1 Hz, 1H), 6.79 (d, J=7.4 Hz, 1H), 5.38 (t, J=3.2 Hz, 1H),
3.95-3.81 (m, 1H), 3.58 (dtd, J=11.2, 4.1, 1.3 Hz, 1H), 2.26 (s,
3H), 2.18 (s, 3H), 2.08-1.97 (m, 1H), 1.91-1.85 (m, 2H), 1.74-1.57
(m, 3H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 155.00, 137.89,
125.92, 125.85, 123.15, 112.16, 96.46, 62.07, 30.75, 25.48, 20.23,
19.15, 11.90.
[0298] Preparation 32: Preparation of 2-iodo-5,6-dimethylphenol: in
a manner similar to Preparation 28 except use
2-(2,3-dimethylphenoxy)tetrahydro-2H-pyran (Preparation 31) to give
2-iodo-5,6-dimethylphenol (34%) as an oil. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.39 (d, J=8.1 Hz, 1H), 6.55 (d, J=8.1 Hz, 1H),
5.26 (s, 1H), 2.27 (s, 3H), 2.26 (s, 3H).
[0299] Preparation 33: Preparation of
1,3-bis(2-iodo-5,6-dimethylphenoxy)propane: replicate Preparation 8
except use 2-iodo-5,6-dimethylphenol (Preparation 32) instead of
2,4-difluoro-6-iodophenol (P7) to give
1,3-bis(2-iodo-5,6-dimethylphenoxy)propane (77%) as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.54 (d, J=7.9 Hz, 2H),
6.71 (d, J=7.9 Hz, 2H), 4.12 (t, J=6.5 Hz, 4H), 2.61-2.41 (m, 2H),
2.31 (s, 6H), 2.27 (s, 6H). .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 156.74, 139.11, 136.02, 131.31, 127.47, 88.79, 70.35,
31.12, 19.93, 13.65.
[0300] Preparation 34: Preparation of
1,3-bis(2-methyl-4-(1,1-dimethylethyl)phenoxy)propane: replicate
Preparation 30 except use 2-methyl-4-(1,1-dimethylethyl)phenol
(Aldrich Chemical) instead of 2-iodo-4-methoxy-6-methylphenol to
give 1,3-bis(2-methyl-4-(1,1-dimethylethyl)phenoxy)propane (64%)
after crystallization from methanol. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.18-7.11 (m, 4H), 6.76 (d, J=8.2 Hz, 2H), 4.15
(t, J=6.1 Hz, 4H), 2.27 (p, J=6.1 Hz, 2H), 2.22 (s, 6H), 1.29 (s,
18H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 154.77, 142.90,
127.88, 126.04, 123.18, 110.35, 64.52, 33.96, 31.57, 29.64,
16.54.
[0301] Preparation 35: Preparation of
1,3-bis(6-bromo-2-methyl-4-(1,1-dimethylethyl)phenoxy)propane:
##STR00042##
Charge a 50 mL round bottom flask with
1,3-bis(4-(tert-butyl)-2-methylphenoxy)propane (15 g, 40.7 mmol,
Preparation 34) and Et.sub.2O (5 mL). Gently heat the resulting
mixture to get a clear solution. Add acetic acid (HOAc) (50 mL).
Cool the resulting solution using a 10.degree. C. water bath. Add
bromine (5.0 mL, 97.68 mmol) dropwise. Stir the resulting mixture
at room temperature for overnight, filter off white solids. Wash
solids with MeOH, and dry in vacuo to give 17.36 g (81%)
1,3-bis(6-bromo-2-methyl-4-(1,1-dimethylethyl)phenoxy)propane.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (d, J=2.1 Hz, 2H),
7.10 (d, J=2.1 Hz, 2H), 4.13 (t, J=6.4 Hz, 4H), 2.40-2.33 (m, 2H),
2.32 (s, 6H), 1.27 (s, 18H). .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 152.07, 148.19, 132.30, 127.96, 127.49, 117.00, 69.90,
34.34, 31.34, 31.18, 17.17.
[0302] Preparation 36: Preparation of
2-bromo-5-(1,1-dimethylethyl)phenol: dissolve tetrabutylammonium
tribromide (48.1 g, 100 mmol) and 2-tert-butylphenol (15 g, 100
mmol) in CH.sub.2Cl.sub.2 (180 mL) and MeOH (120 mL) at 0.degree.
C., and stir overnight. Evaporate the solvent, and partition
residue between Et.sub.2O (150 mL.times.3) and water (200 mL).
Combine organic layers, and wash with 1 M HCl (aqueous, 200 mL) and
brine (100 mL), dry over MgSO.sub.4, filter, and rotary evaporate
to give 23 g (100%) of 2-bromo-5-(1,1-dimethylethyl)phenol as a
yellowish oil. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.39 (d,
J=8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.87 (dd, J=8.5, 2.3 Hz,
1H), 5.57 (s, 1H), 1.31 (s, 9H). .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 153.15, 151.81, 131.37, 119.22, 113.48, 106.88, 34.68,
31.20.
[0303] Preparation 37: Preparation of
1,3-bis(2-bromo-5-(1,1-dimethylethyl)phenoxy)propane:
##STR00043##
Replicate Preparation 8 except use
2-bromo-5-(1,1-dimethylethyl)phenol (Preparation 36) instead of
2,4-difluoro-6-iodophenol (P7) to give
1,3-bis(2-bromo-5-(1,1-dimethylethyl)phenoxy)propane (74%) as a
white solid after crystallization using hot methanol. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. 7.46 (d, J=8.3 Hz, 2H), 7.02 (d,
J=2.1 Hz, 2H), 6.90 (dd, J=8.3, 2.1 Hz, 2H), 4.35 (t, J=6.0 Hz,
4H), 2.40 (p, J=6.0 Hz, 2H), 1.33 (s, 18H). .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 154.83, 152.33, 132.55, 119.23, 111.25, 109.15,
65.60, 34.88, 31.31, 29.34.
[0304] Preparation 38: Preparation of
2-bromo-6-chloro-4-(1,1-dimethylethyl)phenol: replicate Preparation
36 except use 2-chloro-4-(1,1-dimethylethyl)phenol instead of
2-tert-butylphenol to give
2-bromo-6-chloro-4-(1,1-dimethylethyl)phenol (98%) as a yellow oil.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.39 (d, J=2.2 Hz, 1H),
7.29 (d, J=2.2 Hz, 1H), 5.75 (s, 1H), 1.27 (s, 10H).
[0305] Preparation 39: Preparation of
1,3-bis(2-bromo-6-chloro-4-(1,1-dimethylethyl)phenoxy)propane:
##STR00044##
Replicate Preparation 8 except use
2-bromo-6-chloro-4-(1,1-dimethylethyl)phenol (Preparation 38)
instead of 2,4-difluoro-6-iodophenol (P7) to give
1,3-bis(2-bromo-6-chloro-4-(1,1-dimethylethyl)phenoxy)propane as a
white solid (59%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.43
(d, J=2.3 Hz, 2H), 7.31 (d, J=2.3 Hz, 2H), 4.27 (t, J=6.4 Hz, 4H),
2.41 (p, J=6.4 Hz, 2H), 1.28 (s, 18H). .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 150.00, 149.22, 129.02, 128.49, 126.89, 118.08,
70.70, 34.60, 31.12, 30.94.
[0306] Preparation 40: Preparation of
1,4-bis(2-bromo-5-(1,1-dimethylethyl)phenoxy)butane: replicate
Preparation 37 except use 1,4-dibromobutane instead of
1,3-dibromopropane to give
1,4-bis(2-bromo-5-(1,1-dimethylethyl)phenoxy)butane (35%) as
colorless crystals after crystallization using hexanes. .sup.1H NMR
(400 MHz, C.sub.6D.sub.6) .delta. 7.54 (d, J=8.4 Hz, 2H), 6.91 (d,
J=2.1 Hz, 2H), 6.73 (dd, J=8.4, 2.1 Hz, 2H), 3.80 (t, J=5.1 Hz,
4H), 1.94 (t, J=5.3 Hz, 4H), 1.30 (s, 18H).
[0307] Preparation 41: Preparation of 4-chloro-2-ethylphenol: to a
stirred solution of 1.7 g (9.96 mmol) of
1-(5-chloro-2-hydroxyphenyl)ethanone in 20 mL of CH.sub.2Cl.sub.2
and 11.34 g (99.47 mmol) of trifluoroacetic acid, slowly add 3.46 g
of (29.82 mmol) of triethylsilane. Stir resulting solution at room
temperature for 18 hours, and remove volatiles and excess reagents
under reduced pressure to give 1.52 g (97.4%) of
4-chloro-2-ethylphenol as an oil. .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. 7.09 (d, J=2.6 Hz, 1H), 7.03-7.01 (m, 1H), 6.65 (d, J=8.5
Hz, 1H), 4.82 (s, 1H), 2.58 (q, J=7.6 Hz, 2H) and 1.21 (t, J=7.6
Hz, 3H). .sup.13C NMR (126 MHz, CDCl.sub.3) .delta. 151.85, 131.82,
129.62, 126.62, 125.60, 116.28, 22.81 and 13.60. MS m/e 157. The
4-chloro-2-ethylphenol can be used in Preparation 13b.
[0308] Preparation 42: Preparation of
2-iodo-5-(1,1-dimethylethyl)phenol: replicate Preparation 2 except
use 3-(1,1-dimethylethyl)phenol instead of
4-(2,4,4-trimethylpentan-2-yl)phenol to give
2-iodo-5-(1,1-dimethylethyl)phenol (84%) as clear, light red
crystals after crystallization from hexanes. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.55 (d, J=8.4 Hz, 1H), 7.04 (d, J=2.3 Hz, 1H),
6.73 (dd, J=8.4, 2.3 Hz, 1H), 5.20 (s, 1H), 1.29 (s, 8H). .sup.13C
NMR (101 MHz, CDCl.sub.3) .delta. 154.39 (d, J=14.9 Hz), 137.53,
119.95, 112.54, 81.74, 77.32, 76.68, 34.62, 31.12. MS m/e 277
(M+H).
[0309] Preparation 43: Preparation of
4-chloro-2-iodo-5-(1,1-dimethylethyl)phenol: to 35 mL of trimethyl
phosphate (TMP) at 0.degree. C. to 10.degree. C. add
2-iodo-5-(1,1-dimethylethyl)phenol (6.61 g, 23.95 mmol, Preparation
42). To this solution add dropwise over the period of one minute
sulfuryl chloride (2.0 mL, 24.67 mmol) in 35 mL of TMP, and then
stir the resulting mixture for 30 minutes still at 0-10.degree. C.
To the reaction mixture add 130 mL of water, and then extract the
resulting quenchate into CH.sub.2Cl.sub.2. Dry combined organic
phases over anhydrous MgSO.sub.4, filter through silica gel, and
concentrate filtrate. Purify residue by flash chromatography using
5% ethyl acetate in hexanes to give 3.79 g (51%) of
4-chloro-2-iodo-5-(1,1-dimethylethyl)phenol as a golden oil.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.58 (s, 1H), 7.05 (s,
1H), 5.21 (s, 1H), 1.43 (s, 9H). .sup.13C NMR (101 MHz, CDCl.sub.3)
.delta. 153.73, 149.02, 139.63, 125.69, 114.23, 81.61, 77.32,
76.68, 36.03, 29.29. MS m/e 310.
[0310] Preparation 44: Preparation of
1,3-bis(4-chloro-2-iodo-5-(1,1-dimethylethyl)phenoxy)propane:
##STR00045##
Replicate Preparation 30 except use
4-chloro-2-iodo-5-(1,1-dimethylethyl)phenol (Preparation 43)
instead of 1,3-bis(2-iodo-4-methoxy-6-methylphenoxy)propane,
potassium carbonate instead of NaOH, and a reaction temperature of
100.degree. C. for 30 minutes instead of reflux for 2 hours to give
1,3-bis(4-chloro-2-iodo-5-(1,1-dimethylethyl)phenoxy)propane (86%)
as an off-white solid. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.68 (s, 2H), 6.91 (s, 2H), 4.28 (t, J=5.9 Hz, 4H), 2.34 (p, J=5.9
Hz, 2H), 1.45 (s, 18H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
156.20, 148.04, 140.92, 126.22, 111.83, 83.38, 65.93, 36.30, 29.35.
MS m/e 660.
[0311] Some embodiments of the invention are described in more
detail in the following Examples.
[0312] In some embodiments the invention provides the compound
prepared in any one of the aforementioned Preparations.
LIGAND EXAMPLES
[0313] Example (Q1): preparation of ligand,
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3',5'-difluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q1).
##STR00046##
[0314] (General Procedure for Double Suzuki Reaction and
Deprotection Reaction). To a stirred solution of 2.67 g of
3,6-di-tert-butyl-9-(2-(methoxymethoxy)-5-(2,4,4-trimethylpentan-2-yl)phe-
nyl)-9H-carbazole (P4), Preparation 3 in 40 mL of tetrahydrofuran
at 0.degree. C. under nitrogen atmosphere add 3.50 mL (8.75 mmol)
of n-butyl lithium (2.5 M solution in hexanes) over a period of 10
minutes. Stir the resulting solution at 0.degree. C. for three more
hours. Add tri-isopropyl borate (2.0 mL, 8.67 mmol) and continue
stirring at 0.degree. C. for 1 hour. Slowly warm the mixture to
room temperature, and stir for 3 more hours at room temperature.
Concentrate the warmed reaction mixture to dryness by rotary
evaporation, and add 100 mL of ice cold water. Acidify the
resulting mixture using 2 Normal (N) aqueous hydrochloric acid, and
extract with methylene chloride. Remove the solvent (methylene
chloride) by rotary evaporation, and dissolve the residue in 45 mL
of dimethoxyethane. Treat this solution with a solution of 0.80 g
of NaOH in 16 mL of water, 16 mL of tetrahydrofuran and 1.38 g of
1,3-bis(2,4-difluoro-6-iodophenoxy)propane (P8), Preparation 8.
Purge the resulting system with nitrogen gas, and add 0.15 g (0.13
mmol) of Pd(PPh.sub.3).sub.4 (Ph is phenyl). Heat the resulting
mixture to 85.degree. C. for 36 hours under nitrogen gas
atmosphere. Cool the reaction mixture, and remove volatiles by
rotary evaporation. Treat the resulting residue with 100 mL of
water, and extract with methylene chloride. Wash the methylene
chloride solution with water and brine, and dry over anhydrous
magnesium sulfate. Pass the resulting dried solution through a
small bed of silica gel, and concentrate by rotary evaporation.
Dissolve the resulting residue in 25 mL of tetrahydrofuran, and
treat the THF solution with 150 mL of methanol and 0.1 g of
para-toluenesulfonic acid (0.40 mL of concentrated hydrochloric
acid could be used instead). Reflux the resulting solution for 24
hours. Cool the solution and pass it through a small bed of silica
gel, and wash with methanol. Keep the resulting solution in a fume
hood and allow slow evaporation of the solvent. Purify the
resulting crude product by flash chromatography using 5% ethyl
acetate in hexanes to yield 2.1 g (66.6%) of (Q1) as a white
powder.
[0315] .sup.1H NMR (CDCl.sub.3) .delta. 8.15 (d, J=1.51 Hz, 4H),
7.41-7.34 (m, 8H), 7.04 (d, J=8.6 Hz, 4H), 6.92 (m, 2H), 7.79 (m,
2H), 5.63 (s, 2H), 3.93 (t, J=5.7 Hz, 4H), 1.84 (quintet, J=5.7 Hz,
2H), 1.71 (s, 4H), 1.45 (s, 36H), 1.35 (s, 12H) and 0.78 (s,
18H).
[0316] .sup.13C{.sup.1H} NMR (75 MHz, CDCl.sub.3) .delta. 157.71
(dd, J=244.5, 12.5 Hz), 155.39 (dd, J=249.7, 13.0 Hz),
149.87-147.30 (m), 142.98 (s), 142.86 (s), 140.20 (dd, J=11.5, 3.6
Hz), 139.39 (s), 134.27 (d, J=10.9 Hz), 128.75 (s), 127.29 (s),
124.78 (s), 123.67 (s), 123.48 (s), 116.34 (s), 113.36 (d, J=22.8
Hz), 109.22 (s), 104.32 (dd, J=25.9, 24.7 Hz), 71.25 (s), 57.09
(s), 38.32 (s), 34.82 (s), 32.51 (s), 32.13 (s), 31.95 (s), 31.66
(s), 30.56 (s), 30.45 (s).
[0317] .sup.19F NMR (282 MHz) .delta. -114.73 (m), -124.09 (m).
[0318] ES-HRMS: m/e calcd for (M+Na,
C.sub.83H.sub.98N.sub.2F.sub.4O.sub.4Na) 1285.736. Found
1285.743.
[0319] Example Q2: preparation of ligand,
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3',5'-dichloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q2).
##STR00047##
[0320] In a manner similar to the preparation of (Q1) (Example Q1)
except use 3.4 g instead of 2.67 g of
3,6-di-tert-butyl-9-(2-(methoxymethoxy)-5-(2,4,4-trimethylpentan-2-yl)phe-
nyl)-9H-carbazole (P4) and 1.89 g of (P10) instead of (P8)
(Preparation 8), prepare crude (Q2). Purify crude (P12) by flash
chromatography on silica gel using 3% tetrahydrofuran in hexanes to
afford 1.95 g (48%) of (Q2) as a white solid.
[0321] .sup.1H NMR (CDCl.sub.3) .delta. 8.16 (d, J=1.8 Hz, 4H),
7.43-7.33 (m, 12H), 7.06 (d, J=8.5 Hz, 4H), 5.44 (s, 2H), 3.85 (t,
J=6.4 Hz, 4H), 1.90 (quintet, J=6.4 Hz, 2H), 1.71 (s, 4H), 1.46 (s,
36H), 1.34 (s, 12H) and 0.78 (s, 18H).
[0322] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 151.12, 147.42,
143.29, 143.12, 139.42, 134.63, 130.53, 129.51, 129.45, 129.18,
128.81, 127.48, 124.75, 124.67, 123.86, 123.58, 116.45, 109.21,
71.23, 56.95, 38.26, 34.74, 32.39, 32.00, 31.86, 31.58, 30.56.
[0323] ES-HRMS: m/e calcd for (M+NH.sub.4,
C.sub.83H.sub.102N.sub.3Cl.sub.4O.sub.4) 1344.662. Found
1344.663.
[0324] Example Q3: preparation of ligand,
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q3).
##STR00048##
[0325] To a stirred solution of 2.5 g (4.41 mmol) of
3,6-di-tert-butyl-9-(2-(methoxymethoxy)-5-(2,4,4-trimethylpentan-2-yl)phe-
nyl)-9H-carbazole (P6) (Preparation 6) in 25 mL of tetrahydrofuran
at 0.degree. C. under nitrogen atmosphere add 4.05 mL (10.13 mmol)
of n-butyl lithium (2.5 M solution in hexanes) over a period of 10
minutes. Stir the resulting solution at 0.degree. C. for three
hours. To the resulting mixture add tri-isopropyl borate (2.40 mL,
10.40 mmol), and continue stirring at 0.degree. C. for 1 hour.
Allow the mixture to slowly warm to room temperature, and stir it
at room temperature for 3 hours. Concentrate the reaction mixture
to dryness by rotary evaporation, and add to the resulting residue
100 mL of ice cold water. Acidify the resulting mixture using 2
Normal (N) aqueous hydrochloric acid, and extract the acidified
mixture with methylene chloride. Wash the methylene chloride
solution extract with water and brine. Remove the methylene
chloride by rotary evaporation, and dissolve the resulting residue
in 50 mL of dimethoxyethane. Treat this solution with a solution of
0.53 g (13.25 mmol) of NaOH in 16 mL of water, 16 mL of
tetrahydrofuran (THF), and 1.27 g (2.20 mmol) of
1,3-bis(4-chloro-2-iodo-6-methylphenoxy)propane (P12) (Preparation
12) to give a treated mixture in a flask. Purge the flask
containing the treated mixture with nitrogen gas, and add 0.20 g
(0.17 mmol) of palladium tetrakis(triphenylphosphine
(Pd(PPh.sub.3).sub.4). Heat the resulting mixture to 85.degree. C.
for 36 hours under nitrogen atmosphere. Cool the reaction mixture
and remove volatiles by rotary evaporation. Treat the resulting
residue with 100 mL of water, and extract with methylene chloride.
Wash the methylene chloride solution with water and brine, dry over
anhydrous magnesium sulfate, and rotary evaporate to give a
residue. Dissolve the residue in 100 mL of THF/methanol (MeOH)
(1:1), heat the solution to 50.degree. C., add 50 mg of
para-toluenesulfonic acid, and stir for 5 hours. Remove the THF and
MeOH, and purify the resulting residue by flash chromatography on
silica gel using 5% ethyl acetate in hexanes to give partially
purified (Q3). Further purify by crystallization from THF/MeOH to
afford 1.45 g (51.2%) of (Q3) as a white solid.
[0326] .sup.1H NMR (CDCl.sub.3) .delta. 8.14 (d, J=1.78 Hz, 4H),
7.42 (d, J=2.3 Hz, 2H), 7.36 (m, 6H), 7.23 (d, J=2.75 Hz, 2H), 7.13
(d, J=2.75 Hz, 2H), 7.02 (d, J=8.5 Hz, 4H), 6.14 (s, 2H), 3.65 (t,
J=6.3 Hz, 4H), 2.05 (s, 6H), 1.72 (quintet, J=6.3 Hz, 2H), 1.71 (s,
4H), 1.43 (s, 36H), 1.34 (s, 12H) and 0.76 (s, 18H).
[0327] .sup.13C{.sup.1H} NMR (CDCl.sub.3) .delta. 152.71, 147.50,
143.20, 142.69, 139.62, 133.28, 132.99, 130.55, 129.59, 129.57,
128.66, 127.39, 126.09, 125.32, 123.57, 123.37, 116.37, 109.18,
70.67, 57.01, 38.24, 34.70, 32.41, 32.02, 31.84, 31.63, 30.68,
16.25.
[0328] ES-HRMS: m/e calcd for (M+Na,
C.sub.85H.sub.104N.sub.2Cl.sub.2O.sub.4Na) 1309.727. Found
1309.719.
[0329] Example Q3a: preparation of ligand (Q3a):
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(9H-carbazol-9-yl)-3'-me-
thyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol), (Q3a).
##STR00049##
[0330] Replicate procedure of Example Q2 except use (P12) and
9-(2-(methoxymethoxy)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-carbazole
to give ligand (Q3a) as white solid (38% yield). .sup.1H NMR (400
MHz, cdcl.sub.3) .delta. 8.23-8.07 (m, 4H), 7.49 (d, J=2.4 Hz, 2H),
7.44 (d, J=2.4 Hz, 2H), 7.37-7.24 (m, 10H), 7.17 (dd, J=2.6, 0.7
Hz, 2H), 7.11 (d, J=8.0 Hz, 4H), 6.45 (s, 2H), 3.69 (t, J=6.1 Hz,
4H), 2.06 (s, 6H), 1.76 (m, 2H), 1.77 (s, 4H), 1.41 (s, 12H), 0.81
(s, 18H). .sup.13C NMR (101 MHz, cdcl.sub.3) .delta. 152.25,
147.69, 143.42, 141.27, 133.30, 132.96, 130.71, 129.92, 129.61,
128.97, 127.77, 126.30, 125.80, 125.23, 123.33, 120.34, 119.73,
109.71, 70.59, 57.01, 38.26, 32.41, 31.82, 31.61, 30.59, 16.11. HR
MS m/e calcd for C.sub.69H.sub.76Cl.sub.2N.sub.3O.sub.4
(M+NH.sub.4) 1080.521. Found 1080.523.
[0331] Example Q6a: preparation of ligand (Q6a):
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q6a).
##STR00050##
[0332] To a stirred solution of 3.16 g (4.55 mmol) of
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetrame-
thyl-1,3,2-dioxaborolan-2-yl)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-car-
bazole and 1.33 g (2.27 mmol) of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane in 60 mL of
dimethoxyethane add a solution of 0.55 g of NaOH in 16 mL of water
and 16 mL of tetrahydrofuran. Purge the system with nitrogen and
add 0.14 g (0.12 mmol) of Pd(PPh.sub.3).sub.4 (dissolved in
anhydrous THF). Heat the mixture to 85.degree. C. for 36 hours
under nitrogen atmosphere. Cool the reaction mixture, and remove
the volatiles by rotary evaporation. Treat the residue with 100 mL
of water, and extract with methylene chloride. Wash the methylene
chloride solution with water and brine, and dry over anhydrous
magnesium sulfate. Pass this solution through a small bed of silica
gel, and concentrate by rotary evaporation. Dissolve the residue in
50 mL of tetrahydrofuran, and treat with 100 mL of methanol and
0.05 g of p-toluene sulfonic acid. Heat the solution to 50.degree.
C. for 8 hours. Remove the solvent, and purify by flash
chromatography using 3% ethyl acetate in hexanes to give 1.1 g
(37.4%) of ligand (Q6a) as white solid. .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. 8.14 (s, 4H), 7.38 (d, J=8.7 Hz, 6H), 7.30 (s,
2H), 7.15 (s, 2H), 7.07-6.95 (m, 6H), 5.39 (s, 2H), 3.93 (t, J=5.8
Hz, 4H), 1.81 (dd, J=11.9, 5.9 Hz, 2H), 1.69 (s, 4H), 1.44 (s,
36H), 1.32 (s, 12H), 0.77 (s, 18H). .sup.13C NMR (126 MHz,
CDCl.sub.3) .delta. 155.33 (d, J=251.1 Hz), 147.49, 143.09 (d,
J=2.4 Hz), 142.85, 139.45, 134.57, 128.85, 128.39 (d, J=10.8 Hz),
127.26, 126.84, 125.51, 124.56, 123.78, 123.61, 116.75 (d, J=22.8
Hz), 116.43, 109.27, 70.84 (d, J=5.1 Hz), 57.03, 38.25, 34.74,
32.41, 32.02, 31.85, 31.56, 30.50, 30.36. .sup.19F NMR (470 MHz,
CDCl.sub.3) .delta. -126.58 (d, J=10.3 Hz). ES-HRMS: m/e calcd for
(M+NH.sub.4, C.sub.83H.sub.102C.sub.12F.sub.2N.sub.3O.sub.4)
1312.721. Found 1312.722.
[0333] Example Q6b: preparation of ligand (Q6a):
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-(1-methylethyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q6b).
##STR00051##
[0334] To 60 mL of dimethoxyethane add
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetrame-
thyl-1,3,2-dioxaborolan-2-yl)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-car-
bazole (3.33 g, 4.79 mmol),
1,3-bis(4-chloro-2-iodo-6-isopropylphenoxy)propane, (1.44 g, 2.28
mmol), NaOH (0.68 g, 17.00 mmol), 17 mL of water and 17 mL of
tetrahydrofuran. Purge the system with nitrogen, and add
Pd(PPh.sub.3).sub.4 (192 mg, 0.166 mmol) (dissolved in anhydrous
THF), and heat to 85.degree. C. for 48 hours under nitrogen
atmosphere. Cool the reaction mixture, and remove the volatiles by
rotary evaporation. Dissolve the residue in methylene chloride,
wash with brine, dry over anhydrous magnesium sulfate, filter, and
concentrate to yield crude THP-protected ligand (Q6b). Dissolve
this crude ligand in 100 mL of 1:1 THF:methanol, and heat to
65.degree. C. in the presence of about 100 mg of p-toluenesulfonic
acid monohydrate for 6 hours. Cool the reaction mixture, and
concentrate to dryness, take residue up in methylene chloride, and
wash with brine. Dry the organic phase over anhydrous magnesium
sulfate, filter through a pad of silica gel, and concentrate to
give crude (Q6b). Purify by flash chromatography using 3% ethyl
acetate in hexanes to afford 2.23 g (79%) of pure (Q6b) as white
powder. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.14 (d, J=1.7
Hz, 4H), 7.46-7.31 (m, 8H), 7.22 (dd, J=12.1, 2.6 Hz, 4H), 7.02 (d,
J=8.6 Hz, 4H), 6.16 (s, 2H), 3.65 (t, J=6.4 Hz, 4H), 3.09 (sept,
J=13.6, 6.9 Hz, 2H), 1.72 (s, 7H), 1.43 (s, 33H), 1.34 (s, 12H),
1.05 (d, J=6.8 Hz, 12H), 0.77 (s, 17H). .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 151.51, 147.47, 144.03, 143.19, 142.65, 139.64,
133.15, 130.22, 129.46, 128.68, 127.37, 126.51, 126.28, 125.38,
123.57, 123.36, 116.36, 109.10, 71.52, 57.00, 38.22, 34.68, 32.40,
31.92, 31.62, 30.60, 26.81, 23.46.
[0335] Example Q19a: preparation of ligand (Q19a):
2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-carb-
azol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(5''-chl-
oro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)b-
iphenyl-2-ol), (Q19a).
##STR00052##
[0336] Replicate Example Q6b except use
5-chloro-2-(3-(4-chloro-2-iodophenoxy)propoxy)-1-iodo-3-methylbenzene
to give (Q19a) (72.4%) as white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.28-8.25 (m, 2H), 8.24-8.22 (m, 2H), 7.57 (d,
J=2.1 Hz, 1H), 7.51-7.43 (m, 6H), 7.41-7.38 (m, 1H), 7.36 (d, J=2.2
Hz, 1H), 7.32 (d, J=2.2 Hz, 1H), 7.21-7.07 (m, 6H), 6.62 (d, J=8.9
Hz, 1H), 6.51 (s, 1H), 5.49 (s, 1H), 4.03 (t, J=5.2 Hz, 2H), 3.74
(t, J=5.0 Hz, 2H), 2.06 (s, 3H), 1.97 (p, J=5.8 Hz, 2H), 1.82 (s,
2H), 1.77 (s, 2H), 1.53 (s, 36H), 1.47 (s, 6H), 1.42 (s, 6H), 0.87
(s, 9H), 0.84 (s, 9H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
153.87 (s), 152.29, 147.63, 147.48, 143.30, 142.79, 142.74, 142.66,
139.69, 139.58, 133.40, 133.22, 131.56, 130.66, 129.92, 129.50,
128.93, 128.76, 128.68, 127.53, 126.77, 126.28, 125.66, 125.59,
124.37, 123.57, 123.55, 123.45, 123.39, 116.41, 116.38, 113.57,
109.35, 109.28, 70.02, 65.34, 57.09, 57.06, 38.30, 38.22, 34.74,
32.47, 32.41, 32.07, 31.89, 31.86, 31.67, 31.60, 29.76, 16.04.
ES-HRMS: m/e calcd for (M+NH.sub.4,
C.sub.84H.sub.106N.sub.3Cl.sub.2O.sub.4) 1290.755. Found
1290.757.
[0337] Examples Q4 to Q22: Preparation of Ligands (Q4) to (Q22)
[0338] In a manner similar to the preparation of Examples Q1 to Q3,
the ligands (Q4) to (Q9) and (Q14) to (Q19) can be prepared and
ligands (Q10), (Q11), (Q12), (Q13), and (Q20) to (Q22) are
prepared.
[0339] Example (Q10): prepare ligand (Q10) in a manner similar to
Example (Q3) except use (P14a) of Preparation P14a instead of (P12)
to give, after crystallization from acetonitrile, ligand (Q10):
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.17 (d, J=1.6 Hz, 4H),
7.46-7.40 (m, 8H), 7.11-6.99 (m, 8H), 6.64 (s, 2H), 3.71 (t, J=6.3
Hz, 4H), 2.39 (s, 6H), 2.08 (s, 6H), 1.81 (m, 2H), 1.76 (s, 4H),
1.47 (s, 36H), 1.40 (s, 12H), 0.82 (s, 18H). .sup.13C NMR
(CDCl.sub.3) .delta. 151.68, 147.68, 142.79, 142.25, 139.82,
134.42, 131.74, 131.18, 131.15, 130.45, 128.73, 127.57, 127.02,
125.42, 123.38, 123.19, 116.24, 109.28, 70.85, 57.09, 38.21, 34.67,
32.41, 32.05, 31.84, 31.66, 30.72, 20.83, 16.19. ES-HRMS: m/e calcd
for (M+NH.sub.4, C.sub.87H.sub.114N.sub.3O.sub.4) 1264.880. Found
1264.8849.
[0340] Example (Q11): prepare ligand (Q11) in a manner similar to
Example (Q3) except use (P14b) of Preparation P14b instead of
(P12). Alternatively, prepare ligand (Q11) in a manner similar to
Example (Q6a) except use
1,3-bis(4-chloro-2-ethyl-6-iodophenoxy)propane, (P14b), of
Preparation 14b instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane to give, after
flash chromatography on silica gel using hexanes:EtOAc (97.5:2.5),
to give ligand (Q11): .sup.1H NMR (400 MHz, cdcl.sub.3) .delta.
8.23 (d, J=1.8 Hz, 4H), 7.49 (m, 8H), 7.33 (d, J=2.4 Hz, 2H), 7.25
(d, J=2.5 Hz, 2H), 7.11 (d, J=8.5 Hz, 4H), 6.26 (s, 2H), 3.74 (t,
J=6.3 Hz, 4H), 2.54 (q, J=7.6 Hz, 4H), 1.81 (m, 2H), 1.79 (s, 4H),
1.54 (s, 36H), 1.43 (s, 12H), 1.11 (t, J=7.6 Hz, 6H), 0.85 (s,
18H); .sup.13C NMR (CDCl.sub.3) .delta. 152.24, 147.54, 143.22,
142.64, 139.67, 139.26, 133.07, 129.95, 129.58, 128.87, 128.66,
127.46, 126.21, 125.39, 123.56, 123.37, 116.38, 109.13, 71.14,
57.01, 38.24, 34.69, 32.40, 32.02, 31.85, 31.63, 30.66, 22.79 and
14.38. ES-HRMS: m/e calcd for (M+NH.sub.4,
C.sub.87H.sub.112Cl.sub.2N.sub.3O.sub.4) 1332.802. Found
1332.806.
[0341] Example (Q12): prepare ligand (Q12) in a manner similar to
Example (Q6a) except use
1,3-bis(6-bromo-2-methyl-4-(1,1-dimethylethyl)phenoxy)propane of
Preparation 35 instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane to give, after
flash chromatography on silica gel using hexanes:EtOAc (95:5),
ligand (Q12): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (d,
J=1.8 Hz, 4H), 7.45 (dd, J=5.5, 2.3 Hz, 4H), 7.39 (d, J=8.9 Hz,
4H), 7.24 (d, J=2.5 Hz, 2H), 7.18 (d, J=2.3 Hz, 2H), 7.07 (d, J=8.5
Hz, 4H), 6.78 (s, 2H), 3.72 (t, J=6.1 Hz, 4H), 2.08 (s, 6H),
1.85-1.77 (m, 2H), 1.75 (s, 4H), 1.44 (s, 36H), 1.39 (s, 12H), 1.37
(s, 18H), 0.81 (s, 18H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
151.48, 147.86, 147.82, 142.79, 142.25, 139.94, 130.73, 128.99,
128.25, 128.09, 127.22, 127.16, 125.58, 123.46, 123.19, 116.34,
109.33, 70.86, 57.23, 38.26, 34.76, 34.49, 32.51, 32.15, 31.93,
31.54, 30.89, 16.61.
[0342] Example (Q13): prepare ligand (Q13) in a manner similar to
Example (Q3) except use (P14c) of Preparation P14c instead of (P12)
to give, after flash chromatography on silica gel using
hexanes:EtOAc (95:5), ligand (Q13): .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.16 (d, J=1.9 Hz, 4H), 7.45 (d, J=2.4 Hz, 2H),
7.40 (d, J=2.3 Hz, 4H), 7.37 (d, J=1.8 Hz, 2H), 7.04 (d, J=8.6 Hz,
4H), 7.00-6.93 (m, 2H), 6.87 (dd, J=8.6, 3.1 Hz, 2H), 6.43 (s, 2H),
3.66 (t, J=6.4 Hz, 4H), 2.06 (s, 6H), 1.77 (quintet, J=6.4 Hz, 2H),
1.73 (s, 4H), 1.45 (s, 36H), 1.36 (s, 12H), 0.78 (s, 18H).
.sup.13C{.sup.1H}NMR (CDCl.sub.3) .delta. 158.97 (d, J=243.4 Hz),
149.91, 147.43, 143.15, 142.56, 139.68, 133.41 (d, J=8.7 Hz),
132.99 (d, J=8.8 Hz), 128.67, 127.45, 126.43, 125.56, 123.50,
123.32, 117.21 (d, J=22.5 Hz), 116.35, 116.10 (d, J=23.2 Hz),
109.19, 70.88, 57.06, 38.24, 34.70, 34.68, 32.42, 31.85, 31.61,
30.62, 16.44. .sup.19F NMR (376 MHz, CDCl.sub.3) .delta. -118.02
(t, J=8.7 Hz). ES-HRMS: m/e calcd for (M+NH.sub.4) 1272.830. Found
1272.8342.
[0343] Example (Q20): prepare ligand (Q20) in a manner similar to
Example (Q3) except use (P14d) of Preparation P14d instead of (P12)
to give, after crystallization from methanol, ligand (Q20): .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.19 (d, J=1.7 Hz, 4H), 7.45 (d,
J=1.9 Hz, 4H), 7.40-7.30 (m, 8H), 7.07 (d, J=8.6 Hz, 4H), 5.50 (s,
2H), 3.75 (t, J=6.7 Hz, 4H), 1.91 (m, 2H)), 1.71 (s, 4H), 1.47 (s,
36H), 1.33 (s, 12H), 0.80 (s, 18H); .sup.3C NMR (101 MHz,
CDCl.sub.3) .delta. 157.73 (d, J=245.3 Hz), 150.73, 147.27, 143.66,
143.24, 139.41, 135.00 (d, J=8.2 Hz), 128.69, 127.76, 125.83-125.26
(m), 124.66 (d, J=15.4 Hz), 124.03, 123.91, 122.82 (t, J=14.8 Hz),
116.47, 113.97-113.24 (m), 109.14, 72.03, 56.92, 38.28, 34.74,
32.40, 31.99, 31.85, 31.44, 30.13: .sup.19F NMR (376 MHz,
CDCl.sub.3) .delta. 92.00, 36.10 (t, J=8.2 Hz). ES-HRMS: m/e calcd
for (M+H, C.sub.85H.sub.98F.sub.8N.sub.2O.sub.4) 1362.740. Found
1363.7527.
[0344] Example (Q21): prepare ligand (Q21) in a manner similar to
Example (Q3) except use (P15a) of Preparation P15a instead of
(P12). Alternatively, prepare ligand (Q21) in a manner similar to
Example (Q6a) except use
1,4-bis(4-chloro-2-iodo-6-methylphenoxy)butane, (P15a), of
Preparation 15a instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane to give, after
flash chromatography on silica gel using hexanes:THF (95:5), to
give ligand (Q21): .sup.1H NMR (500 MHz, cdcl.sub.3) .delta. 8.17
(d, J=1.6 Hz, 4H), 7.49 (d, J=2.3 Hz, 2H), 7.41 (dd, J=13.1, 5.3
Hz, 6H), 7.28 (d, J=2.4 Hz, 2H), 7.24-7.19 (m, 2H), 7.06 (d, J=8.6
Hz, 4H), 6.58 (s, 2H), 3.43 (s, 4H), 2.13 (s, 6H), 1.77 (s, 4H),
1.52-1.42 (m, 4H), 1.45 (s, 36H), 1.41 (s, 12H), 0.82 (s, 18H).
.sup.13C NMR (126 MHz, CDCl.sub.3) .delta. 152.37, 147.59, 143.22,
142.48, 139.69, 133.36, 133.27, 130.50, 129.83, 129.54, 128.61,
127.52, 126.42, 125.77, 123.38, 123.27, 116.32, 109.20, 73.21,
57.08, 38.26, 34.67, 32.45, 32.01, 31.88, 31.66, 26.53, 16.18.
ES-HRMS: m/e calcd for (M+NH.sub.4,
C.sub.86H.sub.110Cl.sub.2N.sub.3O.sub.4) 1318.787. Found
1318.7905.
[0345] Example (Q22): prepare ligand (Q22) in a manner similar to
Example (Q3) except use (P15b) of preparation P15b instead of
(P12).
[0346] Names of ligands (Q4) to (Q22) are: [0347]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-octyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q4); [0348]
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carba-
zol-9-yl)-3'-chloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q5); [0349]
2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-5'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
, (Q6); [0350]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q6a); [0351]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-(1-methylethyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q6b); [0352]
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol), (Q7);
[0353]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-cyano-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q8); [0354]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-dimethylamino-3-(3,6-di-te-
rt-butyl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)bipheny-
l-2-ol), (Q9); [0355]
2',2''-(propane-1,3-diylbis(oxy))bis(3',5'-dimethyl-3-(3,6-di-tert-butyl--
9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q10); [0356]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-3'-ethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q11); [0357]
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3'-methyl-5'-tert-butyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q12); [0358]
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-5'-fluoro-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q13); [0359]
2',2''-(propane-1,3-diylbis(oxy))bis(3-(9H-carbazol-9-yl)-5'-chloro-3'-me-
thyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol), (Q14); [0360]
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3'-methyl-5'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q15); [0361]
2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(3',5'-dichloro-3--
(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)bipheny-
l-2-ol), (Q16); [0362]
2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6--
di-tert-butyl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)bi-
phenyl-2-ol), (Q17); [0363]
2',2''-(propane-1,3-diylbis(oxy))bis(3'-bromo-5'-chloro-3-(3,6-di-tert-bu-
tyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q18); [0364]
2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl--
9H-carbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(-
3'',5''-dichloro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethyl-
pentan-2-yl)biphenyl-2-ol), (Q19); [0365]
2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-carb-
azol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(5''-chl-
oro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)b-
iphenyl-2-ol), (Q19a); [0366]
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-5'-fluoro-3'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-o-
l), (Q20); [0367]
2',2''-(butane-1,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q21); and [0368]
2',2''-(ethane-1,2-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q22). Structures of ligands (Q1) to (Q8) are shown in FIG. 5.
Structures of ligands (Q9) to (Q16) are shown in FIG. 6. Structures
of ligands (Q17) to (Q24) are shown in FIG. 7. Structures of
ligands (Q25) to (Q31) are shown in FIG. 14. In FIGS. 5 to 14 and
this specification, "t-butyl" is synonymous with tert-butyl,
tertiary-butyl, and 1,1-dimethylethyl. The "Me" means methyl. The
"Et" means ethyl. The "t-octyl" is synonymous with tert-octyl,
tertiary-octyl, and 1,1-dimethylhexyl. The "--CN" is cyano. The
"MeO" means methoxy.
[0369] In some embodiments the invention ligand is any one of
ligands (Q1) to (Q3). In some embodiments the invention ligand is
any one of ligands (Q10), (Q11), (Q13), and (Q20) to (Q22). In some
embodiments the invention ligand is any one of ligands (Q4) to
(Q9), (Q12), and (Q14) to (Q19). In some embodiments the invention
ligand is ligand (Q3). In some embodiments the invention ligand is
ligand (Q13). In some embodiments the invention ligand is any one
of ligands (Q1), (Q2), (Q10), (Q11), and (Q20) to (Q22).
[0370] In some embodiments the invention ligand is any one of
ligands (Q23) to (Q25): [0371]
2',2''-(pentane-1,5-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q23); [0372]
2',2''-(pentane-2,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q24); and [0373]
2',2''-(hexane-1,6-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q25).
[0374] Ligands (Q23) to (Q25) can be prepared by replicating the
preparation of ligand (Q21) except replace 1,4-dibromobutane in
Preparation 15a with 1,5-dibromopentane, 2,4-dibromopentane, and
1,6-dibromohexane, respectively. Alternatively, corresponding
ditosylates, prepared from corresponding diols, can be used in
place of the aforementioned dibromides.
[0375] In some embodiments the invention ligand is any one of
ligands (Q26) to (Q31): [0376]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-methoxy-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q26); [0377]
2',2''-(propane-1,3-diylbis(oxy))bis(3',4'-dimethyl-3-(3,6-di-tert-butyl--
9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q27); [0378]
2',2''-(propane-1,3-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-ter-
t-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q28); [0379]
2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-5'-(tert-butyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q29); [0380]
2',2''-(butane-1,4-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-tert-butyl--
9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
(Q30); and [0381]
2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-4'-(tert-butyl)-3-(-
3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-
-2-ol), (Q31).
[0382] Prepare ligand (Q26) in a manner similar to Example (Q6a)
except use 1,3-bis(2-iodo-4-methoxy-6-methylphenoxy)propane of
Preparation 30 instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane to give, after
crystallization using Et.sub.2O and methanol, ligand (Q26): .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.17 (d, J=1.7 Hz, 4H), 7.47 (s,
4H), 7.40 (d, J=7.8 Hz, 4H), 7.07 (d, J=8.6 Hz, 4H), 6.81 (d, J=3.1
Hz, 2H), 6.79 (s, 2H), 6.74 (d, J=2.9 Hz, 2H), 3.86 (s, 6H), 3.68
(t, J=6.2 Hz, 4H), 2.07 (s, 6H), 1.80-1.76 (m, 2H), 1.76 (s, 4H),
1.47 (s, 36H), 1.40 (s, 12H) 0.81 (s, 18H).
[0383] Prepare ligand (Q27) in a manner similar to Example (Q6a)
except use 1,3-bis(2-iodo-5,6-dimethylphenoxy)propane of
Preparation 33 instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane to give, after
flash chromatography on silica gel using hexanes:EtOAc (95:5),
ligand (Q27): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.15 (d,
J=1.7 Hz, 4H), 7.43 (s, 4H), 7.38 (d, J=8.8 Hz, 4H), 7.18 (d, J=7.8
Hz, 2H), 7.09 (d, J=8.2 Hz, 2H), 7.06 (d, J=8.6 Hz, 4H), 6.68 (s,
2H), 3.70 (t, J=6.3 Hz, 4H), 2.26 (s, 6H), 1.98 (s, 6H), 1.82-1.77
(m, 2H), 1.73 (s, 4H), 1.45 (s, 36H), 1.37 (s, 12H), 0.79 (s, 18H).
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 153.51, 147.64, 142.65,
142.18, 139.78, 138.52, 130.07, 129.09, 129.03, 128.83, 127.66,
126.84, 126.61, 125.38, 123.36, 123.16, 116.21, 109.31, 71.01,
57.09, 38.14, 34.65, 32.40, 32.05, 31.82, 31.63, 20.01, 12.37.
[0384] Prepare ligand (Q28) in a manner similar to Example (Q6a)
except use 1,3-bis(2-bromo-5-(1,1-dimethylethyl)phenoxy)propane of
Preparation 37 instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane to give, after
crystallization using Et.sub.2O and methanol, ligand (Q28): .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 8.41 (d, J=1.7 Hz, 4H), 7.54 (d,
J=2.1 Hz, 2H), 7.51 (d, J=2.1 Hz, 2H), 7.49-7.48 (m, 4H), 7.45 (d,
J=8.0 Hz, 2H), 7.41 (d, J=8.6 Hz, 4H), 6.99 (dd, J=8.0, 1.7 Hz,
2H), 6.83 (d, J=1.6 Hz, 2H), 6.19 (s, 2H), 3.87 (t, J=5.6 Hz, 4H),
1.78 (m, 2H), 1.59 (s, 4H), 1.43 (s, 36H), 1.25 (S, 12H), 1.14 (s,
18H), 0.84 (s, 18H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
154.78, 153.05, 147.99, 142.37, 142.25, 139.87, 131.75, 129.28,
126.92, 126.57, 124.63, 124.58, 123.35, 123.23, 119.29, 116.29,
110.63, 109.38, 65.71, 57.18, 38.16, 34.75, 34.69, 32.44, 32.09,
31.86, 31.64, 31.58, 31.21, 29.53, 22.65, 14.15.
[0385] Prepare ligand (Q29) in a manner similar to Example (Q6a)
except use
1,3-bis(2-bromo-6-chloro-4-(1,1-dimethylethyl)phenoxy)propane of
Preparation 39 instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane and
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-5-(2,4,4-trime-
thylpentan-2-yl)phenyl)-9H-carbazole-3-boronic acid instead of
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetrame-
thyl-1,3,2-dioxaborolan-2-yl)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-car-
bazole to give, after flash chromatography on silica gel using
hexanes:EtOAc (95:5) and crystallization using Et.sub.2O and
methanol, ligand (Q29): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
8.13 (d, J=1.7 Hz, 4H), 7.42 (d, J=2.3 Hz, 2H), 7.41 (d, J=1.8 Hz,
2H), 7.40-7.36 (m, 6H), 7.28 (d, J=2.4 Hz, 2H), 7.07 (d, J=8.6 Hz,
4H), 6.04 (s, 2H), 3.87 (t, J=6.3 Hz, 4H), 1.91 (p, J=6.6 Hz, 2H),
1.71 (s, 4H), 1.53 (s, 2H), 1.43 (s, 36H), 1.34 (s, 12H), 1.34 (s,
18H), 0.78 (s, 18H). .sup.13C NMR (101 MHz, CDCl.sub.3) .delta.
149.35, 148.57, 147.63, 142.95, 142.57, 139.68, 132.64, 128.98,
127.86, 127.81, 127.29, 127.17, 126.65, 125.19, 123.63, 123.32,
116.31, 109.31, 75.00, 71.44, 65.85, 57.07, 38.21, 34.71, 34.65,
32.41, 32.04, 31.86, 31.59, 31.29, 30.71, 15.27.
[0386] Prepare ligand (Q30) in a manner similar to Example (Q6a)
except use 1,4-bis(2-bromo-5-(1,1-dimethylethyl)phenoxy)butane of
Preparation 40 instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane and
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-5-(2,4,4-trimethyl-
pentan-2-yl)phenyl)-9H-carbazole-3-boronic acid instead of
3,6-di-tert-butyl-9-(2-((tetrahydro-2H-pyran-2-yl)oxy)-3-(4,4,5,5-tetrame-
thyl-1,3,2-dioxaborolan-2-yl)-5-(2,4,4-trimethylpentan-2-yl)phenyl)-9H-car-
bazole to give, after flash chromatography on silica gel using
hexanes:EtOAc (95:5) and crystallization using THF and methanol,
ligand (Q30): .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.12 (d,
J=1.6 Hz, 4H), 7.39-7.33 (m, 10H), 7.18 (dd, J=8.1, 1.7 Hz, 2H),
7.06 (d, J=8.6 Hz, 4H), 6.93 (d, J=1.6 Hz, 2H), 6.18 (s, 2H), 3.87
(t, J=4.3 Hz, 4H), 1.70 (s, 4H), 1.68 (broad, 4H), 1.55 (s, 4H),
1.40 (s, 36H), 1.33 (s, 30H), 0.79 (s, 18H). .sup.13C NMR (101 MHz,
CDCl.sub.3) .delta. 154.72, 152.97, 147.95, 142.45, 142.14, 139.78,
131.79, 129.15, 127.17, 126.61, 124.93, 124.72, 123.34, 123.03,
119.48, 116.16, 110.76, 109.36, 68.99, 57.09, 38.12, 34.85, 34.62,
32.42, 32.02, 31.84, 31.59, 31.32, 25.75.
[0387] Prepare ligand (Q31) in a manner similar to Example (Q6a)
except use
1,3-bis(4-chloro-2-iodo-5-(1,1-dimethylethyl)phenoxy)propane of
Preparation 44 instead of
1,3-bis(4-chloro-2-fluoro-6-iodophenoxy)propane to give, after
flash chromatography on silica gel using hexanes:EtOAc (95:5),
ligand (Q31): .sup.1H NMR (400 MHz, cdcl.sub.3) .delta. 8.16 (d,
J=1.5 Hz, 4H), 7.40 (m, 8H), 7.26 (s, 2H), 7.71 (m, 4H), 6.91 (s,
2H), 5.72 (s, 2H), 4.05 (t, J=5.7 Hz, 4H), 2.08 (m, 2H), 1.73 (s,
4H), 1.47 (s, 36H), 1.38 (s, 12H), 1.37 (s, 18H), 0.81 (s, 18H).
.sup.13C NMR (101 MHz, CDCl.sub.3) .delta. 153.60, 147.85, 147.45,
142.76, 142.66, 139.70, 134.67, 129.04, 126.87, 126.62, 126.37,
125.26, 124.58, 123.53, 123.40, 116.37, 113.28, 109.31, 66.18,
57.14, 38.23, 36.15, 34.71, 32.44, 32.05, 31.86, 31.62, 30.34,
29.37. ES-HRMS: m/e calcd for (M+NH.sub.4,
C.sub.91H.sub.120Cl.sub.2N.sub.3O.sub.4) 1388.865. Found
1388.866.
Metal-Ligand Complex Examples:
[0388] Example 1: preparation of
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3',5'-difluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (1).
##STR00053##
[0389] To a 30 mL toluene solution containing 0.508 g (0.4 mmol) of
2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9-y-
l)-3',5'-difluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)
ligand (Q1), Preparation 9, and HfCl.sub.4 add 4.1 mole equivalents
of methyl magnesium bromide (MeMgBr) at room temperature. After
stirring for 1.5 hours, remove solvent under reduced pressure. To
the resulting residue add 10 mL of toluene and 25 mL of hexane.
Filter the resulting mixture to give an off-white filtrate. Remove
solvent to give an off-white solid. NMR of this solid shows
formation of essentially pure (1) with small impurities in
aliphatic region. Dissolve the solid in about 1.5 mL of toluene,
and then add 3 mL of hexane. Filter the resulting solution, and
place filtrate into freezer overnight. Decant resulting liquid, and
wash the remaining white crystalline solid with 1 mL of hexane and
then dry it under reduced pressure to yield 0.32 g (55.5%) of
(1).
[0390] .sup.1H NMR (500 MHz, C.sub.6D.sub.6) .delta. 8.54 (d, J=1.7
Hz, 2H), 8.35 (d, J=1.9 Hz, 2H), 7.84 (d, J=2.4 Hz, 2H), 7.83 (dd,
J=8.1, 2.0 Hz, 2H), 7.73 (dd, J=8.6, 1.9 Hz, 2H), 7.56 (dd, J=8.7,
0.4 Hz, 2H), 7.40 (dd, J=8.8, 1.9 Hz, 2H), 7.19 (d, J=2.5 Hz, 2H),
6.65 (ddd, J=8.9, 2.9, 1.7 Hz, 2H), 6.02 (ddd, J=8.8, 8.1, 3.1 Hz,
2H), 3.84 (dt, J=10.7, 5.6 Hz, 2H), 3.16 (dt, J=10.6, 5.3 Hz, 2H),
1.64 (d, J=14.5 Hz, 2H), 1.58 (s, 18H), 1.57 (d, J=14.5 Hz, 2H),
1.31 (s, 18H), 1.25 (s, 6H), 1.21 (s, 6H), 1.19 (p, J=5.7 Hz, 2H),
0.83 (s, 18H), -0.88 (s, 6H).
[0391] .sup.13C{.sup.1H} NMR (126 MHz, C.sub.6D.sub.6) .delta.
159.84 (dd, J=248.4, 11.6 Hz), 155.50 (dd, J=255.9, 13.6 Hz),
153.76 (s), 142.72 (s), 142.37 (s), 141.10 (s), 140.26 (d, J=2.6
Hz), 139.87 (s), 138.94 (dd, J=12.9, 3.8 Hz), 136.86 (d, J=9.5 Hz),
128.62 (s), 128.40 (s), 128.29 (s), 127.63 (s), 127.33 (s), 125.33
(s), 124.29 (s), 123.54 (s), 122.73 (s), 116.85 (s), 116.07 (s),
113.93 (dd, J=22.9, 3.2 Hz), 112.68 (s), 109.93 (d, J=4.1 Hz),
103.82 (dd, J=26.5, 22.6 Hz), 76.32 (d, J=2.6 Hz), 57.38 (s), 48.72
(s), 38.21 (s), 34.95 (s), 34.70 (s), 32.52 (s), 32.42 (s), 32.03
(s), 31.98 (s), 31.91 (s), 31.28 (s), 28.96 (s).
[0392] .sup.19F NMR (470 MHz, C.sub.6D.sub.6) .delta. -111.15 (m),
-120.40 (t, J=6.8 Hz).
[0393] Example 2: preparation of
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3',5'-dichloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)dimethyl-ha-
fnium, (2).
##STR00054##
[0394] To a 30 mL toluene solution containing 0.342 g (0.27 mmol)
of
2',2''-(propane-1,3-diylbis(oxy))bis(3',5'-dichloro-3-(3,6-di-tert-butyl--
9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol),
ligand (Q2), Example Q2; and HfCl.sub.4 add 3 M diethyl ether
solution of MeMgBr at room temperature. After stirring for 1.5
hour, remove solvent under reduced pressure. To the resulting
residue add 10 mL of toluene and 25 mL of hexane. Filter the
resulting mixture to give an off-white filtrate. Remove solvent
under reduced pressure to yield 0.374 g (89.9%) of (2) as an
off-white solid.
[0395] .sup.1H NMR (500 MHz, C.sub.6D.sub.6) .delta. 8.54 (d, J=1.8
Hz, 2H), 8.34 (d, J=1.8 Hz, 2H), 7.98 (d, J=8.5 Hz, 2H), 7.94 (d,
J=2.4 Hz, 2H), 7.80 (dd, J=8.6, 1.9 Hz, 2H), 7.65 (d, J=8.8 Hz,
2H), 7.43 (dd, J=8.8, 1.9 Hz, 2H), 7.16 (d, J=2.4 Hz, 2H), 7.06 (d,
J=2.6 Hz, 2H), 6.66 (d, J=2.6 Hz, 2H), 3.91 (dt, J=10.3, 5.1 Hz,
2H), 3.28 (dt, J=10.6, 5.5 Hz, 2H), 1.65 (d, J=14.5 Hz, 2H), 1.59
(s, 18H), 1.56 (d, J=14.5 Hz, 2H), 1.35 (s, 18H), 1.31 (dt, J=10.6,
5.1 Hz, 2H), 1.24 (s, 6H), 1.21 (s, 6H), 0.83 (s, 18H), -0.73 (s,
6H).
[0396] .sup.13C{.sup.1H} NMR (126 MHz, C.sub.6D.sub.6) .delta.
153.27 (s), 149.70 (s), 142.90 (s), 142.82 (s), 141.01 (s), 139.97
(s), 139.59 (s), 132.18 (s), 131.96 (s), 130.46 (s), 129.43 (s),
128.90 (s), 128.60 (s), 127.24 (s), 127.10 (s), 125.78 (s), 124.42
(s), 123.64 (s), 123.31 (s), 117.40 (s), 116.09 (s), 113.48 (s),
110.22 (s), 76.49 (s), 57.49 (s), 50.04 (s), 38.23 (s), 35.00 (s),
34.72 (s), 32.53 (s), 32.37 (s), 32.03 (s), 31.97 (s), 31.75 (s),
31.29 (s), 29.67 (s).
[0397] FIG. 8 shows an ORTEP depiction of a single crystal
structure derived by x-ray analysis of invention metal-ligand
complex (2) (Example 2). In FIG. 8 hydrogen atoms are omitted for
clarity.
[0398] Example 3: preparation of
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (3).
##STR00055##
[0399] To a 30 mL toluene solution containing 0.5 g (0.39 mmol) of
ligand (Q3) (Example Q3) and 124 mg (0.39 mmol) of HfCl.sub.4 add
0.53 mL of 3 Molar (M) diethyl ether solution of MeMgBr at room
temperature. After stirring for 1.5 hours, remove solvent under
reduced pressure. To the resulting residue add 10 mL of toluene and
20 mL of hexane, filter the resulting mixture to give a colorless
filtrate. Remove solvent from the colorless filtrate under reduced
pressure to yield 0.456 g (78.6%) of (3) as an off-white solid.
[0400] .sup.1H NMR (500 MHz, C.sub.6D.sub.6) .delta. 8.53 (d, J=1.9
Hz, 2H), 8.35 (d, J=1.9 Hz, 1H), 7.92 (d, J=8.6 Hz, 2H), 7.91 (d,
J=2.5 Hz, 2H), 7.74 (dd, J=8.6, 2.0 Hz, 2H), 7.68 (d, J=8.8 Hz,
2H), 7.43 (dd, J=8.8, 1.9 Hz, 2H), 7.28 (d, J=2.5 Hz, 2H), 7.16 (d,
J=2.6 Hz, 2H), 6.50 (dd, J=2.6, 0.6 Hz, 2H), 3.59 (dt, J=9.9, 4.9
Hz, 2H), 3.24 (dt, J=10.7, 5.5 Hz, 2H), 1.65 (d, J=14.5 Hz, 2H),
1.56 (s, 18H), 1.56 (d, J=14.5 Hz, 2H), 1.33 (s, 18H), 1.32 (p,
J=5.0 Hz, 2H), 1.24 (s, 6H), 1.21 (s, 6H), 1.20 (s, 6H), 0.83 (s,
18H), -0.74 (s, 6H).
[0401] .sup.13C{.sup.1H} NMR (126 MHz, C.sub.6D.sub.6) .delta.
153.28 (s), 152.24 (s), 143.17 (s), 142.98 (s), 140.85 (s), 140.02
(s), 139.47 (s), 135.53 (s), 134.60 (s), 132.08 (s), 131.46 (s),
130.58 (s), 130.09 (s), 128.11 (s), 127.76 (s), 126.57 (s), 125.75
(s), 124.72 (s), 123.36 (s), 123.02 (s), 117.17 (s), 115.92 (s),
113.82 (s), 110.44 (s), 76.10 (s), 57.48 (s), 49.70 (s), 38.20 (s),
34.95 (s), 34.71 (s), 32.51 (d, J=7.3 Hz), 32.35 (s), 31.98 (s),
31.96 (s), 31.79 (s), 31.26 (s), 30.13 (s), 16.23 (s).
[0402] FIG. 9 shows an ORTEP depiction of a single crystal
structure derived by x-ray analysis of invention metal-ligand
complex (3) (Example 3). In FIG. 9 hydrogen atoms are omitted for
clarity.
[0403] Example 3a: preparation of metal-ligand complex (3a):
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(9H-carbazol-9-yl)-3'-m-
ethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafnium,
(3a).
##STR00056##
[0404] Replicate Example 3 except use ligand (Q3a) and 4.5 mole
equivalents of MeMgBr to give metal-ligand complex (3a). Yield 35%.
.sup.1H NMR (400 MHz, CD.sub.2Cl.sub.2) .delta. 8.26-8.19 (m, 2H),
8.15-8.07 (m, 2H), 7.75 (d, J=2.5 Hz, 2H), 7.70 (d, J=8.2 Hz, 2H),
7.51 (ddd, J=8.3, 7.2, 1.2 Hz, 2H), 7.40-7.33 (m, 6H), 7.27 (ddd,
J=8.3, 7.0, 1.3 Hz, 2H), 7.18 (ddd, J=7.8, 7.1, 1.1 Hz, 2H), 7.07
(d, J=2.7 Hz, 2H), 6.68 (dd, J=2.7, 0.7 Hz, 2H), 3.94 (dt, J=9.9,
5.0 Hz, 2H), 3.76-3.65 (m, 2H), 1.86-1.80 (m, 1H), 1.77 (d, J=14.6
Hz, 1H), 1.46 (s, 6H), 1.39 (s, 6H), 1.36-1.14 (m, 10H), 0.93 (s,
1H), 0.83 (s, 18H), -1.47 (s, 6H). .sup.13C NMR (101 MHz,
CD.sub.2Cl.sub.2) .delta. 153.01, 152.04, 141.35, 140.61, 135.62,
134.71, 131.71, 131.26, 130.34, 129.93, 128.51, 127.05, 126.54,
126.03, 125.80, 124.93, 123.40, 120.79, 120.00, 119.95, 119.88,
113.86, 111.19, 76.92, 57.71, 48.41, 38.56, 32.00, 31.96, 31.45,
30.40, 15.90.
[0405] Example 6a: preparation of metal-ligand complex (6a):
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (6a).
##STR00057##
[0406] Replicate Example 1 except use (Q6a) and 4.5 mole
equivalents of MeMgBr to give metal-ligand complex (6a). .sup.1H
NMR (400 MHz, C.sub.6D.sub.6) .delta. 8.55 (d, J=1.6 Hz, 2H, H39),
8.34 (d, J=1.5 Hz, 2H, H36), 7.84 (d, J=2.4 Hz, 2H, H3), 7.83 (dd,
J=8.5, 1.8 Hz, 2H, H41), 7.74 (dd, J=8.6, 1.9 Hz, 2H, H42), 7.53
(d, J=8.7 Hz, 2H, H33), 7.38 (dd, J=8.8, 1.9 Hz, 2H, H34), 7.20 (d,
J=2.4 Hz, 2H, H5), 6.97 (dd, J=2.2 Hz, J.sub.H-F=1.7, 2H, H12),
6.32 (dd, J.sub.H-F=8.7, J=2.5 Hz, 2H, H10), 3.89 (dt, J=10.2, 5.0
Hz, 2H, H27a), 3.22 (dt, J=10.3, 5.0 Hz, 2H, H28b), 1.63 (d, J=14.6
Hz, 2H, t-Oct CH.sub.2), 1.60 (s, 18H, carbazole
C(CH.sub.3).sub.3), 1.56 (d, J=14.6 Hz, 2H, t-Oct CH.sub.2), 1.31
(s, 18H, carbazole C(CH.sub.3).sub.3), 1.23 (s, 6H, t-Oct
CH.sub.3), 1.20 (s, 6H, t-Oct CH.sub.3), 1.17 (m, 2H, H28), 0.83
(s, 18H, t-Oct C(CH.sub.3).sub.3), -0.90 (s, 6H, Hf--CH.sub.3).
.sup.13C{.sup.1H} NMR (101 MHz, C.sub.6D.sub.6) .delta. 155.16 (d,
J=256.9 Hz), 153.74 (quat), 142.74 (quat), 142.42 (quat), 141.30
(quat), 141.19 (quat), 140.16 (d, J=2.4 Hz, quat), 139.80 (quat),
136.78 (quat), 131.83 (d, J=9.9 Hz, quat), 128.53 (quat), 128.14
(d, J=2.3 Hz, quat), 127.60 (s), 127.54 (d, J=3.2 Hz, C12), 127.30
(s), 125.29 (quat), 124.29 (C34), 123.56 (quat), 122.78 (C43),
116.88 (C39), 116.20 (d, J.sub.C-F=21.7 Hz, C10), 116.13 (C36),
112.57 (C33), 109.92 (d, J=4.4 Hz, C42), 75.88 (d, J=3.6 Hz,
OCH.sub.2), 57.35 (CH.sub.2), 48.97 (Hf--CH.sub.3), 38.20 (quat),
34.96 (quat), 34.68 (quat), 32.51 (quat), 32.42
(C(CH.sub.3).sub.3), 32.01 (C(CH.sub.3).sub.3), 31.98
(C(CH.sub.3).sub.3), 31.81 (CH.sub.3), 31.32 (CH.sub.3), 28.85
(C28). .sup.19F NMR (376 MHz, C.sub.6D.sub.6) .delta. -122.02 (d,
J=8.6 Hz). Assignments were made based on 1D and 2D NMR
measurements.
[0407] Example 6b: preparation of metal-ligand complex (6b):
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-(1-methylethyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2--
ol))dimethyl-hafnium, (6b).
##STR00058##
[0408] Replicate Example 1 except use (Q6b) and 4.5 mole
equivalents of MeMgBr to give metal-ligand complex (6b). Yield 27%.
.sup.1H NMR (400 MHz, C.sub.6D.sub.6) .delta. 8.44 (d, J=1.7 Hz,
2H), 8.30 (d, J=1.6 Hz, 2H), 7.91 (d, J=8.6 Hz, 2H), 7.89 (d, J=2.4
Hz, 2H), 7.73 (dd, J=8.6, 1.9 Hz, 2H), 7.55 (d, J=8.7 Hz, 2H), 7.40
(dd, J=8.8, 1.9 Hz, 2H), 7.35 (d, J=2.4 Hz, 2H), 7.20 (d, J=2.7 Hz,
2H), 7.08 (d, J=2.7 Hz, 2H), 4.02 (dt, J=11.7, 6.0 Hz, 2H), 3.52
(dt, J=11.6, 5.8 Hz, 2H), 2.70 (hept, J=6.2 Hz, 2H), 1.68 (d,
J=14.5 Hz, 2H), 1.62 (d, J=14.7 Hz, 2H), 1.56 (s, 18H), 1.38 (s,
18H), 1.36-1.30 (m, 2H), 1.24 (s, 6H), 1.21 (s, 6H), 1.00 (d, J=6.7
Hz, 6H), 0.86 (s, 18H), 0.27 (d, J=6.7 Hz, 6H), -0.77 (s, 6H).
.sup.13C NMR (101 MHz, C.sub.6D.sub.6) .delta. 152.65, 151.40,
144.99, 143.14, 143.09, 141.52, 139.62, 139.32, 135.52, 131.97,
131.83, 130.54, 127.57, 125.86, 125.78, 124.47, 123.75, 123.58,
117.37, 115.92, 113.44, 110.25, 74.06, 57.45, 51.04, 38.27, 34.93,
34.72, 32.53, 32.29, 32.04, 32.02, 31.81, 31.29, 28.84, 27.00,
25.01, 22.32.
[0409] Example 19a: preparation of metal-ligand complex (19a):
(2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(5''-ch-
loro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)-
biphenyl-2-ol))dimethyl-hafnium, (19a).
##STR00059##
[0410] Replicate Example 1 except use (Q19a) and 4.5 mole
equivalents of MeMgBr to give metal-ligand complex (19a). Yield
71.3%, .sup.1H NMR (400 MHz, C.sub.6D.sub.6) .delta. 8.64 (d, J=1.6
Hz, 2H, cbz), 8.55 (d, J=1.1 Hz, 1H, cbz), 8.43 (d, J=1.5 Hz, 1H),
8.31 (d, J=1.5 Hz, 2H, cbz), 7.91 (d, J=8.6 Hz, 1H, cbz), 7.83 (d,
J=2.4 Hz, 1H), 7.80 (dd, J=8.6, 1.8 Hz, 1H, cbz), 7.74 (d, J=2.4
Hz, 1H), 7.73-7.65 (m, 3H), 7.62 (d, J=8.8 Hz, 1H, cbz), 7.45 (dd,
J=9.0, 1.8 Hz, 2H, cbz), 7.43 (dd, J=8.9, 1.8 Hz, 1H, cbz), 7.30
(d, J=2.3 Hz, 1H), 7.25 (d, J=2.6 Hz, 1H), 7.22 (d, J=2.6 Hz, 2H),
6.53 (dd, J=8.6, 2.6 Hz, 2H), 6.40 (d, J=2.4 Hz, 2H), 5.81 (d,
J=8.6 Hz, 2H), 3.68-3.56 (m, 2H, OCH.sub.2), 3.25 (ddd, J=9.9, 8.0,
4.0 Hz, 1H, OCH.sub.2), 2.99 (ddd, J=10.3, 7.5, 2.3 Hz, 1H,
OCH.sub.2), 1.67 (d, J=14.5 Hz, 1H), 1.60 (d, J=14.5 Hz, 1H,
CH.sub.2), 1.60 (s, 9H, C(CH.sub.3).sub.3), 1.58 (d, J=14.5 Hz, 1H,
CH.sub.2), 1.56 (s, 9H, C(CH.sub.3).sub.3), 1.54 (d, J=14.5 Hz, 1H,
CH.sub.2) 1.30 (s, 9H, C(CH.sub.3).sub.3), 1.29 (s, 9H,
C(CH.sub.3).sub.3), 1.24 (s, 3H, CH.sub.3), 1.24 (m, 1H, H28), 1.21
(s, 6H, CH.sub.3), 1.18 (s, 3H, CH.sub.3), 1.14 (m, 1H, H28), 0.86
(s, 3H, CH.sub.3), 0.84 (s, 9H, C(CH.sub.3).sub.3), 0.80 (s, 9H,
C(CH.sub.3).sub.3), -0.68 (s, 3H, Hf--CH.sub.3), -0.98 (s, 3H,
Hf--CH.sub.3). .sup.13C{.sup.1H} NMR (101 MHz, C.sub.6D.sub.6)
.delta. 154.19 (quat), 153.48 (quat), 152.77 (quat), 151.48 (quat),
143.20 (quat), 143.18 (quat), 142.93 (quat), 142.76 (quat), 141.13
(quat), 141.05 (quat), 140.30 (quat), 139.87 (quat), 139.84 (quat),
139.82 (quat), 135.48 (quat), 135.29 (quat), 134.41 (quat), 132.81
(quat), 132.49 (CH), 131.74 (quat), 130.78 (CH), 130.53 (CH),
130.10 (quat), 129.23 (CH), 129.17 (quat), 128.10 (CH), 127.88
(quat), 127.76 (CH), 127.23 (CH), 126.82 (CH), 125.83 (quat),
125.80 (CH), 125.62 (quat), 124.93 (CH), 123.42 (CH), 123.16
(quat), 123.06 (CH), 123.01 (quat), 117.55 (CH), 117.09 (CH),
115.98 (CH), 115.73 (CH), 113.32 (CH), 113.27 (CH), 109.52 (CH),
109.38 (CH), 76.76 (OCH.sub.2), 74.96 (OCH.sub.2), 57.27
(CH.sub.2), 50.05 (Hf--CH.sub.3), 48.62 (Hf--CH.sub.3), 38.19
(quat), 38.17 (quat), 35.05 (quat), 34.93 (quat), 34.73 (quat),
34.70 (quat), 32.52 (quat), 32.35 (C(CH.sub.3).sub.3), 32.06
(CH.sub.3).sub.3), 32.00 (C(CH.sub.3).sub.3), 31.98
((C(CH.sub.3).sub.3), 31.90 (CH.sub.3), 31.75 (CH.sub.3), 31.65
(CH.sub.3), 31.20 (CH.sub.3), 29.44 (CH.sub.2), 15.28 (CH.sub.3).
Assignments were made based on 1D and 2D NMR measurements.
[0411] Examples 4 to 25: preparation of metal-ligand complexes (4)
to (25)
[0412] In a manner similar to the preparation of Examples 1 to 3,
the metal-ligand complexes (4) to (9), (14) to (19), (24), and (25)
can be prepared, and metal-ligand complexes (10), (11), (12), (13),
and (20) to (23) are prepared. The metal-ligand complexes (4) to
(22), (23), (24), and (25) can be or are prepared from ligands (Q4)
to (Q22), (Q3), (Q2), and (Q3), respectively.
[0413] For example, prepare metal-ligand complex (10), (12), (11),
(13), (20), (21), and (22) in a manner similar to Example (3)
except respectively use ligand (Q10) of Example Q10, (Q11) of
Example Q11, (Q13) of Example Q13, (Q20) of Example Q20, (Q21) of
Example Q21, or (Q22) of Example Q22 instead of ligand (Q3).
[0414] Example 10: metal-ligand complex (10): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.57 (d, J=1.9 Hz, 2H), 8.34-8.28 (m, 2H),
8.02 (d, J=8.6 Hz, 2H), 7.93 (d, J=2.5 Hz, 2H), 7.78 (dd, J=8.7,
2.0 Hz, 2H), 7.75 (d, J=8.8 Hz, 2H), 7.43 (d, J=2.5 Hz, 2H), 7.39
(dd, J=8.8, 1.9 Hz, 2H), 6.93 (d, J=2.1 Hz, 2H), 6.35 (d, J=2.3 Hz,
2H), 3.72 (dt, J=9.8, 4.8 Hz, 2H), 3.41 (dt, J=10.5, 5.5 Hz, 2H),
1.79 (s, 6H), 1.70 (d, J=14.5 Hz, 2H), 1.63 (d, J=14.5 Hz, 2H),
1.61 (s, 18H), 1.40 (dt, J=10.3, 5.0 Hz, 2H), 1.34 (s, 6H), 1.32
(s, 6H), 1.30 (s, 18H), 1.28 (s, 6H), 0.87 (s, 18H), -0.74 (s, 6H).
.sup.13C NMR (101 MHz, C.sub.6D.sub.6) .delta. 153.64, 151.68,
142.71 (d, J=16.8 Hz), 140.14, 139.65, 136.33, 133.58, 132.44,
132.20, 131.91, 131.67, 127.90, 125.73, 124.66, 123.26, 122.97,
116.97, 115.81, 113.98, 110.68, 76.11, 57.58, 49.07, 38.23, 34.98,
34.67, 32.58, 32.42, 32.04, 31.98, 31.33, 30.30, 20.50, 16.26.
[0415] Example 11: metal-ligand complex (11): .sup.1H NMR (500 MHz,
C.sub.6D.sub.6) .delta. 8.51 (d, J=1.2 Hz, 2H), 8.31 (d, J=1.1 Hz,
2H), 8.01 (d, J=8.5 Hz, 2H), 7.92 (d, J=2.3 Hz, 2H), 7.75 (dm,
J=7.7 Hz, 2H), 7.62 (d, J=8.8 Hz, 2H), 7.40 (dm, J=8.8 Hz, 2H),
7.28 (d, J=2.3 Hz, 2H), 7.18 (d, J=2.6 Hz, 2H), 6.62 (d, J=2.5 Hz,
2H), 3.65-3.55 (m, 4H), 2.11 (dq, J=14.8, 7.4 Hz, 2H), 1.66 (d,
J=14.5 Hz, 2H), 1.576 (d, J=14.5 Hz, 2H), 1.57 (s, 18H), 1.33 (s,
18H), 1.26 (s, 6H), 1.24 (s, 6H), 1.18 (td, J=15.1, 7.5 Hz, 2H),
0.84 (s, 18H), 0.62 (t, J=7.5 Hz, 6H), -0.85 (s, 6H). .sup.13C NMR
(126 MHz, C.sub.6D.sub.6) .delta. 153.32, 151.38, 143.04, 142.88,
140.74, 140.59, 139.91, 139.64, 135.98, 132.36, 131.70, 130.35,
129.49, 128.06, 127.77, 126.20, 125.63, 124.73, 123.36, 123.20,
117.20, 115.90, 113.84, 110.34, 76.97, 57.61, 49.84, 38.23, 34.95,
34.71, 32.54, 32.33, 31.99, 31.93, 31.89, 31.14, 30.01, 22.32,
16.05.
[0416] Example 12: metal-ligand complex (12): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.66 (d, J=1.6 Hz, 2H), 8.31 (d, J=1.5 Hz,
2H), 8.18 (d, J=8.6 Hz, 2H), 8.07 (d, J=2.2 Hz, 2H), 7.92 (dd,
J=8.6, 1.7 Hz, 2H), 7.81 (d, J=8.8 Hz, 2H), 7.73 (d, J=2.3 Hz, 2H),
7.48 (d, J=2.3 Hz, 2H), 7.36 (dd, J=8.8, 1.8 Hz, 2H), 6.96 (d,
J=2.2 Hz, 2H), 3.89 (m, 2H), 3.50 (m, 2H), 1.85 (d, J=14.4 Hz, 2H),
1.73 (s, 18H), 1.73 (d, J=14.4 Hz, 2H), 1.60 (s, 6H), 1.52 (s, 6H),
1.48 (m, 2H), 1.45 (s, 6H), 1.38 (s, 18H), 1.12 (s, 18H), 0.99 (s,
18H), -0.59 (s, 6H). .sup.13C NMR (101 MHz, C.sub.6D.sub.6) .delta.
153.44, 153.36, 142.52, 142.29, 139.91, 139.28, 138.12, 131.48,
131.25, 130.85, 130.60, 129.08, 128.32, 127.29, 125.64, 125.45,
125.36, 124.50, 122.87, 122.73, 116.56, 115.33, 113.66, 110.34,
75.89, 57.42, 48.48, 38.01, 34.72, 34.44, 32.40, 32.19, 31.96,
31.78, 31.73, 31.01, 19.33, 12.56.
[0417] Example 13: metal-ligand complex (13): .sup.1H NMR (500 MHz,
C.sub.6D.sub.6) .delta. 8.54 (d, J=1.7 Hz, 2H), 8.36 (d, J=1.5 Hz,
2H), 7.92 (d, J=8.5 Hz, 2H), 7.90 (d, J=2.5 Hz, 2H), 7.74 (dd,
J=8.6, 1.9 Hz, 2H), 7.71 (d, J=8.9 Hz, 2H), 7.45 (dd, J=8.8, 1.9
Hz, 2H), 7.28 (d, J=2.5 Hz, 2H), 6.80 (dd, J=8.9, 3.1 Hz, 2H), 6.14
(dd, J=8.2, 2.9 Hz, 2H), 3.56 (dt, J=9.9, 4.8 Hz, 2H), 3.24 (dt,
J=10.6, 5.5 Hz, 2H), 1.65 (d, J=14.5 Hz, 2H), 1.57 (d, J=14.4 Hz,
2H), 1.57 (s, 18H), 1.33 (s, 18H), 1.33-1.29 (m, 2H), 1.26 (s, 6H),
1.22 (s, 6H), 1.19 (s, 6H), 0.83 (s, 18H), -0.73 (s, 6H). .sup.13C
NMR (101 MHz, C.sub.6D.sub.6) .delta.160.28 (d, J=246.1 Hz),
153.30, 149.65 (d, J=2.7 Hz), 143.14, 142.94, 140.72, 140.08,
139.50, 135.66 (d, J=8.5 Hz), 134.92 (d, J=8.9 Hz), 130.37 (d,
J=1.4 Hz), 128.09, 127.83, 126.55, 125.74, 124.72, 123.34, 123.03,
117.74 (d, J=23.3 Hz), 117.34 (d, J=22.5 Hz), 117.11, 115.89,
113.82 (s), 110.45, 76.23, 57.49, 49.45, 38.19, 34.96, 34.72,
32.53, 32.36, 31.99, 31.95, 31.89, 31.21, 30.17, 16.43. .sup.19F
NMR (376 MHz, C.sub.6D.sub.6) .delta. -115.29 (t, J=8.5 Hz).
[0418] Example 20: metal-ligand complex (20): .sup.1H NMR (500 MHz,
C.sub.6D.sub.6) .delta. 8.43 (d, J=1.7 Hz, 2H), 8.32 (s, 2H), 7.85
(d, J=8.6 Hz, 2H), 7.80 (dd, J=9.3, 2.1 Hz, 4H), 7.44-7.39 (m, 4H),
7.14 (d, J=2.5 Hz, 2H), 6.88 (dd, J=8.2, 3.1 Hz, 2H), 6.60 (dd,
J=7.6, 3.1 Hz, 2H), 4.29 (dt, J=10.5, 7.2 Hz, 2H), 3.39 (dt,
J=10.3, 5.1 Hz, 2H), 1.64 (d, J=14.5 Hz, 2H), 1.57 (s, 18H), 1.55
(d, J=14.5 Hz, 2H), 1.50-1.44 (m, 2H), 1.41 (s, 18H), 1.24 (s, 6H),
1.19 (s, 6H), 0.85 (d, J=5.2 Hz, 18H), -1.02 (s, 6H). .sup.13C NMR
(101 MHz, C.sub.6D.sub.6) .delta. 158.17 (d, J=247.8 Hz), 153.51,
149.71, 142.90, 142.64, 142.35, 139.98, 139.35, 136.59 (d, J=7.7
Hz), 129.24, 128.60, 127.51, 127.26, 125.18 (dd, J=31.0, 8.2 Hz),
124.70, 124.27, 123.94, 123.88, 123.66, 116.97, 116.44, 113.50 (dd,
J=25.9, 4.9 Hz), 111.98, 110.10, 72.33, 57.42, 51.60, 38.29, 34.95,
34.77, 32.49, 32.29, 32.10, 31.95, 31.56, 31.46. .sup.19F NMR (376
MHz, C.sub.6D.sub.6) .delta. -60.44 (s, 6F), -114.70 (t, J=7.9 Hz,
2F).
[0419] Example 21: metal-ligand complex (21): .sup.1H NMR (500 MHz,
C.sub.6D.sub.6) .delta. 8.52 (d, J=1.8 Hz, 2H), 8.39 (d, J=1.9 Hz,
2H), 7.94-7.87 (m, 4H), 7.71 (dd, J=8.6, 1.9 Hz, 2H), 7.69 (d,
J=8.8 Hz, 2H), 7.43 (dd, J=8.8, 1.9 Hz, 2H), 7.30 (d, J=2.4 Hz,
2H), 7.14 (d, J=2.7 Hz, 2H), 6.48 (d, J=2.7 Hz, 2H), 4.00 (t,
J=10.7 Hz, 2H), 3.41 (dd, J=11.4, 3.4 Hz, 2H), 1.65 (d, J=14.6 Hz,
2H), 1.58 (d, J=14.6 Hz, 2H), 1.55 (s, 18H), 1.35 (s, 18H),
1.28-1.22 (m, 2H), 1.21 (s, 6H), 1.17 (s, 6H), 1.05 (s, 6H), 0.84
(s, 18H), -0.66 (s, 6H). .sup.13C NMR (126 MHz, C.sub.6D.sub.6)
.delta. 152.83, 152.29, 143.30, 143.13, 141.24, 139.97, 139.31,
135.61, 134.43, 131.54, 131.44, 131.23, 130.84, 127.90, 127.53,
126.22, 125.97, 124.72, 123.46, 123.08, 117.13, 115.72, 114.04,
110.49, 77.48, 57.31, 49.24, 38.19, 34.94, 34.74, 32.53, 32.33,
32.07, 32.01, 31.90, 31.39, 26.62, 16.46.
[0420] Example 23: prepare metal-ligand complex (23) in a manner
similar to Example (3) except use ZrCl.sub.4 instead of HfCl.sub.4
to give (23): .sup.1H NMR (500 MHz, C.sub.6D.sub.6) .delta. 8.52
(d, J=1.5 Hz, 2H), 8.34 (d, J=1.4 Hz, 2H), 7.92 (d, J=8.5 Hz, 2H),
7.89 (d, J=2.4 Hz, 2H), 7.74 (dd, J=8.4, 1.8 Hz, 2H), 7.72 (d,
J=8.6 Hz, 2H), 7.42 (dd, J=8.8, 1.9 Hz, 2H), 7.28 (d, J=2.3 Hz,
2H), 7.18 (d, J=2.3 Hz, 2H), 6.52 (d, J=2.0 Hz, 2H), 3.50 (dt,
J=9.8, 4.8 Hz, 2H), 3.24 (dt, J=10.5, 5.4 Hz, 2H), 1.65 (d, J=14.5
Hz, 3H), 1.57 (d, J=14.7 Hz, 20H), 1.56 (s, 21H), 1.32 (s, 18H),
1.29-1.25 (m, 2H), 1.24 (s, 6H), 1.22 (s, 6H), 1.19 (s, 6H), 0.83
(s, 18H), -0.54 (s, 6H). .sup.13C NMR (126 MHz, C.sub.6D.sub.6)
.delta. 152.91, 152.39, 143.09, 142.96, 140.94, 139.99, 139.48,
135.47, 134.51, 131.97, 131.40, 130.52, 130.36, 129.28, 128.50,
127.76, 127.64, 126.47, 125.66, 125.63, 124.65, 123.36, 123.06,
117.14, 115.93, 113.74, 110.39, 76.19, 57.49, 43.81, 38.24, 34.96,
34.72, 32.56, 32.37, 32.00, 31.98, 31.84, 31.27, 30.27, 16.21.
[0421] Examples 26 to 31: the metal-ligand complexes (26) to (31)
are prepared in a manner similar to the preparation of Examples 1
to 3 except use ligands (Q26) to (Q31), respectively.
[0422] Example 26: metal-ligand complex (26): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.67 (d, J=1.3 Hz, 2H), 8.42 (d, J=1.2 Hz,
2H), 8.14 (d, J=8.5 Hz, 2H), 8.04 (d, J=2.0 Hz, 2H), 7.96-7.83 (m,
4H), 7.57 (d, J=1.9 Hz, 2H), 7.51 (dd, J=8.8, 1.6 Hz, 2H), 6.91 (d,
J=2.7 Hz, 2H), 6.35 (d, J=2.5 Hz, 2H), 3.93-3.72 (m, 2H), 3.62-3.33
(m, 2H), 3.14 (s, 6H), 1.79 (d, J=14.4 Hz, 2H), 1.71 (d, J=14.4 Hz,
2H), 1.70 (s, 18H), 1.53-1.38 (m, 40H), 0.96 (s, 18H), -0.55 (s,
6H). .sup.13C NMR (101 MHz, C.sub.6D.sub.6) .delta. 157.50, 153.40,
147.37, 142.61, 142.42, 140.02, 139.96, 139.42, 134.73, 133.56,
131.35, 129.08, 128.32, 127.26, 125.97, 125.53, 125.45, 124.55,
123.00, 122.78, 116.96, 116.85, 115.67, 115.61, 113.77, 110.41,
76.28, 75.00, 57.26, 54.47, 48.77, 37.96, 34.75, 34.45, 32.34,
32.17, 31.74, 31.10, 30.06, 16.53.
[0423] Example 27: metal-ligand complex (27): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.66 (d, J=1.3 Hz, 2H), 8.44 (d, J=1.2 Hz,
2H), 8.11 (d, J=8.6 Hz, 2H), 8.04 (d, J=2.3 Hz, 2H), 7.86 (dd,
J=8.6, 1.5 Hz, 2H), 7.77 (d, J=8.8 Hz, 2H), 7.59 (d, J=2.2 Hz, 2H),
7.45 (dd, J=8.8, 1.5 Hz, 3H), 7.21 (dd, 2H), 6.83 (d, J=7.9 Hz,
2H), 3.76 (m, 2H), 3.49 (m, 2H), 1.83 (d, J=14.6 Hz, 2H), 1.81 (s,
6H), 1.77 (d, J=14.6 Hz, 2H), 1.70 (s, 18H), 1.50-1.48 (m, 2H),
1.49 (s, 6H), 1.44 (s, 6H), 1.41 (s, 18H), 1.29 (s, 6H), 1.00 (s,
18H), -0.77 (s, 6H). .sup.13C NMR (101 MHz, C.sub.6D.sub.6) .delta.
153.44, 153.36, 142.52, 142.29, 139.91, 139.28, 138.12, 131.48,
131.25, 130.85, 130.60, 129.08, 128.32, 127.29, 125.64, 125.45,
125.36, 124.50, 122.87, 122.73, 116.56, 115.33, 113.66, 110.34,
75.89, 57.42, 48.48, 38.01, 34.72, 34.44, 32.40, 32.19, 31.96,
31.78, 31.73, 31.01, 19.33, 12.56.
[0424] Example 28: metal-ligand complex (28): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.48 (d, J=1.8 Hz, 2H), 8.33 (d, J=1.7 Hz,
2H), 7.96 (d, J=8.8 Hz, 2H), 7.91 (d, J=8.6 Hz, 2H), 7.78 (dd,
J=8.6, 1.9 Hz, 2H), 7.70 (d, J=2.5 Hz, 2H), 7.40 (d, J=2.5 Hz, 2H),
7.37 (dd, J=8.8, 1.9 Hz, 2H), 7.29 (d, J=8.0 Hz, 2H), 7.00 (dd,
J=8.1, 1.9 Hz, 2H), 6.24 (d, J=1.9 Hz, 2H), 4.00-3.95 (m, 2H),
3.45-3.39 (m, 2H), 1.65 (d, J=14.5 Hz, 2H), 1.55 (d, J=14.5 Hz,
2H), 1.53 (s, 18H), 1.34 (s, 18H), 1.31 (s, 6H), 1.36-1.29 (m, 2H),
1.14 (s, 6H), 0.91 (s, 18H), 0.85 (s, 18H), -0.49 (s, 6H).
[0425] Example 29: metal-ligand complex (29): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.61 (d, J=1.8 Hz, 2H), 8.28 (d, J=1.8 Hz,
2H), 8.22 (d, J=8.6 Hz, 2H), 8.10 (d, J=2.4 Hz, 2H), 7.96 (dd,
J=8.6, 1.9 Hz, 2H), 7.79 (d, J=8.8 Hz, 2H), 7.61 (d, J=2.5 Hz, 2H),
7.44 (d, J=2.5 Hz, 2H), 7.37 (dd, J=8.8, 1.9 Hz, 2H), 7.11 (d,
J=2.4 Hz, 2H), 4.24-4.19 (m, 4H), 3.55-3.50 (m, 4H), 1.81 (d,
J=14.5 Hz, 4H), 1.71 (s, 18H), 1.70 (d, J=14.5 Hz, 4H), 1.47 (s,
6H), 1.46-1.43 (m, 3H), 1.40 (s, 6H), 1.39 (s, 18H), 0.97 (s, 18H),
0.96 (s, 18H), -0.55 (s, 6H). .sup.13C NMR (101 MHz,
C.sub.6D.sub.6) .delta. 154.24, 151.19, 149.56, 143.03, 143.00,
140.87, 140.82, 140.40, 138.46, 135.96, 131.52, 130.29, 129.89,
129.71, 129.34, 129.26, 129.13, 129.07, 128.86, 128.62, 128.50,
128.38, 128.25, 127.99, 127.29, 126.50, 126.26, 125.06, 124.11,
123.81, 118.08, 116.69, 114.34, 111.13, 77.22, 58.18, 50.00, 38.86,
35.61, 35.25, 35.00, 33.19, 33.00, 32.57, 32.54, 32.07, 31.37,
30.31.
[0426] Example 30: metal-ligand complex (30): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.58 (d, J=1.7 Hz, 2H), 8.43 (d, J=1.7 Hz,
2H), 8.01 (d, J=8.8 Hz, 2H), 7.93 (d, J=8.6 Hz, 2H), 7.84 (dd,
J=8.6, 1.8 Hz, 2H), 7.77 (d, J=2.4 Hz, 2H), 7.51 (d, J=2.4 Hz, 2H),
7.46 (dd, J=8.8, 1.9 Hz, 2H), 7.37 (d, J=8.1 Hz, 2H), 7.22 (d,
J=7.7 Hz, 2H), 7.08 (dd, J=8.2, 1.7 Hz, 2H), 6.21 (s, 2H),
4.61-4.51 (m, 2H), 3.77-3.68 (m, 2H), 1.73 (d, J=14.5 Hz, 2H), 1.67
(d, J=14.5 Hz, 2H), 1.61 (s, 18H), 1.44 (s, 18H), 1.40 (s, 6H),
1.35-1.30 (s, 4H), 1.18 (s, 6H), 1.09 (s, 18H), 0.95 (s, 18H),
-0.40 (s, 6H).
[0427] Example 31: metal-ligand complex (31): .sup.1H NMR (400 MHz,
C.sub.6D.sub.6) .delta. 8.41 (d, J=1.8 Hz, 2H), 8.29 (d, J=1.9 Hz,
2H), 7.66 (d, J=8.7 Hz, 4H), 7.61 (d, J=2.5 Hz, 2H), 7.55 (s, 2H),
7.47 (d, J=8.6 Hz, 2H), 7.45 (dd, J=8.8, 1.9 Hz, 2H), 7.36 (d,
J=2.5 Hz, 2H), 6.59 (s, 2H), 3.71-3.39 (m, 2H), 1.64 (d, J=14.5 Hz,
2H), 1.56 (s, 18H), 1.52 (d, J=14.5 Hz, 2H), 1.39-1.33 (m, 2H),
1.31 (s, 18H), 1.21 (s, 6H), 1.20 (s, 18H), 0.85 (s, 18H), -0.79
(s, 6H). .sup.13C NMR (101 MHz, C.sub.6D.sub.6) .delta. 154.52,
153.53, 147.97, 143.39, 142.73, 141.86, 141.43, 141.22, 135.91,
132.06, 130.60, 129.40, 129.30, 127.01, 126.25, 124.65, 124.27,
124.01, 120.86, 117.99, 116.02, 112.65, 109.90, 72.99, 57.15,
50.80, 38.20, 35.83, 34.93, 34.71, 32.54, 32.34, 32.10, 32.03,
32.00, 31.24, 29.74, 28.83.
[0428] Examples 32 to 34: the metal-ligand complexes (32) to (34)
are prepared in a manner similar to the preparation of Examples 1
to 3 except use ligands (Q23) to (Q25), respectively.
[0429] Names of metal-ligand complexes (4) to (25) are: [0430]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-octyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (4); [0431]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3'-chloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafniu-
m, (5); [0432]
(2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-5'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (6); [0433]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (6a); [0434]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-(1-methylethyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2--
ol))dimethyl-hafnium, (6b); [0435]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafniu-
m, (7); [0436]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-cyano-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (8); [0437]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-dimethylamino-3-(3,6-di-tert-but-
yl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol-
))dimethyl-hafnium, (9); [0438]
(2',2''-(propane-1,3-diylbis(oxy))bis(3',5'-dimethyl-3-(3,6-di-tert-butyl-
-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (10); [0439]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-ethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (11); [0440]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3'-methyl-5'-tert-butyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))d-
imethyl-hafnium, (12); [0441]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-5'-fluoro-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (13); [0442]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(9H-carbazol-9-yl)-5'-chloro-3'-m-
ethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-hafnium,
(14); [0443]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carb-
azol-9-yl)-3'-methyl-5'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biph-
enyl-2-ol))dimethyl-hafnium, (15); [0444]
(2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(3',5'-dichloro-3-
-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphen-
yl-2-ol)dimethyl-hafnium, (16); [0445]
(2',2''-(2,2-dimethyl-2-silapropane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-
-di-tert-butyl-9H-carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)b-
iphenyl-2-ol))dimethyl-hafnium, (17); [0446]
(2',2''-(propane-1,3-diylbis(oxy))bis(3'-bromo-5'-chloro-3-(3,6-di-tert-b-
utyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (18); [0447]
(2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-fluoro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(3'',5'-
'-dichloro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-
-2-yl)biphenyl-2-ol))dimethyl-hafnium, (19); [0448]
(2',2''-(propane-1,3-diylbis(oxy))-(5'-chloro-3-(3,6-di-tert-butyl-9H-car-
bazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-(5''-ch-
loro-3-(3,6-di-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)-
biphenyl-2-ol))dimethyl-hafnium, (19a); [0449]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-5'-fluoro-3'-trifluoromethyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2--
ol))dimethyl-hafnium, (20); [0450]
(2',2''-(butane-1,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)dimethy-
l-hafnium, (21); [0451]
(2',2''-(ethane-1,2-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (22); [0452]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-zirconium, (23); [0453]
(2',2''-(propane-1,3-diylbis(oxy))bis(3-(3,6-di-tert-butyl-9H-carbazol-9--
yl)-3',5'-dichloro-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-t-
itanium, (24); and [0454]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-titanium, (25).
[0455] The names of metal-ligand complexes (26) to (31) are: [0456]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-methoxy-3-(3,6-di-tert-butyl-9H--
carbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dime-
thyl-hafnium, (26); [0457]
(2',2''-(propane-1,3-diylbis(oxy))bis(3',4'-dimethyl-3-(3,6-di-tert-butyl-
-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)dimethyl-ha-
fnium, (27); [0458]
(2',2''-(propane-1,3-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-tert-buty-
l-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl--
hafnium, (28); [0459]
(2',2''-(propane-1,3-diylbis(oxy))bis(3'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-5'-(tert-butyl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
)dimethyl-hafnium, (29); [0460]
(2',2''-(butane-1,4-diylbis(oxy))bis(4'-(tert-butyl)-3-(3,6-di-tert-butyl-
-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimethyl-h-
afnium, (30); and [0461]
(2',2''-(propane-1,3-diylbis(oxy))bis(5'-chloro-4'-(tert-butyl)-3-(3,6-di-
-tert-butyl-9H-carbazol-9-yl)-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol)-
)dimethyl-hafnium, (31).
[0462] The names of metal-ligand complexes (32) to (34) are: [0463]
(2',2''-(pentane-1,5-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (32); [0464]
(2',2''-(pentane-2,4-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-c-
arbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimet-
hyl-hafnium, (33); and [0465]
(2',2''-(hexane-1,6-diylbis(oxy))bis(5'-chloro-3-(3,6-di-tert-butyl-9H-ca-
rbazol-9-yl)-3'-methyl-5-(2,4,4-trimethylpentan-2-yl)biphenyl-2-ol))dimeth-
yl-hafnium, (34).
[0466] Structures of metal-ligand complexes (1) to (8) are shown in
FIG. 10. Structures of metal-ligand complexes (9) to (16) are shown
in FIG. 11. Structures of metal-ligand complexes (17) to (24) are
shown in FIG. 12. Structure of metal-ligand complexes (25) to (32)
are shown in FIG. 13. Structures of metal-ligand complexes (33) and
(34) are shown in FIG. 15. In FIGS. 10 to 13 and in this
specification, "t-butyl" is synonymous with tert-butyl,
tertiary-butyl, and 1,1-dimethylethyl. The "Me" means methyl. The
"Et" means ethyl. The "t-octyl" is synonymous with tert-octyl,
tertiary-octyl, and 1,1-dimethylhexyl. The "--CN" is cyano. The
"MeO" means methoxy. The structures of metal-ligand complex (33)
and (34) are the same as the structure of metal-ligand complex (32)
except the (CH.sub.2).sub.5 of (32) is replaced by
--CH(CH.sub.3)CH.sub.2CH(CH.sub.3)-- or (CH.sub.2).sub.6,
respectively, in (33) and (34).
[0467] In some embodiments at least one of the one or more
metal-ligand complexes of formula (I) is any one of metal-ligand
complexes (1) to (3). In some embodiments at least one of the one
or more metal-ligand complexes of formula (I) is any one of
metal-ligand complexes (10), (11), (13), and (20) to (23). In some
embodiments at least one of the one or more metal-ligand complexes
of formula (I) is any one of metal-ligand complexes (4) to (9),
(12), (14) to (19), (24), and (25). In some embodiments at least
one of the one or more metal-ligand complexes of formula (I) is
metal-ligand complex (3). In some embodiments at least one of the
one or more metal-ligand complexes of formula (I) is metal-ligand
complex (13). In some embodiments at least one of the one or more
metal-ligand complexes of formula (I) is any one of metal-ligand
complexes (1), (2), (10), (11), and (20) to (23). In some
embodiments at least one of the one or more metal-ligand complexes
of formula (I) is any one of metal-ligand complexes (26) to (31).
In some embodiments at least one of the one or more metal-ligand
complexes of formula (I) is any one of metal-ligand complexes (32)
to (34).
[0468] General procedure for selective polymerization of ethylene
in the presence of a (C.sub.3-C.sub.40)alpha-olefin (e.g.,
1-octene) to give an ethylene-enriched polyolefin
[0469] Summary: conduct ethylene polymerization reactions at a
temperature of 150.degree. C. or 170.degree. C. (as indicated), or
even 190.degree. C., in a 2 liter (L) batch reactor with feeds of
250 grams (g) of 1-octene; 533 g of mixed alkanes solvent (e.g.,
isopar-E); 460 pounds per square inch gauge (psig; 3.17 megapascals
(MPa)) of ethylene gas pressure; and optionally 45 psig (0.31 MPa)
hydrogen gas as a molecular weight control agent. Prepare catalyst
by activating a metal-ligand complex of formula (I) (e.g., the
metal ligand complex of Example Q1, Q2, or Q3) with 1.2 mole
equivalents (relative to the number of moles of the metal ligand
complex of formula (I)) of an activating co-catalyst that is either
trityl borate or the BOMATPB or BOMATPB.sup.mix) and another
activating co-catalyst that is a triisobutylaluminum-modified
methylalumoxane-3A (MMAO-3A). Carry out all polymerization
reactions for 10 minutes and then stop them by venting the ethylene
to atmospheric pressure (i.e., about 101 kilopascals (kPa).
[0470] Pass all feeds through columns of alumina and Q-5.TM.
catalyst (available from Engelhard Chemicals Inc.) prior to
introduction into the 2 L batch reactor. Handle mixtures and
solutions of the metal-ligand complex of formula (I) (e.g., in
toluene) and solutions of the activating co-catalysts (e.g., in
toluene) in a glove box under an inert gas atmosphere (e.g.,
nitrogen or argon gas). With stirring, charge the 2-liter batch
reactor with about 533 g of mixed alkanes solvent (Isopar E) and
250 g of 1-octene. Add 45 psig hydrogen gas (H.sub.2) as a
molecular weight control agent by differential pressure expansion
from a 75 mL volume addition tank at 300 psi (2070 kPa). Heat
contents of the batch reactor to a polymerization temperature of
from 140.degree. C. to 190.degree. C. (e.g., 150.degree. C. or
170.degree. C.), as the case may be, and saturate the contents with
ethylene at 460 psig (3.4 MPa). Premix dilute toluene solutions of
the metal-ligand complex of formula (I) and dilute toluene
solutions of the activating co-catalysts. Then transfer the
resulting premixture to a catalyst addition tank, and inject the
premixture therefrom into the batch reactor. Maintain the olefin
polymerization conditions (e.g., temperature) for 15 minutes,
adding ethylene on demand to maintain a pressure at or above 5
pounds per square inch (psi) (34.5 kilopascals (kPa)); record
weight of ethylene added. Continuously remove heat from the
resulting reaction mixture via heat transfer to an internal cooling
coil. After the 15 minutes, remove the resulting solution from the
batch reactor, quench the reaction with 2-propanol, and stabilize
the resulting quenched mixture against further olefin
polymerization by adding 10 mL of a toluene solution containing
approximately 67 milligrams (mg) of a hindered phenol antioxidant
(IRGANOX.TM. 1010 from Ciba Geigy Corporation) and 133 mg of a
phosphorus stabilizer (IRGAFOS.TM. 168 from Ciba Geigy
Corporation). Recover the resulting ethylene-enriched polyethylene
polymer products by drying them for about 12 hours in a
temperature-ramped vacuum oven with a starting temperature of about
25.degree. C. and a final drying temperature of 140.degree. C.
[0471] Determine melting and crystallization temperatures of
ethylene-enriched polyethylene polymer products by DSC. Determine
M.sub.W and ratio of M.sub.W/M.sub.n (polydispersity index or PDI).
Determine mole percent (mol %) 1-octene incorporation and
density.
[0472] Illustrative procedures are: Determine melting and
crystallization temperatures of ethylene-enriched polyethylene
polymer products by DSC using DSC 2910 instrument from TA
Instruments, Inc. DSC samples are first heated from room
temperature to 180.degree. C. at a heating rate of 10.degree. C.
per minute. Hold at 180.degree. C. for from 2 minutes to 4 minutes,
then cool the sample to -40.degree. C. at a cooling rate of
10.degree. C. per minute. Hold at -40.degree. C. for from 2 minutes
to 4 minutes, and then heat the sample to 160.degree. C. at a
heating rate of 10.degree. C. per minute. Determine M.sub.W and
ratio of M.sub.W/M.sub.n (polydispersity index or PDI) using a
Polymer Labs.TM. 210 high temperature gel permeation calorimeter.
Determine mole percent (mol %) 1-octene incorporation and density,
Prepare samples using 13 milligrams (mg) of polyolefin sample.
Dilute the polyolefin sample with 16 mL of 1,2,4-trichlorobenzene
(TCB; stabilized with BHT), and heat and shake the resulting
diluted mixture at 160.degree. C. for 2 hours to give a solution,
which is cooled to room temperature. Deposit 140 microliters of
cooled polyolefin solution onto a silica wafer, heat to 140.degree.
C. until the sample is dried, and analyze the dried sample using a
Nicolet Nexus 670 FT-IR instrument with version 7.1 software and
equipped with an AutoPro auto sampler.
[0473] Between polymerization runs, wash the batch reactor out by
adding thereto 850 g of mixed alkanes and heating to 150.degree. C.
Then empty the batch reactor of the resulting heated mixed alkanes
immediately before beginning a new polymerization run.
[0474] For perspective, employing non-invention catalysts prepared
from non-invention metal-ligand complexes that are of formula (I)
except they lack R.sup.1a and R.sup.1b in the general procedure
prepare polyethylenes having either greater than 14.0 mol %, and in
some cases greater than 17 mol %, covalent incorporation of
1-octene (i.e., are not ethylene-enriched); a density of less than
0.86 grams per milliliter (g/mL); a melting temperature of less
than 50.degree. C., and in some cases less than 30.degree. C.; or a
combination thereof when prepared by the aforementioned
process.
[0475] Examples A to N: Selective polymerization of ethylene in the
presence of 1-octene to give a high density polyethylene
(ethylene-enriched, having low incorporation of 1-octene) using the
metal-ligand complex (1), (2), (3) (seven times), (11) (two times),
(13) (two times), and (21) of Examples 1, 2, 3 (seven times), 11
(two times), 13 (two times), and 21, respectively.
[0476] Follow the general procedure described above using the
metal-ligand complex (1), (2), or (3) of Example 1, 2, or 3,
respectively, as the metal-ligand complex of formula (I) in three
separate runs for Examples A, B, and C, respectively:
[0477] Example A: using 0.3 micromoles (.mu.mol) of the
metal-ligand complex (1) of Example 1; activating co-catalysts that
are BOMATPB.sup.mix (0.36 .mu.mol) and MMAO-3A (3 .mu.mol); and a
polymerization reaction temperature of 150.degree. C.; and
[0478] Example B: using 0.2 .mu.mol of the metal-ligand complex of
(2) of Example 2; activating co-catalysts that are BOMATPB.sup.mix
(0.24 .mu.mol) and MMAO-3A (2 .mu.mol); and a polymerization
reaction temperature of 150.degree. C.
[0479] Example C: using 0.1 .mu.mol of the metal-ligand complex (3)
of Example 3; activating co-catalysts that are BOMATPB.sup.mix
(0.12 .mu.mol) and MMAO-3A (1.2 .mu.mol); and a polymerization
reaction temperature of 170.degree. C.
[0480] Follow the general procedure described previously using the
metal-ligand complex (3) (six times), (11) (two times), (13) (two
times), and (21) of Examples 3 (six times), 11 (two times), 13 (two
times), and 21, respectively in eleven separate runs for Examples D
to N, respectively:
[0481] Examples D and E: using 0.1 .mu.mol of the metal-ligand
complex (3) of Example 3; activating co-catalysts that are
BOMATPB.sup.mix (0.12 .mu.mol) and MMAO-3A (1.0 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0482] Examples F and G: using 0.075 .mu.mol of the metal-ligand
complex (3) of Example 3; activating co-catalysts that are
BOMATPB.sup.mix (0.09 .mu.mol) and MMAO-3A (0.75 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0483] Examples H and I: using 0.05 .mu.mol of the metal-ligand
complex (3) of Example 3; activating co-catalysts that are
BOMATPB.sup.mix (0.06 .mu.mol) and MMAO-3A (0.5 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0484] Example J: using 0.05 .mu.mol of the metal-ligand complex
(11) of Example 11; activating co-catalysts that are
BOMATPB.sup.mix (0.06 .mu.mol) and MMAO-3A (0.5 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0485] Example K: using 0.08 .mu.mol of the metal-ligand complex
(11) of Example 11; activating co-catalysts that are
BOMATPB.sup.mix (0.096 .mu.mol) and MMAO-3A (0.8 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0486] Example L: using 0.1 .mu.mol of the metal-ligand complex
(13) of Example 13; activating co-catalysts that are
BOMATPB.sup.mix (0.12 .mu.mol) and MMAO-3A (1.0 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0487] Example M: using 0.075 .mu.mol of the metal-ligand complex
(13) of Example 13; activating co-catalysts that are
BOMATPB.sup.mix (0.09 .mu.mol) and MMAO-3A (0.75 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0488] Example N: using 0.08 .mu.mol of the metal-ligand complex
(21) of Example 21; activating co-catalysts that are
BOMATPB.sup.mix (0.096 .mu.mol) and MMAO-3A (0.8 .mu.mol); and a
polymerization reaction temperature of 170.degree. C.
[0489] Example O: using 605 g mixed alkanes, 300 g 1-octene, 288
psi (1,990 kPa) ethylene, 0.15 .mu.mol of the metal-ligand complex
(6a) of Example 6a; activating co-catalysts that are
BOMATPB.sup.mix (0.18 .mu.mol) and MMAO-3A (1.5 .mu.mol); and a
polymerization reaction temperature of 140.degree. C. and run time
of 10 minutes.
[0490] Example P: using 605 g mixed alkanes, 300 g 1-octene, 288
psi (1,990 kPa) ethylene, 0.2 .mu.mol of the metal-ligand complex
(6b) of Example 6b; activating co-catalysts that are
BOMATPB.sup.mix (0.24 .mu.mol) and MMAO-3A (2 .mu.mol); and a
polymerization reaction temperature of 140.degree. C. and run time
of 10 minutes.
Results of Examples A to N are shown below in Tables 1 and 2.
TABLE-US-00001 TABLE 1 certain characterizations of processes of
Examples A to P employing metal-ligand complexes (1) to (3) (seven
times), (11) (two times), (13) (two times), (21), (6a), and (6b),
respectively. Metal- Metal- ligand Weight Yield Catalyst ligand
complex of of Efficiency Ex. complex amount Activating co-catalysts
Ethylene PEO (gPEO/ No. Number (.mu.mol) (amount in .mu.mol) added
(g) (g) gM) A (1) 0.3 BOMATPB.sup.mix (0.36)/ 21.7 26.6 497,000
MMAO-3A (3) B (2) 0.2 BOMATPB.sup.mix (0.24)/ 11.0 12.6 353,000
MMAO-3A (2) C (3) 0.1 BOMATPB.sup.mix (0.12)/ 16.8 17.3 969,000
MMAO-3A (1.2) D (3) 0.1 BOMATPB.sup.mix (0.12)/ 11.7 13.2 740,000
MMAO-3A (1.0) E (3) 0.1 BOMATPB.sup.mix (0.12)/ 25.1 26.6 1,490,000
MMAO-3A (1.0) F (3) 0.075 BOMATPB.sup.mix (0.09)/ 11.7 13.0 971,000
MMAO-3A (0.75) G (3) 0.075 BOMATPB.sup.mix (0.09)/ 12.8 14.6
1,091,000 MMAO-3A (0.75) H (3) 0.05 BOMATPB.sup.mix (0.06)/ 8.3 8.3
930,000 MMAO-3A (0.5) I (3) 0.05 BOMATPB.sup.mix (0.06)/ 25.1 26.0
2,913,000 MMAO-3A (0.5) J (11) 0.05 BOMATPB.sup.mix (0.06)/ 8.6 8.4
941,000 MMAO-3A (0.5) K (11) 0.08 BOMATPB.sup.mix (0.096)/ 19.8
21.2 1,485,000 MMAO-3A (0.8) L (13) 0.1 BOMATPB.sup.mix (0.12)/
13.5 34.5 1,933,000 MMAO-3A (1.0) M (13) 0.075 BOMATPB.sup.mix
(0.09)/ 12.8 14.3 1,068,000 MMAO-3A (0.75) N (21) 0.08
BOMATPB.sup.mix (0.096)/ 1.3 1.2 84,000 MMAO-3A (0.8) O (6a) 0.15
BOMATPB.sup.mix (0.18)/ 22.2 34.3 1,281,000 MMAO-3A (1.5) P (6b)
0.2 BOMATPB.sup.mix (0.24)/ 18.1 25.9 726,000 MMAO-3A (2) Ex. No. =
Example Number; PEO = ethylene-enriched poly(ethylene-co-1-octene)
copolymer; Catalyst Efficiency (gPEO/gM) = catalyst efficiency
calculated by dividing weight in grams of PEO product by weight in
grams of metal M in metal-ligand complex used.
[0491] The reactivity ratio for metal-ligand complex (1) is
r.sub.1=40. The reactivity ratio for metal-ligand complex (2) is
r.sub.1=75. The reactivity ratio for metal-ligand complex (3) is
r.sub.1=60. The reactivity ratio for metal-ligand complex (6b) is
r.sub.1=100. The reactivity ratio for metal-ligand complex (19a) is
r.sub.1=15.
TABLE-US-00002 TABLE 2 certain characterizations of high density
polyethylenes of Examples A to P. Mol % Ex. Tm M.sub.w Density
octene No. (.degree. C.) (g/mol) M.sub.w/M.sub.n (g/mL) (NMR) A
103.6 22,200 2.5 0.903 4.4 B 115.2 56,400 4.1 0.924 2.4 C 114.8
153,800 4.7 0.922 3.1 D 113.0 111,000 6.6 N/p N/p E 115.5 97,600
4.9 N/p N/p F 115.5 98,000 8.7 N/p N/p G 117.0 92,000 10.4 N/p N/p
H 116.9 123,000 5.0 N/p N/p I 117.1 114,000 4.5 N/p N/p J 116.5
83,400 3.4 N/p N/p K 117.9 75,300 3.8 N/p N/p L 111.6 94,900 2.8
N/p N/p M 114.8 111,000 5.7 N/p N/p N 107.8 136,000 2.7 N/p N/p O
85.4 24,000 2.1 N/p 8.7 (by FT-IR) P 117.1 90,000 1.9 N/p 1.9
(FT-IR) Ex. No. = Example Number; T.sub.m = melting temperature;
M.sub.w (g/mol) [or M.sub.w (g/mol)] = weight average molecular
weight in grams per mole determined by GPC; M.sub.w/M.sub.n =
polydispersity index (PDI) = M.sub.w divided by number average
molecular weight (M.sub.n) (g/mol); Mol % octene (NMR) = mole
percent of 1-octene incorporated into PEO (ethylene-enriched) as
determined by .sup.1H-NMR spectroscopy; N/p means not provided.
[0492] Examples AA to AG: repeat the General polymerization
procedure except use a 1 gallon (3.8 liter) reactor, 190.degree. C.
polymerization temperature, 250 g 1-octene, 450 psi overall
pressure, 10 minute run time, metal-ligand complexes (26), (27),
(12), (28), (29), (30), and (13), a molar ratio of metal-ligand
complex to BOMATPB.sup.mix to MMAO-3A of 1 to 1.2 to 50, and the
conditions described below in Table 3.
TABLE-US-00003 TABLE 3 preparation of ethylene-enriched PEO. Metal-
Metal- ligand Yield ligand complex of Catalyst Ex. complex amount
H.sub.2 gas PEO Efficiency M.sub.w No. Number (.mu.mol) (mmol) (g)
(gPEO/gM) Tm (.degree. C.) (g/mol) M.sub.w/M.sub.n r.sub.1 AA (26)
1.75 0 18 60,000 119.8 70,100 2.0 AB (27) 1.75 0 38 120,000 116.2
102,500 2.0 AC (12) 1.75 0 12 40,000 117.1 76,100 2.1 AD (28) 0.5
20 20 220,000 110.2/98.8 33,200 2.7 AE (29) 1 20 43 240,000 120
24,200 3.2 AF (30) 2 20 12 30,000 100 197,600 2.3 AG (13) 1.75 0 20
60,000 116.4 80,100 2.0
[0493] Examples BA to BG: repeat the General polymerization
procedure except use a 2 liter batch reactor, 140.degree. C.
polymerization temperature, 605 g mixed alkanes, 300 g 1-octene,
288 psi ethylene pressure, 10 minute run time, metal-ligand
complexes (10), (6b), (3), (31), (2), (19a), and (13), a molar
ratio of metal-ligand complex to BOMATPB.sup.mix to MMAO-3A of 1 to
1.2 to 10, and the conditions described below in Table 4.
TABLE-US-00004 TABLE 4 preparation of ethylene-enriched PEO. Metal-
Metal- ligand Yield ligand complex of Catalyst Ex. complex amount
PEO Efficiency M.sub.w No. Number (.mu.mol) (g) (gPEO/gM) Tm
(.degree. C.) (g/mol) M.sub.w/M.sub.n r.sub.1 BA (10) 0.02 17.8
4,986,000 108.2 269,000 1.6 82 BB (6b) 0.2 25.9 726,000 117.1
89,600 1.9 95 BC (3) 0.055 36.6 3,728,000 101.1 298,000 1.7 44 BD
(31) 0.35 21.9 351,000 72.7/91.0 15,700 3.1 17 BE (2) 0.12 31.7
1,480,000 106.9 42,900 6.9 45 BF (19a) 0.03 30.3 5,659,000 53.9
986,000 1.7 15 BG (13) 0.017 10.5 3,460,000 102.0 253,000 2.3
33
[0494] Example A': replicate Example A except further employ
diethyl zinc as a chain shuttling agent, twice the amounts of
BOMATPB.sup.mix and MMAO-3A, and 0.3 .mu.mol of the Catalyst (A1)
as the promiscuous olefin polymerization catalyst (i.e., the first
olefin polymerization catalyst) to give a
poly(ethylene-co-1-octene)olefin block copolymer.
[0495] Examples A'' to P'', AA'' to AG'', and BA'' to BG'' except
substitute BOMATPB for BOMATPB.sup.mix.
[0496] As shown by the above description, including the Examples,
the invention catalysts prepared from the invention metal-ligand
complexes selectively polymerize ethylene in presence of an
alpha-olefin when used in the invention process. This selective
polymerization of the invention process desirably yields the rich
polyethylene (also referred to herein as a rich polyethylene), or
the rich polyethylene segment of a poly(ethylene alpha-olefin)
copolymer, the rich polyethylene and rich polyethylene segment
independently having low mole percent incorporation of alpha-olefin
therein. Thus in chain shuttling embodiments described previously,
the invention process would selectively give an ethylene-derived
hard segment of an OBC in the presence of a
(C.sub.3-C.sub.40)alpha-olefin. A particularly preferred
metal-ligand complex(es) of formula (I) is one capable of preparing
such a catalyst(s) that can achieve a high selectivity for
polymerizing ethylene in the presence of the
(C.sub.3-C.sub.40)alpha-olefin, wherein the high selectivity is
characterized in the preferred embodiments as described previously.
The invention process is also useful for preparing the
aforementioned polymer blends with good catalyst efficiency.
[0497] The present invention is described herein by its preferred
advantages, embodiments and features such as preferred selections,
ranges, constituents, elements, steps, examples, and other
preferred features. However, the intent of this description is not
to limit the present invention to the particular preferred
advantages, embodiments and features so described, but to also
cover, and the present invention does cover, any and all
advantages, modifications, equivalents, variations, adaptations,
and alternatives falling within the spirit and scope of the
description. Thus, characterizations of such embodiments and
features as "preferred" should in no way be interpreted as
designating such advantages, embodiments and features as being
required, essential or critical to the present invention described
herein, including the aspects thereof hereupon claimed.
* * * * *
References